Clinical trial results:
A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and other cancers

Summary

EudraCT number	2014-004982-25
Trial protocol	GB NL ES FR
Global end of trial date	

Results information

Result version number	v1
This version publication date	09 May 2019
First version publication date	09 May 2019

Trial information

Trial identification

Sponsor protocol code	115521

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	27 November 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	13 April 2018
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

- To determine the safety, tolerability and maximum tolerated dose (MTD) of GSK525762 in subjects 16 years or older following QD and/or BID dosing schedules. - To evaluate the clinical activity of GSK525762 in NMC and other solid tumors. - [US Clinical sites only] To evaluate, after single dose administration, the relative bioavailability of the GSK525762 besylate tablet compared to the amorphous free-base tablet, the effect of high-fat high-calorie meal on the bioavailability of the besylate tablet and the dose proportionality of two doses of GSK525762 administered as the besylate tablets.

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 March 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 5
Country: Number of subjects enrolled	France: 57
Country: Number of subjects enrolled	Korea, Republic of: 6
Country: Number of subjects enrolled	Netherlands: 3
Country: Number of subjects enrolled	Spain: 30
Country: Number of subjects enrolled	United Kingdom: 13
Country: Number of subjects enrolled	United States: 82
Worldwide total number of subjects	196
EEA total number of subjects	103

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	3
Adults (18-64 years)	134
From 65 to 84 years	58
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

The results presented are based on primary analysis and the study was ongoing at the time of analysis.

Pre-assignment

Screening details:

This was a 2-Part study conducted in 8 countries-Part 1 (dose-escalation) and Part 2 (dose expansion). A besylate sub-study was conducted in 10 participants in the United States.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Part1: GSK525762 2-16 mg QD

Arm description:

Participants were administered once daily (QD) oral dose of 2 to 16 milligrams (mg) GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	Part 1: GSK525762 30 mg QD

Arm description:

Participants were administered once daily oral dose of 30 mg GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	Part 1: GSK525762 60 mg QD

Arm description:

Participants were administered once daily oral dose of 60 mg GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	Part 1: GSK525762 80 mg QD

Arm description:

Participants were administered once daily oral dose of 80 mg GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	Part 1: GSK525762 100 mg QD

Arm description:

Participants were administered once daily oral dose of 100 mg GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	Part 1: GSK525762 20 mg BID

Arm description:

Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 twice daily via the oral route with 240 milliliters of water.

Arm title	Part 1: GSK525762 30 mg BID

Arm description:

Participants were administered twice daily oral dose of 30 mg GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 twice daily via the oral route with 240 milliliters of water.

Arm title	Part 1: GSK525762 40 mg BID

Arm description:

Participants were administered twice daily oral dose of 40 mg GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 twice daily via the oral route with 240 milliliters of water.

Arm title	Part 2: Participants with NMC

Arm description:

Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	Part 2: Participants with SCLC

Arm description:

Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	Part 2: Participants with CRPC

Arm description:

Participants with Castrate-Resistant Prostate Cancer (CRPR) were administered continuous once daily oral dose of 75 mg GSK525762

Arm type	Experimental

Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	Part 2: Participants with TNBC

Arm description:

Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	Part 2: Participants with ER+BC

Arm description:

Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	Part 2: Participants with GIST

Arm description:

Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762.

Arm type	Experimental
Investigational medicinal product name	GSK525762
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Arm title	All participants in Besylate substudy

Arm description:

All participants who entered besylate substudy and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included.

Arm type	Experimental

Investigational medicinal product name	GSK525762 besylate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to slightly coloured, round, biconvex, film coated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Investigational medicinal product name	13C-GSK525762 Stable isotope powder for oral solution
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

13C-GSK525762 was available as white to slightly colored powder. The powder was dissolved in 20 milliliters of water with bicarbonate buffer and administered with GSK525762 tablets.

Investigational medicinal product name	GSK525762 amorphous freebase
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GSK525762 was available as white to off-white, round, biconvex, uncoated tablets. Participants were administered GSK525762 once daily via the oral route with 240 milliliters of water.

Number of subjects in period 1	Part1: GSK525762 2-16 mg QD	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD
Started	11	4	9
Completed	0	0	1
Not completed	11	4	8
Adverse event, serious fatal	10	4	7
Physician decision	1	-	-
Consent withdrawn by subject	-	-	-
Ongoing (in follow-up)	-	-	-
Site closed	-	-	-
Lost to follow-up	-	-	1

Number of subjects in period 1	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD	Part 1: GSK525762 20 mg BID
Started	32	9	4
Completed	0	0	1
Not completed	32	9	3
Adverse event, serious fatal	30	7	1
Physician decision	-	-	-
Consent withdrawn by subject	-	-	1
Ongoing (in follow-up)	-	-	-
Site closed	2	-	-

Lost to follow-up	-	2	1

Number of subjects in period 1	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	Part 2: Participants with NMC
Started	10	5	12
Completed	0	0	0
Not completed	10	5	12
Adverse event, serious fatal	9	3	8
Physician decision	-	-	-
Consent withdrawn by subject	-	1	-
Ongoing (in follow-up)	-	-	1
Site closed	1	1	2
Lost to follow-up	-	-	1

Number of subjects in period 1	Part 2: Participants with SCLC	Part 2: Participants with CRPC	Part 2: Participants with TNBC
Started	14	23	19
Completed	0	1	0
Not completed	14	22	19
Adverse event, serious fatal	12	21	16
Physician decision	-	-	-
Consent withdrawn by subject	-	-	-
Ongoing (in follow-up)	-	-	-
Site closed	2	1	1
Lost to follow-up	-	-	2

Number of subjects in period 1	Part 2: Participants with ER+BC	Part 2: Participants with GIST	All participants in Besylate substudy
Started	21	13	10
Completed	0	0	0
Not completed	21	13	10
Adverse event, serious fatal	17	5	9
Physician decision	-	-	-
Consent withdrawn by subject	1	-	1
Ongoing (in follow-up)	-	-	-
Site closed	3	8	-
Lost to follow-up	-	-	-

Baseline characteristics

Reporting groups	
Reporting group title	Part1: GSK525762 2-16 mg QD
Reporting group description:	
Participants were administered once daily (QD) oral dose of 2 to 16 milligrams (mg) GSK525762.	
Reporting group title	Part 1: GSK525762 20 mg BID
Reporting group description:	
Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.	
Reporting group title	Part 1: GSK525762 30 mg BID
Reporting group description:	
Participants were administered twice daily oral dose of 30 mg GSK525762.	
Reporting group title	Part 1: GSK525762 40 mg BID
Reporting group description:	
Participants were administered twice daily oral dose of 40 mg GSK525762.	
Reporting group title	Part 2: Participants with NMC
Reporting group description:	
Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762.	
Reporting group title	Part 2: Participants with SCLC
Reporting group description:	
Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762	
Reporting group title	Part 2: Participants with CRPC
Reporting group description:	
Participants with Castrate-Resistant Prostate Cancer (CRPR) were administered continuous once daily oral dose of 75 mg GSK525762	
Reporting group title	Part 2: Participants with TNBC
Reporting group description:	
Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762.	
Reporting group title	Part 2: Participants with ER+BC
Reporting group description:	
Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762	
Reporting group title	Part 2: Participants with GIST
Reporting group description:	
Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762.	
Reporting group title	All participants in Besylate substudy
Reporting group description:	
All participants who entered besylate substudy and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included.	

Reporting group values	Part1: GSK525762 2-16 mg QD	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID
Number of subjects	11	4	10
Age categorical Units: Subjects			
All study participants	11	4	10

Age Continuous			
Units: Years			
arithmetic mean	46.2	66.5	63.5
standard deviation	± 16.27	± 6.45	± 8.42
Sex: Female, Male			
Units: Subjects			
Female	8	2	4
Male	3	2	6
Race/Ethnicity, Customized			
Units: Subjects			
American Indian or Alaska Native	1	0	0
Central/South Asian Heritage (Her)	1	0	0
Japanese Her/East Asian Her/South East Asian Her	1	1	0
Black or African American	1	0	0
White	7	3	10
Missing	0	0	0

Reporting group values	Part 1: GSK525762 40 mg BID	Part 2: Participants with NMC	Part 2: Participants with SCLC
Number of subjects	5	12	14
Age categorical			
Units: Subjects			
All study participants	5	12	14
Age Continuous			
Units: Years			
arithmetic mean	60.4	42.9	58.3
standard deviation	± 4.83	± 18.05	± 11.04
Sex: Female, Male			
Units: Subjects			
Female	1	7	9
Male	4	5	5
Race/Ethnicity, Customized			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Central/South Asian Heritage (Her)	0	1	0
Japanese Her/East Asian Her/South East Asian Her	0	2	3
Black or African American	0	0	2
White	5	6	8
Missing	0	3	1

Reporting group values	Part 2: Participants with CRPC	Part 2: Participants with TNBC	Part 2: Participants with ER+BC
Number of subjects	23	19	21
Age categorical			
Units: Subjects			
All study participants	23	19	21
Age Continuous			
Units: Years			
arithmetic mean	63.8	50.8	59.7
standard deviation	± 6.11	± 8.66	± 10.34

Sex: Female, Male Units: Subjects			
Female	0	19	21
Male	23	0	0
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0	0	0
Central/South Asian Heritage (Her)	0	0	0
Japanese Her/East Asian Her/South East Asian Her	0	1	0
Black or African American	0	2	1
White	23	15	18
Missing	0	1	2

Reporting group values	Part 2: Participants with GIST	All participants in Besylate substudy	Total
Number of subjects	13	10	142
Age categorical Units: Subjects			
All study participants	13	10	142
Age Continuous Units: Years			
arithmetic mean	61.0	55.2	
standard deviation	± 13.23	± 9.96	-
Sex: Female, Male Units: Subjects			
Female	6	5	82
Male	7	5	60
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0	0	1
Central/South Asian Heritage (Her)	0	0	2
Japanese Her/East Asian Her/South East Asian Her	1	0	9
Black or African American	1	1	8
White	10	9	114
Missing	1	0	8

Subject analysis sets

Subject analysis set title	All participants in Besylate substudy
Subject analysis set type	Sub-group analysis

Subject analysis set description:

All participants who entered besylate sub-study and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included.

Subject analysis set title	Participants with NMC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with SCLC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with CRPC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with TNBC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with ER+BC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with GIST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	All participants in Besylate sub-study
Subject analysis set type	Sub-group analysis

Subject analysis set description:

All participants who entered besylate sub-study and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included.

Subject analysis set title	Participants with NMC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with CRPC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with ER+BC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with GIST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with ER+BC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	GSK525762 80 mg amorphous+6 mg stable isotope

Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered GSK525762 80 mg amorphous free-base tablet along with 6 mg stable isotope in the fasted state.

Subject analysis set title	GSK525762 80 mg besylate+6 mg stable isotope
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered GSK525762 80 mg besylate tablet along with 6 mg stable isotope in solution in fasted state.

Subject analysis set title	GSK525762 30 mg besylate+6 mg stable isotope
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered GSK525762 30 mg besylate tablet along with 6 mg stable isotope in solution in fasted state.

Subject analysis set title	GSK525762 80 mg besylate fed
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered GSK525762 80 mg besylate tablet along with Food and Drug Administration (FDA) recommended high fat breakfast.

Subject analysis set title	Participants with NMC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with SCLC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with CRPC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with TNBC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with ER+BC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with GIST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	All participants in Besylate sub-study
Subject analysis set type	Sub-group analysis

Subject analysis set description:

All participants who entered besylate sub-study and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included.

Subject analysis set title	Part 1: GSK525762 2-16 mg QD
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants were administered once daily (QD) oral dose of 2 to 16 milligrams (mg) GSK525762.	
Subject analysis set title	Part 1: GSK525762 2-16 mg QD
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants were administered once daily (QD) oral dose of 2 to 16 milligrams (mg) GSK525762.	
Subject analysis set title	Part 1: GSK525762 2 mg QD
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants were administered once daily oral dose of 2 mg GSK525762.	
Subject analysis set title	Part 1: GSK525762 4 mg QD
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants were administered once daily oral dose of 4 mg GSK525762.	
Subject analysis set title	Part 1: GSK525762 8 mg QD
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants were administered once daily oral dose of 8 mg GSK525762.	
Subject analysis set title	Part 1: GSK525762 16 mg QD
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants were administered once daily oral dose of 16 mg GSK525762.	
Subject analysis set title	Part 1: GSK525762 20 mg QD
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants were administered once daily oral dose of 30 mg GSK525762.	

Reporting group values	All participants in Besylate substudy	Participants with NMC	Participants with SCLC
Number of subjects	10	12	14
Age categorical Units: Subjects			
All study participants			
Age Continuous Units: Years			
arithmetic mean			
standard deviation	±	±	±
Sex: Female, Male Units: Subjects			
Female	5		
Male	5		
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0		
Central/South Asian Heritage (Her)	0		
Japanese Her/East Asian Her/South East Asian Her	0		
Black or African American	1		
White	9		
Missing	0		

Reporting group values	Participants with CRPC	Participants with TNBC	Participants with ER+BC
Number of subjects	23	19	21
Age categorical			
Units: Subjects			
All study participants			
Age Continuous			
Units: Years			
arithmetic mean			
standard deviation	±	±	±
Sex: Female, Male			
Units: Subjects			
Female			
Male			
Race/Ethnicity, Customized			
Units: Subjects			
American Indian or Alaska Native			
Central/South Asian Heritage (Her)			
Japanese Her/East Asian Her/South East Asian Her			
Black or African American			
White			
Missing			

Reporting group values	Participants with GIST	All participants in Besylate sub-study	Participants with NMC
Number of subjects	13	10	11
Age categorical			
Units: Subjects			
All study participants			
Age Continuous			
Units: Years			
arithmetic mean			
standard deviation	±	±	±
Sex: Female, Male			
Units: Subjects			
Female			
Male			
Race/Ethnicity, Customized			
Units: Subjects			
American Indian or Alaska Native			
Central/South Asian Heritage (Her)			
Japanese Her/East Asian Her/South East Asian Her			
Black or African American			
White			
Missing			

Reporting group values	Participants with CRPC	Participants with ER+BC	Participants with GIST
Number of subjects	22	20	12

Age categorical Units: Subjects			
All study participants			
Age Continuous Units: Years arithmetic mean standard deviation	±	±	±
Sex: Female, Male Units: Subjects			
Female Male			
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native Central/South Asian Heritage (Her) Japanese Her/East Asian Her/South East Asian Her Black or African American White Missing			

Reporting group values	Participants with ER+BC	GSK525762 80 mg amorphous+6 mg stable isotope	GSK525762 80 mg besylate+6 mg stable isotope
Number of subjects	19	9	10
Age categorical Units: Subjects			
All study participants			
Age Continuous Units: Years arithmetic mean standard deviation	±	±	±
Sex: Female, Male Units: Subjects			
Female Male			
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native Central/South Asian Heritage (Her) Japanese Her/East Asian Her/South East Asian Her Black or African American White Missing			

Reporting group values	GSK525762 30 mg besylate+6 mg stable isotope	GSK525762 80 mg besylate fed	Participants with NMC
Number of subjects	10	8	2
Age categorical Units: Subjects			
All study participants			

Age Continuous Units: Years arithmetic mean standard deviation	± 	± 	±
Sex: Female, Male Units: Subjects			
Female Male			
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native Central/South Asian Heritage (Her) Japanese Her/East Asian Her/South East Asian Her Black or African American White Missing			

Reporting group values	Participants with SCLC	Participants with CRPC	Participants with TNBC
Number of subjects	14	23	19
Age categorical Units: Subjects			
All study participants			
Age Continuous Units: Years arithmetic mean standard deviation	± 	± 	±
Sex: Female, Male Units: Subjects			
Female Male			
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native Central/South Asian Heritage (Her) Japanese Her/East Asian Her/South East Asian Her Black or African American White Missing			

Reporting group values	Participants with ER+BC	Participants with GIST	All participants in Besylate sub-study
Number of subjects	21	13	10
Age categorical Units: Subjects			
All study participants			
Age Continuous Units: Years arithmetic mean standard deviation	± 	± 	±

Sex: Female, Male Units: Subjects			
Female			
Male			
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native			
Central/South Asian Heritage (Her)			
Japanese Her/East Asian Her/South East Asian Her			
Black or African American			
White			
Missing			

Reporting group values	Part 1: GSK525762 2-16 mg QD	Part 1: GSK525762 2-16 mg QD	Part 1: GSK525762 2 mg QD
Number of subjects	11	1	3
Age categorical Units: Subjects			
All study participants			
Age Continuous Units: Years			
arithmetic mean			
standard deviation	±	±	±
Sex: Female, Male Units: Subjects			
Female	8		
Male	3		
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	1		
Central/South Asian Heritage (Her)	1		
Japanese Her/East Asian Her/South East Asian Her	1		
Black or African American	1		
White	7		
Missing	0		

Reporting group values	Part 1: GSK525762 4 mg QD	Part 1: GSK525762 8 mg QD	Part 1: GSK525762 16 mg QD
Number of subjects	4	1	3
Age categorical Units: Subjects			
All study participants			
Age Continuous Units: Years			
arithmetic mean			
standard deviation	±	±	±
Sex: Female, Male Units: Subjects			
Female			
Male			

Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native Central/South Asian Heritage (Her) Japanese Her/East Asian Her/South East Asian Her Black or African American White Missing			

Reporting group values	Part 1: GSK525762 20 mg QD		
Number of subjects	4		
Age categorical Units: Subjects			
All study participants			
Age Continuous Units: Years arithmetic mean standard deviation	 ±		
Sex: Female, Male Units: Subjects			
Female Male			
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native Central/South Asian Heritage (Her) Japanese Her/East Asian Her/South East Asian Her Black or African American White Missing			

End points

End points reporting groups

Reporting group title	Part1: GSK525762 2-16 mg QD
Reporting group description:	
Participants were administered once daily (QD) oral dose of 2 to 16 milligrams (mg) GSK525762.	
Reporting group title	Part 1: GSK525762 30 mg QD
Reporting group description:	
Participants were administered once daily oral dose of 30 mg GSK525762.	
Reporting group title	Part 1: GSK525762 60 mg QD
Reporting group description:	
Participants were administered once daily oral dose of 60 mg GSK525762.	
Reporting group title	Part 1: GSK525762 80 mg QD
Reporting group description:	
Participants were administered once daily oral dose of 80 mg GSK525762.	
Reporting group title	Part 1: GSK525762 100 mg QD
Reporting group description:	
Participants were administered once daily oral dose of 100 mg GSK525762.	
Reporting group title	Part 1: GSK525762 20 mg BID
Reporting group description:	
Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.	
Reporting group title	Part 1: GSK525762 30 mg BID
Reporting group description:	
Participants were administered twice daily oral dose of 30 mg GSK525762.	
Reporting group title	Part 1: GSK525762 40 mg BID
Reporting group description:	
Participants were administered twice daily oral dose of 40 mg GSK525762.	
Reporting group title	Part 2: Participants with NMC
Reporting group description:	
Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762.	
Reporting group title	Part 2: Participants with SCLC
Reporting group description:	
Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762	
Reporting group title	Part 2: Participants with CRPC
Reporting group description:	
Participants with Castrate-Resistant Prostate Cancer (CRPR) were administered continuous once daily oral dose of 75 mg GSK525762	
Reporting group title	Part 2: Participants with TNBC
Reporting group description:	
Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762.	
Reporting group title	Part 2: Participants with ER+BC
Reporting group description:	
Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762	
Reporting group title	Part 2: Participants with GIST
Reporting group description:	
Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762.	
Reporting group title	All participants in Besylate substudy

Reporting group description:

All participants who entered besylate substudy and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included.

Subject analysis set title	All participants in Besylate substudy
Subject analysis set type	Sub-group analysis

Subject analysis set description:

All participants who entered besylate sub-study and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included.

Subject analysis set title	Participants with NMC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with SCLC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with CRPC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with TNBC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with ER+BC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with GIST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	All participants in Besylate sub-study
Subject analysis set type	Sub-group analysis

Subject analysis set description:

All participants who entered besylate sub-study and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included.

Subject analysis set title	Participants with NMC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with CRPC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with ER+BC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with GIST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with ER+BC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	GSK525762 80 mg amorphous+6 mg stable isotope
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered GSK525762 80 mg amorphous free-base tablet along with 6 mg stable isotope in the fasted state.

Subject analysis set title	GSK525762 80 mg besylate+6 mg stable isotope
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered GSK525762 80 mg besylate tablet along with 6 mg stable isotope in solution in fasted state.

Subject analysis set title	GSK525762 30 mg besylate+6 mg stable isotope
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered GSK525762 30 mg besylate tablet along with 6 mg stable isotope in solution in fasted state.

Subject analysis set title	GSK525762 80 mg besylate fed
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered GSK525762 80 mg besylate tablet along with Food and Drug Administration (FDA) recommended high fat breakfast.

Subject analysis set title	Participants with NMC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with SCLC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with CRPC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Castrate-Resistant Prostate Cancer (CRPC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with TNBC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with ER+BC
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	Participants with GIST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762

Subject analysis set title	All participants in Besylate sub-study
Subject analysis set type	Sub-group analysis

Subject analysis set description:

All participants who entered besylate sub-study and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included.

Subject analysis set title	Part 1: GSK525762 2-16 mg QD
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered once daily (QD) oral dose of 2 to 16 milligrams (mg) GSK525762.

Subject analysis set title	Part 1: GSK525762 2-16 mg QD
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered once daily (QD) oral dose of 2 to 16 milligrams (mg) GSK525762.

Subject analysis set title	Part 1: GSK525762 2 mg QD
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered once daily oral dose of 2 mg GSK525762.

Subject analysis set title	Part 1: GSK525762 4 mg QD
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered once daily oral dose of 4 mg GSK525762.

Subject analysis set title	Part 1: GSK525762 8 mg QD
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered once daily oral dose of 8 mg GSK525762.

Subject analysis set title	Part 1: GSK525762 16 mg QD
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered once daily oral dose of 16 mg GSK525762.

Subject analysis set title	Part 1: GSK525762 20 mg QD
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered once daily oral dose of 30 mg GSK525762.

Primary: Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Part 1 QD

End point title	Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Part 1 QD[1][2]

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level.

End point type	Primary

End point timeframe:

Median of 1.38 months of drug exposure

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[3]	9[4]	32[5]	9[6]
Units: Participants				
Any AE	3	9	31	9
Any SAE	1	2	21	3

Notes:

[3] - All Treated Population-participants who received at least one dose of study treatment

[4] - All Treated Population

[5] - All Treated Population

[6] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[7]			
Units: Participants				
Any AE	11			
Any SAE	2			

Notes:

[7] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with AEs and SAEs-Part 1 BID

End point title	Number of participants with AEs and SAEs-Part 1 BID[8][9]

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment

End point type	Primary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[10]	10[11]	5[12]	
Units: Participants				
Any AE	4	10	5	
Any SAE	0	4	2	

Notes:

[10] - All Treated Population

[11] - All Treated Population

[12] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with AEs and SAEs-Part 2

End point title	Number of participants with AEs and SAEs-Part 2[13]

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment.

End point type	Primary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	Participants with NMC	Participants with SCLC	Participants with CRPC	Participants with TNBC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	12[14]	14[15]	23[16]	19[17]
Units: Participants				
Any AE	11	14	23	19
Any SAE	6	9	16	11

Notes:

[14] - All Treated Population

[15] - All Treated Population

[16] - All Treated Population

[17] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	21[18]	13[19]		
Units: Participants				
Any AE	21	13		
Any SAE	15	8		

Notes:

[18] - All Treated Population

[19] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Besylate sub-study

End point title	Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Besylate sub-study[20]

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; any new primary cancers; significant cardiac dysfunction; Grade 4 laboratory abnormalities; and drug related hepatobiliary event leading to permanent discontinuation of study treatment. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data.

End point type	Primary

End point timeframe:

Median of 1.87 months of drug exposure

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[21]			
Units: Participants				
Any AE	10			
Any SAE	6			

Notes:

[21] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with dose reductions or delays-Part 1 QD

End point title	Number of participants with dose reductions or delays-Part 1 QD[22][23]

End point description:

The number of participants who had any dose reductions or delays is presented. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level.

End point type	Primary

End point timeframe:

Median of 1.38 months of drug exposure

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[24]	9[25]	32[26]	9[27]
Units: Participants	0	2	8	7

Notes:

[24] - All Treated Population

[25] - All Treated Population

[26] - All Treated Population

[27] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[28]			
Units: Participants	0			

Notes:

[28] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with dose reductions or delays-Part 1 BID

End point title	Number of participants with dose reductions or delays-Part 1 BID[29][30]

End point description:

The number of participants who had any dose reductions or delays is presented.

End point type	Primary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[31]	10[32]	5[33]	
Units: Participants	0	3	1	

Notes:

[31] - All Treated Population

[32] - All Treated Population

[33] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with dose reductions or delays-Part 2

End point title	Number of participants with dose reductions or delays-Part 2[34]

End point description:

The number of participants who had any dose reductions or delays is presented.

End point type	Primary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	Participants with NMC	Participants with SCLC	Participants with CRPC	Participants with TNBC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	12[35]	14[36]	23[37]	19[38]
Units: Participants	7	4	11	6

Notes:

[35] - All Treated Population

[36] - All Treated Population

[37] - All Treated Population

[38] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	21[39]	13[40]		
Units: Participants	6	4		

Notes:

[39] - All Treated Population

[40] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with dose reductions or delays-Besylate sub-study

End point title	Number of participants with dose reductions or delays-Besylate sub-study[41]

End point description:

The number of participants who had any dose reductions or delays is presented. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.

End point type	Primary

End point timeframe:

Median of 1.87 months of drug exposure

Notes:

[41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[42]			
Units: Participants	4			

Notes:

[42] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants withdrawn due to toxicities-Part 1 QD

End point title	Number of participants withdrawn due to toxicities-Part 1 QD

	[43][44]

End point description:

Number of participants withdrawn due to toxicities is presented. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level.

End point type	Primary

End point timeframe:

Median of 1.38 months of drug exposure

Notes:

[43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[45]	9[46]	32[47]	9[48]
Units: Participants	0	2	7	2

Notes:

[45] - All Treated Population

[46] - All Treated Population

[47] - All Treated Population

[48] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[49]			
Units: Participants	1			

Notes:

[49] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants withdrawn due to toxicities-Part 1 BID

End point title	Number of participants withdrawn due to toxicities-Part 1

End point description:

Number of participants withdrawn due to toxicities is presented.

End point type	Primary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[50] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[52]	10[53]	5[54]	
Units: Participants	0	2	2	

Notes:

[52] - All Treated Population

[53] - All Treated Population

[54] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants withdrawn due to toxicities-Part 2

End point title	Number of participants withdrawn due to toxicities-Part 2[55]

End point description:

Number of participants withdrawn due to toxicities is presented.

End point type	Primary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[55] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	Participants with NMC	Participants with SCLC	Participants with CRPC	Participants with TNBC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	12[56]	14[57]	23[58]	19[59]
Units: Participants	1	3	6	4

Notes:

[56] - All Treated Population

[57] - All Treated Population

[58] - All Treated Population

[59] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	21[60]	13[61]		
Units: Participants	6	2		

Notes:

[60] - All Treated Population

[61] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants withdrawn due to toxicities-Besylate sub-study

End point title	Number of participants withdrawn due to toxicities-Besylate sub-study[62]

End point description:

Number of participants withdrawn due to toxicities is presented. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.

End point type	Primary

End point timeframe:

Median of 1.87 months of drug exposure

Notes:

[62] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[63]			
Units: Participants	0			

Notes:

[63] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with grade change from Baseline in clinical chemistry data-Part 1 QD

End point title	Number of participants with grade change from Baseline in clinical chemistry data-Part 1 QD[64][65]

End point description:

Blood samples were collected for analysis of: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), direct bilirubin (Dir bil), bilirubin, N-Terminal proB-type natriuretic peptide (NT-BNP), calcium, cholesterol, creatine kinase (CK), chloride, carbon dioxide (CO2), creatinine, gamma glutamyl transferase (GGT), high and low density lipoprotein (HDL and LDL), insulin, potassium, lactate dehydrogenase (LDH), lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Grading using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Data for worst case post-Baseline is presented. Only participants with data available at specified time points were analyzed (indicated by n=X in category titles). 99999 indicates data not available due to insufficient participants.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

Notes:

[64] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[65] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[66]	9[67]	32[68]	9[69]
Units: Participants				
Glucose; Any grade increase; n=10, 4, 9, 32, 9	2	7	24	8
Glucose; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	2	3
Glucose; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
Albumin; Any grade increase; n=10, 4, 9, 32, 9	1	3	12	1
Albumin; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	0
Albumin; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
ALP; Any grade increase; n=10, 4, 9, 31, 9	1	0	7	0
ALP; Increase to Grade 3; n=10, 4, 9, 31, 9	0	0	1	0
ALP; Increase to Grade 4; n=10, 4, 9, 31, 9	0	0	0	0
ALT; Any grade increase; n=10, 4, 9, 32, 9	1	1	9	2
ALT; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	0
ALT; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
Amylase; Any grade increase; n=10, 4, 9, 32, 9	2	0	10	1
Amylase; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	1	1
Amylase; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	1	0
AST; Any grade increase; n=10, 4, 9, 32, 9	2	1	14	3
AST; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	1
AST; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
Dir bil; Any grade increase; n=10, 4, 9, 30, 9	0	0	0	0
Dir bil; Increase to Grade 3; n=10, 4, 9, 30, 9	0	0	0	0
Dir bil; Increase to Grade 4; n=10, 4, 9, 30, 9	0	0	0	0
Bilirubin; Any grade increase; n=10, 4, 9, 32, 9	1	1	15	8
Bilirubin; Increase to Grade 3; n=10, 4, 9, 32, 9	1	0	5	1
Bilirubin; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
NT-BNP; Any grade increase; n=10, 4, 9, 30, 9	0	0	0	0
NT-BNP; Increase to Grade 3; n=10, 4, 9, 30, 9	0	0	0	0
NT-BNP; Increase to Grade 4; n=10, 4, 9, 30, 9	0	0	0	0
Calcium; Any grade increase; n=10, 4, 9, 32, 9	2	1	17	3

Calcium; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	0
Calcium; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
Cholesterol; Any grade increase; n=8, 4, 7, 29, 9	0	0	11	1
Cholesterol; Increase to Grade 3; n=8, 4, 7, 29, 9	0	0	0	0
Cholesterol; Increase to Grade 4; n=8, 4, 7, 29, 9	0	0	0	0
CK; Any grade increase; n=11, 4, 9, 31, 9	1	0	11	5
CK; Increase to Grade 3; n=11, 4, 9, 31, 9	0	0	2	0
CK; Increase to Grade 4; n=11, 4, 9, 31, 9	0	0	0	0
Chloride; Any grade increase; n=10, 4, 9, 32, 9	0	0	0	0
Chloride; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	0
Chloride; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
CO2; Any grade increase; n=10, 4, 9, 32, 9	0	0	0	0
CO2; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	0
CO2; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
Creatinine; Any grade increase; n=10, 4, 9, 32, 9	1	0	7	3
Creatinine; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	1	0
Creatinine; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
GGT; Any grade increase; n=9, 4, 9, 31, 7	1	0	11	1
GGT; Increase to Grade 3; n=9, 4, 9, 31, 7	0	0	2	0
GGT; Increase to Grade 4; n=9, 4, 9, 31, 7	0	0	1	0
HDL; Any grade increase; n=8, 4, 7, 28, 9	0	0	0	0
HDL; Increase to Grade 3; n=8, 4, 7, 28, 9	0	0	0	0
HDL; Increase to Grade 4; n=8, 4, 7, 28, 9	0	0	0	0
Insulin; Any grade increase; n=10, 4, 9, 31, 9	0	0	0	0
Insulin; Increase to Grade 3; n=10, 4, 9, 31, 9	0	0	0	0
Insulin; Increase to Grade 4; n=10, 4, 9, 31, 9	0	0	0	0
Potassium; Any grade increase; n=11, 4, 9, 32, 9	0	2	13	3
Potassium; Increase to Grade 3; n=11, 4, 9, 32, 9	0	0	1	1
Potassium; Increase to Grade 4; n=11, 4, 9, 32, 9	0	0	1	0
LDH; Any grade increase; n=0, 0, 1, 0, 0	99999	0	99999	99999
LDH; Increase to Grade 3; n=0, 0, 1, 0, 0	99999	0	99999	99999

LDH; Increase to Grade 4; n=0, 0, 1, 0, 0	99999	0	99999	99999
LDL; Any grade increase; n=8, 4, 7, 28, 8	0	0	0	0
LDL; Increase to Grade 3; n=8, 4, 7, 28, 8	0	0	0	0
LDL; Increase to Grade 4; n=8, 4, 7, 28, 8	0	0	0	0
Lipase; Any grade increase; n=10, 4, 9, 31, 9	0	0	8	2
Lipase; Increase to Grade 3; n=10, 4, 9, 31, 9	0	0	3	0
Lipase; Increase to Grade 4; n=10, 4, 9, 31, 9	0	0	0	0
Magnesium; Any grade increase; n=11, 4, 9, 32, 9	1	0	9	2
Magnesium; Increase to Grade 3; n=11, 4, 9, 32, 9	0	0	0	0
Magnesium; Increase to Grade 4; n=11, 4, 9, 32, 9	0	0	0	0
Protein; Any grade increase; n=10, 4, 9, 32, 9	0	0	0	0
Protein; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	0
Protein; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
Sodium; Any grade increase; n=11, 4, 9, 32, 9	2	3	16	4
Sodium; Increase to Grade 3; n=11, 4, 9, 32, 9	1	0	4	0
Sodium; Increase to Grade 4; n=11, 4, 9, 32, 9	0	0	0	0
Thyroxine; Any grade increase; n=8, 4, 7, 29, 9	0	0	0	0
Thyroxine; Increase to Grade 3; n=8, 4, 7, 29, 9	0	0	0	0
Thyroxine; Increase to Grade 4; n=8, 4, 7, 29, 9	0	0	0	0
Testosterone; Any grade increase; n=1, 3, 3, 14, 7	0	0	0	0
Testosterone; Increase to Grade 3; n=1, 3, 3, 14,7	0	0	0	0
Testosterone; Increase to Grade 4; n=1, 3, 3, 14,7	0	0	0	0
Triglycerides; Any grade increase; n=8,4,7,29,9	2	2	17	6
Triglycerides; Increase to Grade 3; n=8,4,7,29,9	0	0	0	0
Triglycerides; Increase to Grade 4; n=8,4,7,29,9	0	0	0	1
Troponin I; Any grade increase; n=0, 2, 5, 24, 5	0	0	0	0
Troponin I; Increase to Grade 3; n=0, 2, 5, 24, 5	0	0	0	0
Troponin I; Increase to Grade 4; n=0, 2, 5, 24, 5	0	0	0	0
Troponin T; Any grade increase; n=11, 4, 9, 31, 9	0	0	0	0
Troponin T; Increase to Grade 3; n=11, 4, 9, 31, 9	0	0	0	0
Troponin T; Increase to Grade 4; n=11, 4, 9, 31, 9	0	0	0	0

Urate; Any grade increase; n=10, 4, 9, 32, 9	1	0	1	0
Urate; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	0
Urate; Increase to Grade 4; n=10, 4, 9, 32, 9	1	0	1	0
Urea; Any grade increase; n=10, 4, 9, 31, 9	0	0	0	0
Urea; Increase to Grade 3; n=10, 4, 9, 31, 9	0	0	0	0
Urea; Increase to Grade 4; n=10, 4, 9, 31, 9	0	0	0	0

Notes:

[66] - All Treated Population

[67] - All Treated Population

[68] - All Treated Population

[69] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[70]			
Units: Participants				
Glucose; Any grade increase; n=10, 4, 9, 32, 9	6			
Glucose; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
Glucose; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
Albumin; Any grade increase; n=10, 4, 9, 32, 9	2			
Albumin; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
Albumin; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
ALP; Any grade increase; n=10, 4, 9, 31, 9	2			
ALP; Increase to Grade 3; n=10, 4, 9, 31, 9	0			
ALP; Increase to Grade 4; n=10, 4, 9, 31, 9	0			
ALT; Any grade increase; n=10, 4, 9, 32, 9	1			
ALT; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
ALT; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
Amylase; Any grade increase; n=10, 4, 9, 32, 9	3			
Amylase; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
Amylase; Increase to Grade 4; n=10, 4, 9, 32, 9	1			
AST; Any grade increase; n=10, 4, 9, 32, 9	4			
AST; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
AST; Increase to Grade 4; n=10, 4, 9, 32, 9	0			

Dir bil; Any grade increase; n=10, 4, 9, 30, 9	0			
Dir bil; Increase to Grade 3; n=10, 4, 9, 30, 9	0			
Dir bil; Increase to Grade 4; n=10, 4, 9, 30, 9	0			
Bilirubin; Any grade increase; n=10, 4, 9, 32, 9	1			
Bilirubin; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
Bilirubin; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
NT-BNP; Any grade increase; n=10, 4, 9, 30, 9	0			
NT-BNP; Increase to Grade 3; n=10, 4, 9, 30, 9	0			
NT-BNP; Increase to Grade 4; n=10, 4, 9, 30, 9	0			
Calcium; Any grade increase; n=10, 4, 9, 32, 9	3			
Calcium; Increase to Grade 3; n=10, 4, 9, 32, 9	1			
Calcium; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
Cholesterol; Any grade increase; n=8, 4, 7, 29, 9	0			
Cholesterol; Increase to Grade 3; n=8, 4, 7, 29, 9	0			
Cholesterol; Increase to Grade 4; n=8, 4, 7, 29, 9	0			
CK; Any grade increase; n=11, 4, 9, 31, 9	1			
CK; Increase to Grade 3; n=11, 4, 9, 31, 9	0			
CK; Increase to Grade 4; n=11, 4, 9, 31, 9	0			
Chloride; Any grade increase; n=10, 4, 9, 32, 9	0			
Chloride; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
Chloride; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
CO2; Any grade increase; n=10, 4, 9, 32, 9	0			
CO2; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
CO2; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
Creatinine; Any grade increase; n=10, 4, 9, 32, 9	0			
Creatinine; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
Creatinine; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
GGT; Any grade increase; n=9, 4, 9, 31, 7	1			
GGT; Increase to Grade 3; n=9, 4, 9, 31, 7	0			
GGT; Increase to Grade 4; n=9, 4, 9, 31, 7	0			
HDL; Any grade increase; n=8, 4, 7, 28, 9	0			

HDL; Increase to Grade 3; n=8, 4, 7, 28, 9	0			
HDL; Increase to Grade 4; n=8, 4, 7, 28, 9	0			
Insulin; Any grade increase; n=10, 4, 9, 31, 9	0			
Insulin; Increase to Grade 3; n=10, 4, 9, 31, 9	0			
Insulin; Increase to Grade 4; n=10, 4, 9, 31, 9	0			
Potassium; Any grade increase; n=11, 4, 9, 32, 9	7			
Potassium; Increase to Grade 3; n=11, 4, 9, 32, 9	0			
Potassium; Increase to Grade 4; n=11, 4, 9, 32, 9	0			
LDH; Any grade increase; n=0, 0, 1, 0, 0	99999			
LDH; Increase to Grade 3; n=0, 0, 1, 0, 0	99999			
LDH; Increase to Grade 4; n=0, 0, 1, 0, 0	99999			
LDL; Any grade increase; n=8, 4, 7, 28, 8	0			
LDL; Increase to Grade 3; n=8, 4, 7, 28, 8	0			
LDL; Increase to Grade 4; n=8, 4, 7, 28, 8	0			
Lipase; Any grade increase; n=10, 4, 9, 31, 9	1			
Lipase; Increase to Grade 3; n=10, 4, 9, 31, 9	0			
Lipase; Increase to Grade 4; n=10, 4, 9, 31, 9	1			
Magnesium; Any grade increase; n=11, 4, 9, 32, 9	4			
Magnesium; Increase to Grade 3; n=11, 4, 9, 32, 9	0			
Magnesium; Increase to Grade 4; n=11, 4, 9, 32, 9	0			
Protein; Any grade increase; n=10, 4, 9, 32, 9	0			
Protein; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
Protein; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
Sodium; Any grade increase; n=11, 4, 9, 32, 9	5			
Sodium; Increase to Grade 3; n=11, 4, 9, 32, 9	0			
Sodium; Increase to Grade 4; n=11, 4, 9, 32, 9	1			
Thyroxine; Any grade increase; n=8, 4, 7, 29, 9	0			
Thyroxine; Increase to Grade 3; n=8, 4, 7, 29, 9	0			
Thyroxine; Increase to Grade 4; n=8, 4, 7, 29, 9	0			
Testosterone; Any grade increase; n=1, 3, 3, 14, 7	0			
Testosterone; Increase to Grade 3; n=1, 3, 3, 14,7	0			

Testosterone; Increase to Grade 4; n=1, 3, 3, 14,7	0			
Triglycerides; Any grade increase; n=8,4,7,29,9	2			
Triglycerides; Increase to Grade 3; n=8,4,7,29,9	0			
Triglycerides; Increase to Grade 4; n=8,4,7,29,9	0			
Troponin I; Any grade increase; n=0, 2, 5, 24, 5	0			
Troponin I; Increase to Grade 3; n=0, 2, 5, 24, 5	0			
Troponin I; Increase to Grade 4; n=0, 2, 5, 24, 5	0			
Troponin T; Any grade increase; n=11, 4, 9, 31, 9	0			
Troponin T; Increase to Grade 3; n=11, 4, 9, 31, 9	0			
Troponin T; Increase to Grade 4; n=11, 4, 9, 31, 9	0			
Urate; Any grade increase; n=10, 4, 9, 32, 9	1			
Urate; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
Urate; Increase to Grade 4; n=10, 4, 9, 32, 9	1			
Urea; Any grade increase; n=10, 4, 9, 31, 9	0			
Urea; Increase to Grade 3; n=10, 4, 9, 31, 9	0			
Urea; Increase to Grade 4; n=10, 4, 9, 31, 9	0			

Notes:

[70] - All Treated Population. To better interpret data low doses were combined

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with grade change from Baseline in clinical chemistry data-Part 1 BID

End point title	Number of participants with grade change from Baseline in clinical chemistry data-Part 1 BID[71][72]

End point description:

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life–threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post-Baseline is presented. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Notes:

[71] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[72] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[73]	10[74]	5[75]	
Units: Participants				
Glucose; Any grade increase; n=4, 10, 5	1	9	5	
Glucose; Increase to Grade 3; n=4, 10, 5	1	3	1	
Glucose; Increase to Grade 4; n=4, 10, 5	0	0	0	
Albumin; Any grade increase; n=4, 10, 5	0	4	1	
Albumin; Increase to Grade 3; n=4, 10, 5	0	0	0	
Albumin; Increase to Grade 4; n=4, 10, 5	0	0	0	
ALP; Any grade increase; n=4, 10, 5	0	4	2	
ALP; Increase to Grade 3; n=4, 10, 5	0	2	0	
ALP; Increase to Grade 4; n=4, 10, 5	0	0	0	
ALT; Any grade increase; n=4, 10, 5	0	5	1	
ALT; Increase to Grade 3; n=4, 10, 5	0	1	0	
ALT; Increase to Grade 4; n=4, 10, 5	0	0	0	
Amylase; Any grade increase; n=4, 10, 5	0	2	2	
Amylase; Increase to Grade 3; n=4, 10, 5	0	0	0	
Amylase; Increase to Grade 4; n=4, 10, 5	0	0	0	
AST; Any grade increase; n=4, 10, 5	2	6	1	
AST; Increase to Grade 3; n=4, 10, 5	0	2	0	
AST; Increase to Grade 4; n=4, 10, 5	0	0	0	
Dir bil; Any grade increase; n=4, 9, 4	0	0	0	
Dir bil; Increase to Grade 3; n=4, 9, 4	0	0	0	
Dir bil; Increase to Grade 4; n=4, 9, 4	0	0	0	
Bilirubin; Any grade increase; n=4, 10, 5	1	7	2	
Bilirubin; Increase to Grade 3; n=4, 10, 5	1	1	1	
Bilirubin; Increase to Grade 4; n=4, 10, 5	0	1	0	
NT-BNP; Any grade increase; n=4, 10, 5	0	0	0	
NT-BNP; Increase to Grade 3; n=4, 10, 5	0	0	0	
NT-BNP; Increase to Grade 4; n=4, 10, 5	0	0	0	
Calcium; Any grade increase; n=4, 10, 5	1	2	1	

Calcium; Increase to Grade 3; n=4, 10, 5	0	0	0	
Calcium; Increase to Grade 4; n=4, 10, 5	0	0	0	
Cholesterol; Any grade increase; n=2, 9, 5	0	2	0	
Cholesterol; Increase to Grade 3; n=2, 9, 5	0	0	0	
Cholesterol; Increase to Grade 4; n=2, 9, 5	0	0	0	
CK; Any grade increase; n=4, 10, 5	0	3	2	
CK; Increase to Grade 3; n=n=4, 10, 5	0	0	0	
CK; Increase to Grade 4; n=n=4, 10, 5	0	0	0	
Chloride; Any grade increase; n=4, 10, 5	0	0	0	
Chloride; Increase to Grade 3; n=4, 10, 5	0	0	0	
Chloride; Increase to Grade 4; n=4, 10, 5	0	0	0	
CO2; Any grade increase; n=4, 10, 5	0	0	0	
CO2; Increase to Grade 3; n=4, 10, 5	0	0	0	
CO2; Increase to Grade 4; n=4, 10, 5	0	0	0	
Creatinine; Any grade increase; n=4, 10, 5	0	2	2	
Creatinine; Increase to Grade 3; n=4, 10, 5	0	0	0	
Creatinine; Increase to Grade 4; n=4, 10, 5	0	0	0	
GGT; Any grade increase; n=4, 10, 5	0	4	1	
GGT; Increase to Grade 3; n=4, 10, 5	0	1	0	
GGT; Increase to Grade 4; n=4, 10, 5	0	1	0	
HDL; Any grade increase; n=2, 9, 5	0	0	0	
HDL; Increase to Grade 3; n=2, 9, 5	0	0	0	
HDL; Increase to Grade 4; n=2, 9, 5	0	0	0	
Insulin; Any grade increase; n=4, 10, 5	0	0	0	
Insulin; Increase to Grade 3; n=4, 10, 5	0	0	0	
Insulin; Increase to Grade 4; n=4, 10, 5	0	0	0	
Potassium; Any grade increase; n=4, 10, 5	1	5	2	
Potassium; Increase to Grade 3; n=4, 10, 5	0	0	0	
Potassium; Increase to Grade 4; n=4, 10, 5	0	0	0	
LDL; Any grade increase; n=2, 9, 5	0	0	0	
LDL; Increase to Grade 3; n=2, 9, 5	0	0	0	
LDL; Increase to Grade 4; n=2, 9, 5	0	0	0	
Lipase; Any grade increase; n=4, 10, 5	0	2	3	
Lipase; Increase to Grade 3; n=4, 10, 5	0	1	0	
Lipase; Increase to Grade 4; n=4, 10, 5	0	0	0	
Magnesium; Any grade increase; n=4, 10, 5	0	2	2	
Magnesium; Increase to Grade 3; n=4, 10, 5	0	0	0	
Magnesium; Increase to Grade 4; n=4, 10, 5	0	1	0	
Protein; Any grade increase; n=4, 10, 5	0	0	0	
Protein; Increase to Grade 3; n=4, 10, 5	0	0	0	

Protein; Increase to Grade 4; n=4, 10, 5	0	0	0	
Sodium; Any grade increase; n=4, 10, 5	0	7	2	
Sodium; Increase to Grade 3; n=4, 10, 5	0	2	0	
Sodium; Increase to Grade 4; n=4, 10, 5	0	0	0	
Thyroxine; Any grade increase; n=3, 9, 5	0	0	0	
Thyroxine; Increase to Grade 3; n=3, 9, 5	0	0	0	
Thyroxine; Increase to Grade 4; n=3, 9, 5	0	0	0	
Testosterone; Any grade increase; n=1, 4, 4	0	0	0	
Testosterone; Increase to Grade 3; n=1, 4, 4	0	0	0	
Testosterone; Increase to Grade 4; n=1, 4, 4	0	0	0	
Triglycerides; Any grade increase; n=2, 9, 5	0	4	4	
Triglycerides; Increase to Grade 3; n=2, 9, 5	0	0	0	
Triglycerides; Increase to Grade 4; n=2, 9, 5	0	0	0	
Troponin I; Any grade increase; n=3, 10, 5	0	0	0	
Troponin I; Increase to Grade 3; n=3, 10, 5	0	0	0	
Troponin I; Increase to Grade 4; n=3, 10, 5	0	0	0	
Troponin T; Any grade increase; n=4, 10, 5	0	0	0	
Troponin T; Increase to Grade 3; n=4, 10, 5	0	0	0	
Troponin T; Increase to Grade 4; n=4, 10, 5	0	0	0	
Urate; Any grade increase; n=4, 10, 5	0	0	0	
Urate; Increase to Grade 3; n=4, 10, 5	0	0	0	
Urate; Increase to Grade 4; n=4, 10, 5	0	0	0	
Urea; Any grade increase; n=4, 10, 5	0	0	0	
Urea; Increase to Grade 3; n=4, 10, 5	0	0	0	
Urea; Increase to Grade 4; n=4, 10, 5	0	0	0	

Notes:

[73] - All Treated Population

[74] - All Treated Population

[75] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with grade change from Baseline in clinical chemistry data-Part 2

End point title	Number of participants with grade change from Baseline in clinical chemistry data-Part 2[76][77]

End point description:

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT,

HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides (triglyc), troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life–threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post-Baseline is presented. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Notes:

[76] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[77] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 2: Participants with NMC	Part 2: Participants with SCLC	Part 2: Participants with CRPC	Part 2: Participants with TNBC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12[78]	14[79]	23[80]	19[81]
Units: Participants				
Glucose; Any grade increase; n=11,13,23,19,21,12	10	10	20	16
Glucose; Increase to Grade 3; n=11,13,23,19,21,12	0	0	0	0
Glucose; Increase to Grade 4; n=11,13,23,19,21,12	0	0	0	0
Albumin; Any grade increase; n=11,13,23,19,21,12	5	6	9	8
Albumin; Increase to Grade 3; n=11,13,23,19,21,12	0	0	0	0
Albumin; Increase to Grade 4; n=11,13,23,19,21,12	0	0	0	0
ALP; Any grade increase; n=11,13,23,19,21,12	3	1	6	3
ALP; Increase to Grade 3; n=11,13,23,19,21,12	0	0	2	0
ALP; Increase to Grade 4; n=11,13,23,19,21,12	0	0	0	0
ALT; Any grade increase; n=11,14,23,19,21,12	3	6	6	5
ALT; Increase to Grade 3; n=11,14,23,19,21,12	0	1	0	0
ALT; Increase to Grade 4; n=11,14,23,19,21,12	0	0	0	0
Amylase; Any grade increase; n=11,12,22,19,20,12	5	5	9	5
Amylase; Increase to Grade 3; n=11,12,22,19,20,12	1	2	2	2
Amylase; Increase to Grade 4; n=11,12,22,19,20,12	0	0	0	0
AST; Any grade increase; n=11,13,23,19,21,12	3	5	10	8
AST; Increase to Grade 3; n=11,13,23,19,21,12	0	0	1	1
AST; Increase to Grade 4; n=11,13,23,19,21,12	0	0	0	0

Dir bil; Any grade increase; n=11,13,23,19,20,12	0	0	0	0
Dir bil; Increase to Grade 3; n=11,13,23,19,20,12	0	0	0	0
Dir bil; Increase to Grade 4; n=11,13,23,19,20,12	0	0	0	0
Bilirubin;Any grade increase;n=11,14,23,19,21,12	8	10	13	6
Bilirubin;Increase to Grade 3; n=11,14,23,19,21,12	1	1	2	0
Bilirubin;Increase to Grade 4; n=11,14,23,19,21,12	0	0	0	0
NT-BNP; Any grade increase; n=11,12,22,17,15,12	0	0	0	0
NT-BNP; Increase to Grade 3; n=11,12,22,17,15,12	0	0	0	0
NT-BNP; Increase to Grade 4; n=11,12,22,17,15,12	0	0	0	0
Calcium; Any grade increase; n=11,13,23,19,21,12	6	3	8	4
Calcium; Increase to Grade 3; n=11,13,23,19,21,12	1	0	2	0
Calcium; Increase to Grade 4; n=11,13,23,19,21,12	0	0	0	0
Cholesterol;Any grade increase;n=10,12,22,19,20,12	5	2	2	2
Cholesterol;Increase to Grade3;n=10,12,22,19,20,12	0	0	0	0
Cholesterol;Increase to Grade4;n=10,12,22,19,20,12	0	0	0	0
CK; Any grade increase; n=9,9,21,17,18,11	3	2	4	0
CK; Increase to Grade 3; n=9,9,21,17,18,11	0	0	0	0
CK; Increase to Grade 4; n=9,9,21,17,18,11	0	0	0	0
Chloride; Any grade increase; n=11,13,23,19,21,12	0	0	0	0
Chloride; Increase to Grade 3; n=11,13,23,19,21,12	0	0	0	0
Chloride; Increase to Grade 4; n=11,13,23,19,21,12	0	0	0	0
CO2; Any grade increase; n=11,12,23,19,21,12	0	0	0	0
CO2; Increase to Grade 3; n=11,12,23,19,21,12	0	0	0	0
CO2; Increase to Grade 4; n=11,12,23,19,21,12	0	0	0	0
Creatinine;Any grade increase;n=11,14,23,19,21,12	3	4	9	2
Creatinine;Increase to Grade3;n=11,14,23,19,21,12	0	0	2	0
Creatinine;Increase to Grade4;n=11,14,23,19,21,12	0	0	1	0
GGT; Any grade increase; n=11,13,22,19,20,12	0	3	7	5
GGT; Increase to Grade 3; n=11,13,22,19,20,12	0	0	2	2
GGT; Increase to Grade 4; n=11,13,22,19,20,12	0	0	0	0
HDL; Any grade increase; n=10,10,22,19,19,12	0	0	0	0

HDL; Increase to Grade 3; n=10,10,22,19,19,12	0	0	0	0
HDL; Increase to Grade 4;n=10,10,22,19,19,12	0	0	0	0
Insulin; Any grade increase; n=11,12,22,19,20,12	0	0	0	0
Insulin; Increase to Grade 3; n=11,12,22,19,20,12	0	0	0	0
Insulin; Increase to Grade 4; n=11,12,22,19,20,12	0	0	0	0
Potassium; Any grade increase; n=11,14,23,19,21,12	6	4	10	5
Potassium;Increase to Grade3;n=11,14,23,19,21,12	0	0	1	0
Potassium;Increase to Grade4;n=11,14,23,19,21,12	0	0	0	0
LDL; Any grade increase; n=10,10,22,19,19,12	0	0	0	0
LDL; Increase to Grade 3; n=10,10,22,19,19,12	0	0	0	0
LDL; Increase to Grade 4;n=10,10,22,19,19,12	0	0	0	0
Lipase; Any grade increase; n=11,12,22,19,20,12	3	5	7	5
Lipase; Increase to Grade 3;n=11,12,22,19,20,12	2	3	0	1
Lipase; Increase to Grade 4;n=11,12,22,19,20,12	0	0	0	1
Magnesium; Any grade increase; n=11,12,22,19,21,12	2	2	5	1
Magnesium; Increase to Grade 3;n=11,12,22,19,21,12	0	0	0	0
Magnesium; Increase to Grade4;n=11,12,22,19,21,12	0	0	0	0
Protein; Any grade increase; n=11,13,23,19,21,12	0	0	0	0
Protein; Increase to Grade 3;n=11,13,23,19,21,12	0	0	0	0
Protein; Increase to Grade 4;n=11,13,23,19,21,12	0	0	0	0
Sodium; Any grade increase; n=11, 14,23,19,21,12	5	5	8	5
Sodium; Increase to Grade 3; n=11, 14,23,19,21,12	0	1	1	2
Sodium; Increase to Grade 4; n=11, 14,23,19,21,12	1	0	0	0
Thyroxine; Any grade increase;n=7,7,20,15,18,8	0	0	0	0
Thyroxine; Increase to Grade3;n=7,7,20,15,18,8	0	0	0	0
Thyroxine; Increase to Grade4;n=7,7,20,15,18,8	0	0	0	0
Testosterone; Any grade increase; n=4,3,18,0,1,5	0	0	0	0
Testosterone; Increase to Grade3; n=4,3,18,0,1,5	0	0	0	0
Testosterone; Increase to Grade4; n=4,3,18,0,1,5	0	0	0	0
Triglyc;Any grade increase;n=10,12,22,19,20,12	7	7	15	10
Triglyc;Increase to Grade3;n=10,12,22,19,20,12	1	0	4	0

Triglyc;Increase to Grade4;n=10,12,22,19,20,12	0	0	0	0
Troponin I; Any grade increase; n=7,6,15,15,14,7	0	0	0	0
Troponin I; Increase to Grade 3; n=7,6,15,15,14,7	0	0	0	0
Troponin I; Increase to Grade 4; n=7,6,15,15,14,7	0	0	0	0
Troponin T;Any grade increase;n=11,12,22,19,20,12	0	0	0	0
Troponin T;Increase to Grade3;n=11,12,22,19,20,12	0	0	0	0
Troponin T;Increase to Grade4;n=11,12,22,19,20,12	0	0	0	0
Urate; Any grade increase; n=11,12,22,19,20,12	0	0	2	0
Urate; Increase to Grade 3; n=11,12,22,19,20,12	0	0	0	0
Urate; Increase to Grade 4; n=11,12,22,19,20,12	0	0	2	0
Urea; Any grade increase; n=11,14,23,17,17,11	0	0	0	0
Urea; Increase to Grade 3; n=11,14,23,17,17,11	0	0	0	0
Urea; Increase to Grade 4;n=11,14,23,17,17,11	0	0	0	0

Notes:

[78] - All Treated Population

[79] - All Treated Population

[80] - All Treated Population

[81] - All Treated Population

End point values	Part 2: Participants with ER+BC	Part 2: Participants with GIST		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	21[82]	13[83]		
Units: Participants				
Glucose; Any grade increase; n=11,13,23,19,21,12	18	9		
Glucose; Increase to Grade 3; n=11,13,23,19,21,12	1	2		
Glucose; Increase to Grade 4; n=11,13,23,19,21,12	0	0		
Albumin; Any grade increase; n=11,13,23,19,21,12	7	5		
Albumin; Increase to Grade 3; n=11,13,23,19,21,12	1	0		
Albumin; Increase to Grade 4; n=11,13,23,19,21,12	0	0		
ALP; Any grade increase; n=11,13,23,19,21,12	4	4		
ALP; Increase to Grade 3; n=11,13,23,19,21,12	0	0		
ALP; Increase to Grade 4; n=11,13,23,19,21,12	0	0		
ALT; Any grade increase; n=11,14,23,19,21,12	12	3		
ALT; Increase to Grade 3; n=11,14,23,19,21,12	0	0		

ALT; Increase to Grade 4; n=11,14,23,19,21,12	0	0		
Amylase; Any grade increase; n=11,12,22,19,20,12	6	1		
Amylase; Increase to Grade 3; n=11,12,22,19,20,12	2	0		
Amylase; Increase to Grade 4; n=11,12,22,19,20,12	0	0		
AST; Any grade increase; n=11,13,23,19,21,12	14	6		
AST; Increase to Grade 3; n=11,13,23,19,21,12	3	0		
AST; Increase to Grade 4; n=11,13,23,19,21,12	0	0		
Dir bil; Any grade increase; n=11,13,23,19,20,12	0	0		
Dir bil; Increase to Grade 3; n=11,13,23,19,20,12	0	0		
Dir bil; Increase to Grade 4; n=11,13,23,19,20,12	0	0		
Bilirubin;Any grade increase;n=11,14,23,19,21,12	13	4		
Bilirubin;Increase to Grade 3; n=11,14,23,19,21,12	3	0		
Bilirubin;Increase to Grade 4; n=11,14,23,19,21,12	0	0		
NT-BNP; Any grade increase; n=11,12,22,17,15,12	0	0		
NT-BNP; Increase to Grade 3; n=11,12,22,17,15,12	0	0		
NT-BNP; Increase to Grade 4; n=11,12,22,17,15,12	0	0		
Calcium; Any grade increase; n=11,13,23,19,21,12	3	3		
Calcium; Increase to Grade 3; n=11,13,23,19,21,12	1	0		
Calcium; Increase to Grade 4; n=11,13,23,19,21,12	0	0		
Cholesterol;Any grade increase;n=10,12,22,19,20,12	9	5		
Cholesterol;Increase to Grade3;n=10,12,22,19,20,12	0	0		
Cholesterol;Increase to Grade4;n=10,12,22,19,20,12	0	0		
CK; Any grade increase; n=9,9,21,17,18,11	7	5		
CK; Increase to Grade 3; n=9,9,21,17,18,11	0	0		
CK; Increase to Grade 4; n=9,9,21,17,18,11	0	0		
Chloride; Any grade increase; n=11,13,23,19,21,12	0	0		
Chloride; Increase to Grade 3; n=11,13,23,19,21,12	0	0		
Chloride; Increase to Grade 4; n=11,13,23,19,21,12	0	0		
CO2; Any grade increase; n=11,12,23,19,21,12	0	0		
CO2; Increase to Grade 3; n=11,12,23,19,21,12	0	0		
CO2; Increase to Grade 4; n=11,12,23,19,21,12	0	0		

Creatinine;Any grade increase;n=11,14,23,19,21,12	6	3		
Creatinine;Increase to Grade3;n=11,14,23,19,21,12	0	0		
Creatinine;Increase to Grade4;n=11,14,23,19,21,12	0	0		
GGT; Any grade increase; n=11,13,22,19,20,12	6	1		
GGT; Increase to Grade 3; n=11,13,22,19,20,12	3	0		
GGT; Increase to Grade 4; n=11,13,22,19,20,12	1	0		
HDL; Any grade increase; n=10,10,22,19,19,12	0	0		
HDL; Increase to Grade 3; n=10,10,22,19,19,12	0	0		
HDL; Increase to Grade 4;n=10,10,22,19,19,12	0	0		
Insulin; Any grade increase; n=11,12,22,19,20,12	0	0		
Insulin; Increase to Grade 3; n=11,12,22,19,20,12	0	0		
Insulin; Increase to Grade 4; n=11,12,22,19,20,12	0	0		
Potassium; Any grade increase; n=11,14,23,19,21,12	7	7		
Potassium;Increase to Grade3;n=11,14,23,19,21,12	0	1		
Potassium;Increase to Grade4;n=11,14,23,19,21,12	0	0		
LDL; Any grade increase; n=10,10,22,19,19,12	0	0		
LDL; Increase to Grade 3; n=10,10,22,19,19,12	0	0		
LDL; Increase to Grade 4;n=10,10,22,19,19,12	0	0		
Lipase; Any grade increase; n=11,12,22,19,20,12	4	2		
Lipase; Increase to Grade 3;n=11,12,22,19,20,12	0	0		
Lipase; Increase to Grade 4;n=11,12,22,19,20,12	1	0		
Magnesium; Any grade increase; n=11,12,22,19,21,12	4	1		
Magnesium; Increase to Grade 3;n=11,12,22,19,21,12	0	0		
Magnesium; Increase to Grade4;n=11,12,22,19,21,12	0	0		
Protein; Any grade increase; n=11,13,23,19,21,12	0	0		
Protein; Increase to Grade 3;n=11,13,23,19,21,12	0	0		
Protein; Increase to Grade 4;n=11,13,23,19,21,12	0	0		
Sodium; Any grade increase; n=11, 14,23,19,21,12	4	5		
Sodium; Increase to Grade 3; n=11, 14,23,19,21,12	0	2		
Sodium; Increase to Grade 4; n=11, 14,23,19,21,12	0	0		
Thyroxine; Any grade increase;n=7,7,20,15,18,8	0	0		

Thyroxine; Increase to Grade3;n=7,7,20,15,18,8	0	0		
Thyroxine; Increase to Grade4;n=7,7,20,15,18,8	0	0		
Testosterone; Any grade increase; n=4,3,18,0,1,5	0	0		
Testosterone; Increase to Grade3; n=4,3,18,0,1,5	0	0		
Testosterone; Increase to Grade4; n=4,3,18,0,1,5	0	0		
Triglyc;Any grade increase;n=10,12,22,19,20,12	11	8		
Triglyc;Increase to Grade3;n=10,12,22,19,20,12	1	0		
Triglyc;Increase to Grade4;n=10,12,22,19,20,12	0	0		
Troponin I; Any grade increase; n=7,6,15,15,14,7	0	0		
Troponin I; Increase to Grade 3; n=7,6,15,15,14,7	0	0		
Troponin I; Increase to Grade 4; n=7,6,15,15,14,7	0	0		
Troponin T;Any grade increase;n=11,12,22,19,20,12	0	0		
Troponin T;Increase to Grade3;n=11,12,22,19,20,12	0	0		
Troponin T;Increase to Grade4;n=11,12,22,19,20,12	0	0		
Urate; Any grade increase; n=11,12,22,19,20,12	0	2		
Urate; Increase to Grade 3; n=11,12,22,19,20,12	0	0		
Urate; Increase to Grade 4; n=11,12,22,19,20,12	0	2		
Urea; Any grade increase; n=11,14,23,17,17,11	0	0		
Urea; Increase to Grade 3; n=11,14,23,17,17,11	0	0		
Urea; Increase to Grade 4;n=11,14,23,17,17,11	0	0		

Notes:

[82] - All Treated Population

[83] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with grade change from Baseline in clinical chemistry data-Besylate sub-study

End point title	Number of participants with grade change from Baseline in clinical chemistry data-Besylate sub-study[84]

End point description:

Blood samples were collected for the analysis of clinical chemistry parameters: glucose, albumin, ALP, ALT, amylase, AST, Dir bil, bilirubin, NT-BNP, calcium, cholesterol, CK, chloride, CO2, creatinine, GGT, HDL and LDL cholesterol, insulin, potassium, LDH, lipase, magnesium, protein, sodium, thyroxine, testosterone, triglycerides, troponin I and T, urate and urea. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life–threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Data for Besylate sub-study participants were combined for analysis to provide useful

interpretation of study data as pre-specified in RAP. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

Notes:

[84] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[85]			
Units: Participants				
Glucose; Any grade increase; n=10	9			
Glucose; Increase to Grade 3; n=10	0			
Glucose; Increase to Grade 4; n=10	0			
Albumin; Any grade increase; n=10	6			
Albumin; Increase to Grade 3; n=10	1			
Albumin; Increase to Grade 4; n=10	0			
ALP; Any grade increase; n=10	1			
ALP; Increase to Grade 3; n=10	0			
ALP; Increase to Grade 4; n=10	0			
ALT; Any grade increase; n=10	2			
ALT; Increase to Grade 3; n=10	0			
ALT; Increase to Grade 4; n=10	0			
Amylase; Any grade increase; n=10	0			
Amylase; Increase to Grade 3; n=10	0			
Amylase; Increase to Grade 4; n=10	0			
AST; Any grade increase; n=10	3			
AST; Increase to Grade 3; n=10	0			
AST; Increase to Grade 4; n=10	0			
Dir bil; Any grade increase; n=10	0			
Dir bil; Increase to Grade 3; n=10	0			
Dir bil; Increase to Grade 4; n=10	0			
Bilirubin; Any grade increase; n=10	7			
Bilirubin; Increase to Grade 3; n=10	3			
Bilirubin; Increase to Grade 4; n=10	0			
NT-BNP; Any grade increase; n=10	0			
NT-BNP; Increase to Grade 3; n=10	0			
NT-BNP; Increase to Grade 4; n=10	0			
Calcium; Any grade increase; n=10	3			
Calcium; Increase to Grade 3; n=10	0			
Calcium; Increase to Grade 4; n=10	0			
Cholesterol; Any grade increase; n=8	1			
Cholesterol; Increase to Grade 3; n=8	0			
Cholesterol; Increase to Grade 4; n=8	0			
CK; Any grade increase; n=10	2			
CK; Increase to Grade 3; n=10	0			
CK; Increase to Grade 4; n=10	0			
Chloride; Any grade increase; n=10	0			

Chloride; Increase to Grade 3; n=10	0			
Chloride; Increase to Grade 4; n=10	0			
CO2; Any grade increase; n=10	0			
CO2; Increase to Grade 3; n=10	0			
CO2; Increase to Grade 4; n=10	0			
Creatinine; Any grade increase; n=10	2			
Creatinine; Increase to Grade 3; n=10	0			
Creatinine; Increase to Grade 4; n=10	0			
GGT; Any grade increase; n=10	0			
GGT; Increase to Grade 3; n=10	0			
GGT; Increase to Grade 4; n=10	0			
HDL; Any grade increase; n=8	0			
HDL; Increase to Grade 3; n=8	0			
HDL; Increase to Grade 4; n=8	0			
Insulin; Any grade increase; n=10	0			
Insulin; Increase to Grade 3; n=10	0			
Insulin; Increase to Grade 4; n=10	0			
Potassium; Any grade increase; n=10	6			
Potassium; Increase to Grade 3; n=10	0			
Potassium; Increase to Grade 4; n=10	0			
LDL; Any grade increase; n=8	0			
LDL; Increase to Grade 3; n=8	0			
LDL; Increase to Grade 4; n=8	0			
Lipase; Any grade increase; n=9	0			
Lipase; Increase to Grade 3; n=9	0			
Lipase; Increase to Grade 4;n=9	0			
Magnesium; Any grade increase; n=10	3			
Magnesium; Increase to Grade 3; n=10	1			
Magnesium; Increase to Grade 4; n=10	0			
Protein; Any grade increase; n=10	0			
Protein; Increase to Grade 3; n=10	0			
Protein; Increase to Grade 4; n=10	0			
Sodium; Any grade increase; n=10	5			
Sodium; Increase to Grade 3; n=10	1			
Sodium; Increase to Grade 4; n=10	0			
Thyroxine; Any grade increase; n=8	0			
Thyroxine; Increase to Grade 3; n=8	0			
Thyroxine; Increase to Grade 4; n=8	0			
Testosterone; Any grade increase; n=3	0			
Testosterone; Increase to Grade 3; n=3	0			
Testosterone; Increase to Grade 4; n=3	0			
Triglycerides; Any grade increase; n=8	3			
Triglycerides; Increase to Grade 3; n=8	0			
Triglycerides; Increase to Grade 4; n=8	0			
Troponin I; Any grade increase; n=1	0			
Troponin I; Increase to Grade 3; n=1	0			
Troponin I; Increase to Grade 4; n=1	0			
Troponin T; Any grade increase; n=10	0			
Troponin T; Increase to Grade 3; n=10	0			
Troponin T; Increase to Grade 4; n=10	0			
Urate; Any grade increase; n=10	0			
Urate; Increase to Grade 3; n=10	0			

Urate; Increase to Grade 4; n=10	0			
Urea; Any grade increase; n=10	0			
Urea; Increase to Grade 3; n=10	0			
Urea; Increase to Grade 4; n=10	0			

Notes:

[85] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with grade change from Baseline in hematology data-Part 1 QD

End point title	Number of participants with grade change from Baseline in hematology data-Part 1 QD[86][87]

End point description:

Blood samples were collected for the analysis of hematology parameters: activated partial thromboplastin time (aPTT), platelet count, red blood cell count (RBC), white blood cell count (WBC), prothrombin international normalized ratio (INR), prothrombin time (PT), fibrinogen (Fib), hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life–threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

Notes:

[86] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[87] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[88]	9[89]	32[90]	9[91]
Units: Participants				
Basophils; Any grade increase; n=10, 4, 9, 32, 9	0	0	0	0
Basophils; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	0
Basophils; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
Eosinophils; Any grade increase; n=10, 4, 9, 32, 9	0	0	0	0
Eosinophils; Increase to Grade3; n=10,4,9,32,9	0	0	0	0
Eosinophils; Increase to Grade4; n=10,4,9,32,9	0	0	0	0
Hemoglobin; Any grade increase; n=10, 4, 9, 32, 9	2	2	21	7

Hemoglobin; Increase to Grade 3; n=10, 4, 9, 32, 9	1	1	9	1
Hemoglobin; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
INR; Any grade increase; n=10, 4, 9, 32, 9	0	1	21	2
INR; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	0
INR; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
Lymphocytes; Any grade increase; n=10, 4, 9, 32, 9	2	5	19	4
Lymphocytes; Increase to Grade3; n=10,4,9,32,9	0	2	8	1
Lymphocytes; Increase to Grade4; n=10,4,9,32,9	0	0	1	1
Monocytes; Any grade increase; n=10,4,9,32,9	0	0	0	0
Monocytes;Increase to Grade3; n=10,4,9,32,9	0	0	0	0
Monocytes; Increase to Grade 4; n=10,4,9,32,9	0	0	0	0
Neutrophils; Any grade increase; n=10,4,9,32,9	0	0	7	3
Neutrophils; Increase to Grade 3; n=10,4,9,32,9	0	0	0	1
Neutrophils; Increase to Grade 4; n=10,4,9,32,9	0	0	1	0
Platelets; Any grade increase; n=10,4,9,32,9	2	5	26	8
Platelets; Increase to Grade 3; n=10,4,9,32,9	0	0	11	5
Platelets; Increase to Grade 4; n=10,4,9,32,9	0	1	5	2
PT; Any grade increase;n=10,4,9,32,9	0	0	0	0
PT; Increase to Grade 3; n=10,4,9,32,9	0	0	0	0
PT; Increase to Grade 4; n=10,4,9,32,9	0	0	0	0
RBC; Any grade increase; n=10, 4, 9, 32, 9	0	0	0	0
RBC; Increase to Grade 3; n=10, 4, 9, 32, 9	0	0	0	0
RBC; Increase to Grade 4; n=10, 4, 9, 32, 9	0	0	0	0
WBC; Any grade increase; n=10,4,9,32,9	0	3	11	5
WBC; Increase to Grade 3; n=10,4,9,32,9	0	0	0	1
WBC; Increase to Grade 4; n=10,4,9,32,9	0	0	1	0
Fib; Any grade increase; n=9, 4, 9, 32, 9	0	0	4	0
Fib; Increase to Grade 3; n=9, 4, 9, 32, 9	0	0	0	0
Fib; Increase to Grade 4; n=9, 4, 9, 32, 9	0	0	0	0
aPTT; Any grade increase; n=10,4,9,32,9	0	0	14	2
aPTT; Increase to Grade 3; n=10,4,9,32,9	0	0	1	0
aPTT; Increase to Grade 4; n=10,4,9,32,9	0	0	0	0

Notes:

[88] - All Treated Population

[89] - All Treated Population

[90] - All Treated Population

[91] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[92]			
Units: Participants				
Basophils; Any grade increase; n=10, 4, 9, 32, 9	0			
Basophils; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
Basophils; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
Eosinophils; Any grade increase; n=10, 4, 9, 32, 9	0			
Eosinophils; Increase to Grade3; n=10,4,9,32,9	0			
Eosinophils; Increase to Grade4; n=10,4,9,32,9	0			
Hemoglobin; Any grade increase; n=10, 4, 9, 32, 9	4			
Hemoglobin; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
Hemoglobin; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
INR; Any grade increase; n=10, 4, 9, 32, 9	5			
INR; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
INR; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
Lymphocytes; Any grade increase; n=10, 4, 9, 32, 9	4			
Lymphocytes; Increase to Grade3; n=10,4,9,32,9	1			
Lymphocytes; Increase to Grade4; n=10,4,9,32,9	0			
Monocytes; Any grade increase; n=10,4,9,32,9	0			
Monocytes;Increase to Grade3; n=10,4,9,32,9	0			
Monocytes; Increase to Grade 4; n=10,4,9,32,9	0			
Neutrophils; Any grade increase; n=10,4,9,32,9	0			
Neutrophils; Increase to Grade 3; n=10,4,9,32,9	0			
Neutrophils; Increase to Grade 4; n=10,4,9,32,9	0			
Platelets; Any grade increase; n=10,4,9,32,9	1			
Platelets; Increase to Grade 3; n=10,4,9,32,9	1			
Platelets; Increase to Grade 4; n=10,4,9,32,9	0			

PT; Any grade increase;n=10,4,9,32,9	0			
PT; Increase to Grade 3; n=10,4,9,32,9	0			
PT; Increase to Grade 4; n=10,4,9,32,9	0			
RBC; Any grade increase; n=10, 4, 9, 32, 9	0			
RBC; Increase to Grade 3; n=10, 4, 9, 32, 9	0			
RBC; Increase to Grade 4; n=10, 4, 9, 32, 9	0			
WBC; Any grade increase; n=10,4,9,32,9	1			
WBC; Increase to Grade 3; n=10,4,9,32,9	0			
WBC; Increase to Grade 4; n=10,4,9,32,9	0			
Fib; Any grade increase; n=9, 4, 9, 32, 9	0			
Fib; Increase to Grade 3; n=9, 4, 9, 32, 9	0			
Fib; Increase to Grade 4; n=9, 4, 9, 32, 9	0			
aPTT; Any grade increase; n=10,4,9,32,9	0			
aPTT; Increase to Grade 3; n=10,4,9,32,9	0			
aPTT; Increase to Grade 4; n=10,4,9,32,9	0			

Notes:

[92] - All Treated Population. Low doses were combined to better interpret data

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with grade change from Baseline in hematology data-Part 1 BID

End point title	Number of participants with grade change from Baseline in hematology data-Part 1 BID[93][94]

End point description:

Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life–threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Notes:

[93] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[94] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[95]	10[96]	5[97]	
Units: Participants				
Basophils; Any grade increase; n=4,10,5	0	0	0	
Basophils; Increase to Grade 3; n=4,10,5	0	0	0	
Basophils; Increase to Grade 4; n=4,10,5	0	0	0	
Eosinophils; Any grade increase; n=4,10,5	0	0	0	
Eosinophils; Increase to Grade3; n=4,10,5	0	0	0	
Eosinophils; Increase to Grade4; n=4,10,5	0	0	0	
Hemoglobin; Any grade increase; n=4,10,5	4	8	4	
Hemoglobin; Increase to Grade 3; n=4,10,5	0	3	2	
Hemoglobin; Increase to Grade 4; n=4,10,5	0	0	0	
INR; Any grade increase; n=4,10,5	0	6	3	
INR; Increase to Grade 3; n=4,10,5	0	0	0	
INR; Increase to Grade 4; n=4,10,5	0	0	0	
Lymphocytes; Any grade increase; n=4,10,5	2	8	2	
Lymphocytes; Increase to Grade3; n=4,10,5	0	4	0	
Lymphocytes; Increase to Grade4; n=4,10,5	0	0	0	
Monocytes; Any grade increase; n=4,10,5	0	0	0	
Monocytes;Increase to Grade3; n=4,10,5	0	0	0	
Monocytes; Increase to Grade 4; n=4,10,5	0	0	0	
Neutrophils; Any grade increase; n=4,10,5	0	0	1	
Neutrophils; Increase to Grade 3; n=4,10,5	0	0	0	
Neutrophils; Increase to Grade 4; n=4,10,5	0	0	0	
Platelets; Any grade increase; n=4,10,5	1	10	5	
Platelets; Increase to Grade 3; n=4,10,5	0	2	2	
Platelets; Increase to Grade 4; n=4,10,5	0	0	1	
PT; Any grade increase;n=4,10,5	0	0	0	
PT; Increase to Grade 3; n=4,10,5	0	0	0	
PT; Increase to Grade 4; n=4,10,5	0	0	0	
RBC; Any grade increase; n=4,10,5	0	0	0	
RBC; Increase to Grade 3; n=4,10,5	0	0	0	
RBC; Increase to Grade 4; n=4,10,5	0	0	0	
WBC; Any grade increase; n=4,10,5	1	0	1	
WBC; Increase to Grade 3; n=4,10,5	0	0	0	
WBC; Increase to Grade 4; n=4,10,5	0	0	0	

Fib; Any grade increase; n=4,10,5	0	0	0	
Fib; Increase to Grade 3; n=4,10,5	0	0	0	
Fib; Increase to Grade 4; n=4,10,5	0	0	0	
aPTT; Any grade increase; n=4,10,5	0	5	2	
aPTT; Increase to Grade 3; n=4,10,5	0	0	0	
aPTT; Increase to Grade 4; n=4,10,5	0	0	0	

Notes:

[95] - All Treated Population

[96] - All Treated Population

[97] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with grade change from Baseline in hematology data-Part 2

End point title	Number of participants with grade change from Baseline in hematology data-Part 2[98]

End point description:

Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life–threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Notes:

[98] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	Participants with NMC	Participants with SCLC	Participants with CRPC	Participants with TNBC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	12[99]	14[100]	23[101]	19[102]
Units: Participants				
Basophils; Any grade increase; n=11,13,23,19,21,13	0	0	0	0
Basophils; Increase to Grade3; n=11,13,23,19,21,13	0	0	0	0
Basophils; Increase to Grade4; n=11,13,23,19,21,13	0	0	0	0
Eosinophils;Any grade increase;n=11,13,23,19,21,13	0	0	0	0
Eosinophils;Increase to Grade3;n=11,13,23,19,21,13	0	0	0	0
Eosinophils;Increase to Grade4;n=11,13,23,19,21,13	0	0	0	0
Hemoglobin;Any grade increase;n=11,14,23,19,21,13	6	10	18	10
Hemoglobin;Increase to Grade3;n=11,14,23,19,21,13	3	2	9	4
Hemoglobin;Increase to Grade4;n=11,14, 23,19,21,13	0	0	0	0

INR; Any grade increase; n=11,12,21,17,18,12	8	6	13	8
INR; Increase to Grade3; n=11,12,21,17,18,12	0	0	0	0
INR; Increase to Grade4; n=11,12,21,17,18,12	0	0	0	0
Lymphocytes;Any grade increase;n=11,13,23,19,21,13	8	7	14	9
Lymphocytes;Increase to Grade3;n=11,13,23,19,21,13	2	2	6	2
Lymphocytes;Increase to Grade4;n=11,13,23,19,21,13	0	1	0	0
Monocytes; Any grade increase; n=11,13,23,19,21,13	0	0	0	0
Monocytes;Increase to Grade3; n=11,13,23,19,21,13	0	0	0	0
Monocytes; Increase to Grade4; n=11,13,23,19,21,13	0	0	0	0
Neutrophils;Any grade increase;n=11,14,23,19,21,13	4	4	8	3
Neutrophils;Increase to Grade3;n=11,14,23,19,21,13	1	1	0	2
Neutrophils;Increase to Grade4;n=11,14,23,19,21,13	0	0	0	0
Platelets; Any grade increase; n=11,14,23,19,21,13	7	12	20	17
Platelets; Increase to Grade3; n=11,14,23,19,21,13	4	4	5	6
Platelets; Increase to Grade4; n=11,14,23,19,21,13	2	3	8	4
PT; Any grade increase;n=10,10, 18, 17, 18, 12	0	0	0	0
PT; Increase to Grade 3; n=10,10, 18, 17, 18, 12	0	0	0	0
PT; Increase to Grade 4; n=10,10, 18, 17, 18, 12	0	0	0	0
RBC; Any grade increase; n=11, 13, 23, 19, 21, 13	0	0	0	0
RBC; Increase to Grade 3; n=11, 13, 23, 19, 21, 13	0	0	0	0
RBC; Increase to Grade 4; n=11, 13, 23, 19, 21, 13	0	0	0	0
WBC; Any grade increase; n=11, 14, 23, 19, 21, 13	7	5	9	5
WBC; Increase to Grade 3; n=11, 14, 23, 19, 21, 13	1	0	1	1
WBC; Increase to Grade 4; n=11, 14, 23, 19, 21, 13	0	0	0	0
Fib; Any grade increase; n=11, 11, 21, 17, 18, 12	2	0	1	0
Fib; Increase to Grade 3; n=11, 11, 21, 17, 18, 12	1	0	0	0
Fib; Increase to Grade 4; n=11, 11, 21, 17, 18, 12	0	0	0	0
aPTT; Any grade increase; n=11,12,21,17,18,12	4	4	1	3
aPTT; Increase to Grade3; n=11,12,21, 17, 18, 12	0	0	0	1
aPTT; Increase to Grade4; n=11,12,21,17,18,12	0	0	0	0

Notes:

[99] - All Treated Population

[100] - All Treated Population

[101] - All Treated Population

[102] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	21[103]	13[104]		
Units: Participants				
Basophils; Any grade increase; n=11,13,23,19,21,13	0	0		
Basophils; Increase to Grade3; n=11,13,23,19,21,13	0	0		
Basophils; Increase to Grade4; n=11,13,23,19,21,13	0	0		
Eosinophils;Any grade increase;n=11,13,23,19,21,13	0	0		
Eosinophils;Increase to Grade3;n=11,13,23,19,21,13	0	0		
Eosinophils;Increase to Grade4;n=11,13,23,19,21,13	0	0		
Hemoglobin;Any grade increase;n=11,14,23,19,21,13	18	6		
Hemoglobin;Increase to Grade3;n=11,14,23,19,21,13	5	3		
Hemoglobin;Increase to Grade4;n=11,14, 23,19,21,13	0	0		
INR; Any grade increase; n=11,12,21,17,18,12	11	7		
INR; Increase to Grade3; n=11,12,21,17,18,12	0	0		
INR; Increase to Grade4; n=11,12,21,17,18,12	0	0		
Lymphocytes;Any grade increase;n=11,13,23,19,21,13	13	6		
Lymphocytes;Increase to Grade3;n=11,13,23,19,21,13	1	0		
Lymphocytes;Increase to Grade4;n=11,13,23,19,21,13	0	0		
Monocytes; Any grade increase; n=11,13,23,19,21,13	0	0		
Monocytes;Increase to Grade3; n=11,13,23,19,21,13	0	0		
Monocytes; Increase to Grade4; n=11,13,23,19,21,13	0	0		
Neutrophils;Any grade increase;n=11,14,23,19,21,13	6	1		
Neutrophils;Increase to Grade3;n=11,14,23,19,21,13	1	0		
Neutrophils;Increase to Grade4;n=11,14,23,19,21,13	0	0		
Platelets; Any grade increase; n=11,14,23,19,21,13	18	7		
Platelets; Increase to Grade3; n=11,14,23,19,21,13	6	0		
Platelets; Increase to Grade4; n=11,14,23,19,21,13	2	0		

PT; Any grade increase;n=10,10, 18, 17, 18, 12	0	0		
PT; Increase to Grade 3; n=10,10, 18, 17, 18, 12	0	0		
PT; Increase to Grade 4; n=10,10, 18, 17, 18, 12	0	0		
RBC; Any grade increase; n=11, 13, 23, 19, 21, 13	0	0		
RBC; Increase to Grade 3; n=11, 13, 23, 19, 21, 13	0	0		
RBC; Increase to Grade 4; n=11, 13, 23, 19, 21, 13	0	0		
WBC; Any grade increase; n=11, 14, 23, 19, 21, 13	6	3		
WBC; Increase to Grade 3; n=11, 14, 23, 19, 21, 13	0	0		
WBC; Increase to Grade 4; n=11, 14, 23, 19, 21, 13	0	0		
Fib; Any grade increase; n=11, 11, 21, 17, 18, 12	0	1		
Fib; Increase to Grade 3; n=11, 11, 21, 17, 18, 12	0	0		
Fib; Increase to Grade 4; n=11, 11, 21, 17, 18, 12	0	0		
aPTT; Any grade increase; n=11,12,21,17,18,12	5	4		
aPTT; Increase to Grade3; n=11,12,21, 17, 18, 12	0	0		
aPTT; Increase to Grade4; n=11,12,21,17,18,12	0	0		

Notes:

[103] - All Treated Population

[104] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with grade change from Baseline in hematology data-Besylate sub-study

End point title	Number of participants with grade change from Baseline in hematology data-Besylate sub-study[105]

End point description:

Blood samples were collected for the analysis of hematology parameters: aPTT, platelet count, RBC, WBC, INR, PT, Fib, hemoglobin, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life–threatening consequences; Grade 5: death. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

Notes:

[105] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[106]			
Units: Participants				
Basophils; Any grade increase; n=10	0			
Basophils; Increase to Grade 3; n=10	0			
Basophils; Increase to Grade 4; n=10	0			
Eosinophils; Any grade increase; n=10	0			
Eosinophils; Increase to Grade 3; n=10	0			
Eosinophils; Increase to Grade 4; n=10	0			
Hemoglobin; Any grade increase; n=10	7			
Hemoglobin; Increase to Grade 3; n=10	4			
Hemoglobin; Increase to Grade 4; n=10	0			
INR; Any grade increase; n=10	2			
INR; Increase to Grade 3; n=10	0			
INR; Increase to Grade 4; n=10	0			
Lymphocytes; Any grade increase; n=10	7			
Lymphocytes; Increase to Grade 3; n=10	1			
Lymphocytes; Increase to Grade 4; n=10	2			
Monocytes; Any grade increase; n=10	0			
Monocytes; Increase to Grade 3; n=10	0			
Monocytes; Increase to Grade 4; n=10	0			
Neutrophils; Any grade increase; n=10	2			
Neutrophils; Increase to Grade 3; n=10	0			
Neutrophils; Increase to Grade 4; n=10	0			
Platelets; Any grade increase; n=10	10			
Platelets; Increase to Grade 3; n=10	2			
Platelets; Increase to Grade 4; n=10	4			
PT; Any grade increase; n=10	0			
PT; Increase to Grade 3; n=10	0			
PT; Increase to Grade 4; n=10	0			
RBC; Any grade increase; n=10	0			
RBC; Increase to Grade 3; n=10	0			
RBC; Increase to Grade 4; n=10	0			
WBC; Any grade increase; n=10	4			
WBC; Increase to Grade 3; n=10	0			
WBC; Increase to Grade 4; n=10	0			
Fib; Any grade increase; n=10	0			
Fib; Increase to Grade 3; n=10	0			
Fib; Increase to Grade 4; n=10	0			
aPTT; Any grade increase; n=10	6			
aPTT; Increase to Grade 3; n=10	0			
aPTT; Increase to Grade 4; n=10	0			

Notes:

[106] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with maximum urinalysis change from Baseline-Part 1 QD

End point title	Number of participants with maximum urinalysis change from Baseline-Part 1 QD[107][108]

End point description:

Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level. 99999 indicates data was not available due to insufficient participants. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)

Notes:

[107] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[108] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[109]	9[110]	32[111]	9[112]
Units: Participants				
Cellular casts; Week 9; n=0,0,1,4,1	99999	0	1	1
Cellular casts; Week 17; n=0,0,0,1,0	99999	99999	1	99999
Cellular casts; Disc/Prog; n=0,0,1,5,1	99999	0	1	0
Hyaline casts;Week 5; n=1,1,2,5,3	0	0	2	1
Hyaline casts;Week 9; n=1,0,1,5,3	99999	0	0	1
Glucose;Week 5; n=7,2,7,20,7	0	0	4	2
Glucose;Week 9; n=3,1,3,12,5	0	0	1	1
Glucose;Week 25; n=1,0,0,3,1	99999	99999	0	1
Glucose;Disc/Prog; n=2,0,3,17,2	99999	0	1	0
Ketones;Week 5; n=7,2,7,20,7	0	0	2	1
Ketones;Week 9; n=3,1,3,12,5	0	0	2	0
Occult blood;Week 5; n=7,2,7,17,7	2	0	2	0
Occult blood;Week 9; n=3,1,3,11,5	0	0	3	0
Occult blood;Week 17; n=1,0,0,5,3	99999	99999	1	0
Occult blood;Week 25; n=1,0,0,3,1	99999	99999	1	0
Occult blood;Week 33; n=1,0,0,2,0	99999	99999	1	99999
Occult blood;Disc/Prog; n=2,0,3,17,2	99999	0	2	0
pH;Week 5; n=7,2,7,20,7	0	5	6	3
pH;Week 9; n=3,1,3,12,5	0	2	8	2
pH;Week 25; n=1,0,0,3,1	99999	99999	1	1
pH;Week 33; n=1,0,0,2,0	99999	99999	0	99999
pH;Disc/Prog; n=2,0,3,17,2	99999	1	9	1

Protein;Week 5; n=7,2,7,20,7	0	3	9	4
Protein;Week 9; n=3,1,3,12,5	0	1	7	3
Protein;Week 17; n=1,0,0,5,3	99999	99999	1	0
Protein;Week 25; n=1,0,0,3,1	99999	99999	1	0
Protein;Disc/Prog; n=2,0,3,17,2	99999	0	5	1
Specific gravity;Week 5; n=7,2,7,20,7	2	5	7	5
Specific gravity;Week 9; n=3,1,3,12,5	0	2	6	4
Specific gravity;Week 17; n=1,0,0,5,3	99999	99999	4	2
Specific gravity;Week 25; n=1,0,0,3,1	99999	99999	1	0
Specific gravity;Week 33; n=1,0,0,2,0	99999	99999	1	99999
Specific gravity;Disc/Prog; n=2,0,3,16,2	99999	1	6	1
Specific gravity;Week 41; n=0,0,0,1,0	99999	99999	1	99999
Specific gravity;Week 49; n=0,0,0,1,0	99999	99999	1	99999
Leukocytes;Week 5; n=5,2,6,11,6	1	2	4	2
Leukocytes;Week 9; n=3,1,1,6,4	1	0	3	1
Leukocytes;Week 17; n=1,0,0,1,2	99999	99999	1	0
Leukocytes;Disc/Prog; n=2,0,2,6,1	99999	0	4	1

Notes:

[109] - All Treated Population

[110] - All Treated Population

[111] - All Treated Population

[112] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[113]			
Units: Participants				
Cellular casts; Week 9; n=0,0,1,4,1	99999			
Cellular casts; Week 17; n=0,0,0,1,0	99999			
Cellular casts; Disc/Prog; n=0,0,1,5,1	99999			
Hyaline casts;Week 5; n=1,1,2,5,3	0			
Hyaline casts;Week 9; n=1,0,1,5,3	0			
Glucose;Week 5; n=7,2,7,20,7	0			
Glucose;Week 9; n=3,1,3,12,5	0			
Glucose;Week 25; n=1,0,0,3,1	0			
Glucose;Disc/Prog; n=2,0,3,17,2	1			
Ketones;Week 5; n=7,2,7,20,7	0			
Ketones;Week 9; n=3,1,3,12,5	0			
Occult blood;Week 5; n=7,2,7,17,7	1			
Occult blood;Week 9; n=3,1,3,11,5	0			
Occult blood;Week 17; n=1,0,0,5,3	0			
Occult blood;Week 25; n=1,0,0,3,1	0			
Occult blood;Week 33; n=1,0,0,2,0	0			
Occult blood;Disc/Prog; n=2,0,3,17,2	0			
pH;Week 5; n=7,2,7,20,7	1			
pH;Week 9; n=3,1,3,12,5	2			
pH;Week 25; n=1,0,0,3,1	1			
pH;Week 33; n=1,0,0,2,0	1			
pH;Disc/Prog; n=2,0,3,17,2	1			
Protein;Week 5; n=7,2,7,20,7	0			

Protein;Week 9; n=3,1,3,12,5	1			
Protein;Week 17; n=1,0,0,5,3	0			
Protein;Week 25; n=1,0,0,3,1	0			
Protein;Disc/Prog; n=2,0,3,17,2	0			
Specific gravity;Week 5; n=7,2,7,20,7	4			
Specific gravity;Week 9; n=3,1,3,12,5	1			
Specific gravity;Week 17; n=1,0,0,5,3	1			
Specific gravity;Week 25; n=1,0,0,3,1	1			
Specific gravity;Week 33; n=1,0,0,2,0	1			
Specific gravity;Disc/Prog; n=2,0,3,16,2	2			
Specific gravity;Week 41; n=0,0,0,1,0	99999			
Specific gravity;Week 49; n=0,0,0,1,0	99999			
Leukocytes;Week 5; n=5,2,6,11,6	0			
Leukocytes;Week 9; n=3,1,1,6,4	0			
Leukocytes;Week 17; n=1,0,0,1,2	0			
Leukocytes;Disc/Prog; n=2,0,2,6,1	0			

Notes:

[113] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with maximum urinalysis change from Baseline data-Part 1 BID

End point title	Number of participants with maximum urinalysis change from Baseline data-Part 1 BID[114][115]

End point description:

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. 99999 indicates data was not available due to insufficient participants. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and Weeks 5,9,17 and discharge/progression

Notes:

[114] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[115] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[116]	10[117]	5[118]	
Units: Participants				
Glucose; Week 5;n=2,7,3	0	0	1	
Glucose; Week 9;n=0,4,2	99999	1	0	
Glucose; Week 17;n=0,2,0	99999	1	99999	

Glucose; disc/prog;n=0,6,1	99999	1	0	
Ketones; Week 5;n=2,7,3	0	1	0	
Ketones; Week 17;n=0,2,0	99999	1	99999	
Occult blood; Week 5;n=2,7,3	0	2	0	
Occult blood; Week 9;n=0,4,2	99999	1	0	
Occult blood; disc/prog;n=0,6,1	99999	2	0	
pH; Week 5;n=2,7,3	2	4	2	
pH; Week 9;n=0,4,2	99999	4	1	
pH; Week 17;n=0,2,0	99999	1	99999	
pH; disc/prog;n=0,7,1	99999	4	1	
Protein; Week 5;n=2,7,3	0	3	1	
Protein; Week 9;n=0,4,2	99999	2	0	
Protein; Week 17;n=0,2,0	99999	2	99999	
Protein; disc/prog;n=0,7,1	99999	1	1	
Erythrocytes; Week 5;n=1,5,1	1	4	1	
Erythrocytes; Week 9;n=0,1,1	99999	0	1	
Erythrocytes; Week 17;n=0,1,0	99999	1	99999	
Specific gravity; Week 5;n=2,7,3	2	1	2	
Specific gravity; Week 9;n=0,4,2	99999	1	1	
Specific gravity; Week 17;n=0,2,0	99999	1	99999	
Specific gravity; disc/prog;n=0,7,1	99999	2	0	
Leukocytes; Week 5;n=1,5,1	0	4	1	
Leukocytes; Week 9;n=0,1,1	99999	0	1	
Leukocytes; Week 17;n=0,1,0	99999	1	99999	

Notes:

[116] - All Treated Population

[117] - All Treated Population

[118] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with maximum urinalysis change from Baseline-Part 2

End point title	Number of participants with maximum urinalysis change from Baseline-Part 2[119][120]

End point description:

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. 99999 indicates data was not available due to insufficient participants. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1), Weeks 5,9,13,25,37, 49, 73, 85 and discharge/progression

Notes:

[119] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[120] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 2: Participants with NMC	Part 2: Participants with SCLC	Part 2: Participants with CRPC	Part 2: Participants with TNBC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12[121]	14[122]	23[123]	19[124]
Units: Participants				
Granular cast;Week5;n=0,2,2,1,3,0	99999	0	0	0
Granular cast;disc/prog;n=1,2,6,3,4,0	0	0	2	0
Hyaline cast;Week5;n=1,2,2,2,4,0	1	0	0	1
Hyaline cast;Week9;n=0,0,1,2,1,1	99999	99999	0	0
Hyaline cast;Week13;n=1,1,0,0,0,0	0	1	99999	99999
Hyaline cast;disc/prog;n=1,2,6,3,4,0	0	0	2	0
Glucose;Week 5;n=8,7,18,12,14,8	1	2	2	0
Glucose;Week9;n=8,3,12,3,6,5	2	1	0	0
Glucose;Week13;n=7,2,6,1,2,2	2	1	1	0
Glucose;Week37;n=3,0,1,0,0,0	1	99999	0	99999
Glucose;Week49;n=1,0,1,0,0,0	1	99999	0	99999
Glucose;Week73;n=1,0,0,0,0,0	1	99999	99999	99999
Glucose;Week85;n=1,0,0,0,0,0	1	99999	99999	99999
Glucose;disc/prog;n=3,6,16,12,12,5	0	0	0	0
Ketones;Week5;n=8,7,18,12,14,8	0	1	0	0
Ketones;Week9;n=8,3,12,3,6,5	0	1	0	0
Ketones;disc/prog;n=3,6,16,12,12,5	0	1	2	0
Occult blood;Week5;n=8,7,18,12,14,8	1	0	5	0
Occult blood;Week9;n=8,3,12,3,6,5	0	1	5	0
Occult blood;Week13;n=7,2,6,1,2,2	1	0	0	0
Occult blood;Week25;n=2,0,3,0,0,0	0	99999	1	99999
Occult blood;Week37;n=3,0,1,0,0,0	1	99999	0	99999
Occult blood;disc/prog;n=3,6,16,12,12,5	0	0	8	0
pH;Week5;n=8,7,18,12,14,8	6	3	8	3
pH;Week9;n=8,3,12,3,6,5	5	1	7	2
pH;Week13;n=7,2,6,1,2,2	2	1	3	1
pH;Week25;n=2,0,3,0,0,0	1	99999	1	99999
pH;Week37;n=3,0,1,0,0,0	3	99999	0	99999
pH;Week49;n=1,0,1,0,0,0	1	99999	0	99999
pH;Week73;n=1,0,0,0,0,0	1	99999	99999	99999
pH;Week85;n=1,0,0,0,0,0	1	99999	99999	99999
pH;disc/prog;n=3,6,16,12,12,5	1	2	6	6
Protein;Week5;n=8,7,18,12,14,8	1	1	9	3
Protein;Week9;n=8,3,12,3,6,5	3	2	4	0
Protein;Week13;n=7,2,6,1,2,2	3	1	2	0
Protein;Week37;n=1,0,1,0,0,0	1	99999	0	99999
Protein;disc/prog;n=3,6,16,12,12,5	1	1	6	2
Erythrocytes;Week5;n=3,3,8,4,4,4	2	0	5	2
Erythrocytes;Week9;n=4,0,2,2,1,2	2	99999	1	1
Erythrocytes;Week13;n=3,1,0,0,0,1	3	1	99999	99999
Erythrocytes;disc/prog;n=1,2,6,3,4,2	0	0	5	1
Specific gravity;Week5;n=8,7,18,12,14,8	4	4	2	5
Specific gravity;Week9;n=8,3,12,3,6,5	2	1	2	2
Specific gravity;Week13;n=7,2,6,1,2,2	2	1	1	0

Specific gravity;disc/prog;n=3,6,16,12,12,5	0	2	3	3
Leukocytes;Week5;n=3,3,8,4,4,4	1	1	5	3
Leukocytes;Week9;n=4,0,2,2,1,3	0	99999	2	1
Leukocytes;Week13;n=3,1,0,0,0,1	1	0	99999	99999
Leukocytes;Week25;n=2,0,1,0,0,0	0	99999	1	99999
Leukocytes;disc/prog;n=1,2,7,3,4,1	0	1	2	3

Notes:

[121] - All Treated Population

[122] - All Treated Population

[123] - All Treated Population

[124] - All Treated Population

End point values	Part 2: Participants with ER+BC	Part 2: Participants with GIST		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	21[125]	13[126]		
Units: Participants				
Granular cast;Week5;n=0,2,2,1,3,0	1	99999		
Granular cast;disc/prog;n=1,2,6,3,4,0	0	0		
Hyaline cast;Week5;n=1,2,2,2,4,0	1	99999		
Hyaline cast;Week9;n=0,0,1,2,1,1	0	1		
Hyaline cast;Week13;n=1,1,0,0,0,0	99999	99999		
Hyaline cast;disc/prog;n=1,2,6,3,4,0	0	99999		
Glucose;Week 5;n=8,7,18,12,14,8	0	1		
Glucose;Week9;n=8,3,12,3,6,5	0	0		
Glucose;Week13;n=7,2,6,1,2,2	0	0		
Glucose;Week37;n=3,0,1,0,0,0	99999	99999		
Glucose;Week49;n=1,0,1,0,0,0	99999	99999		
Glucose;Week73;n=1,0,0,0,0,0	99999	99999		
Glucose;Week85;n=1,0,0,0,0,0	99999	99999		
Glucose;disc/prog;n=3,6,16,12,12,5	1	0		
Ketones;Week5;n=8,7,18,12,14,8	1	0		
Ketones;Week9;n=8,3,12,3,6,5	0	0		
Ketones;disc/prog;n=3,6,16,12,12,5	1	0		
Occult blood;Week5;n=8,7,18,12,14,8	0	0		
Occult blood;Week9;n=8,3,12,3,6,5	0	0		
Occult blood;Week13;n=7,2,6,1,2,2	0	0		
Occult blood;Week25;n=2,0,3,0,0,0	99999	99999		
Occult blood;Week37;n=3,0,1,0,0,0	99999	99999		
Occult blood;disc/prog;n=3,6,16,12,12,5	0	0		
pH;Week5;n=8,7,18,12,14,8	6	3		
pH;Week9;n=8,3,12,3,6,5	4	2		
pH;Week13;n=7,2,6,1,2,2	0	1		
pH;Week25;n=2,0,3,0,0,0	99999	99999		
pH;Week37;n=3,0,1,0,0,0	99999	99999		
pH;Week49;n=1,0,1,0,0,0	99999	99999		
pH;Week73;n=1,0,0,0,0,0	99999	99999		
pH;Week85;n=1,0,0,0,0,0	99999	99999		
pH;disc/prog;n=3,6,16,12,12,5	5	2		
Protein;Week5;n=8,7,18,12,14,8	5	6		

Protein;Week9;n=8,3,12,3,6,5	0	3		
Protein;Week13;n=7,2,6,1,2,2	0	0		
Protein;Week37;n=1,0,1,0,0,0	99999	99999		
Protein;disc/prog;n=3,6,16,12,12,5	3	2		
Erythrocytes;Week5;n=3,3,8,4,4,4	3	2		
Erythrocytes;Week9;n=4,0,2,2,1,2	1	1		
Erythrocytes;Week13;n=3,1,0,0,0,1	99999	0		
Erythrocytes;disc/prog;n=1,2,6,3,4,2	2	0		
Specific gravity;Week5;n=8,7,18,12,14,8	7	2		
Specific gravity;Week9;n=8,3,12,3,6,5	5	3		
Specific gravity;Week13;n=7,2,6,1,2,2	0	1		
Specific gravity;disc/prog;n=3,6,16,12,12,5	5	1		
Leukocytes;Week5;n=3,3,8,4,4,4	4	4		
Leukocytes;Week9;n=4,0,2,2,1,3	0	3		
Leukocytes;Week13;n=3,1,0,0,0,1	99999	0		
Leukocytes;Week25;n=2,0,1,0,0,0	99999	99999		
Leukocytes;disc/prog;n=1,2,7,3,4,1	3	1		

Notes:

[125] - All Treated Population

[126] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with maximum urinalysis change from Baseline-Besylate sub-study

End point title	Number of participants with maximum urinalysis change from Baseline-Besylate sub-study[127]

End point description:

Urine samples were collected for the analysis of following urine parameters: pH, glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1), Weeks 5,9,17,25 and disc/prog

Notes:

[127] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[128]			
Units: Participants				
Hyaline casts; Week5;n=2	2			
Hyaline casts; Week9;n=3	3			
Hyaline casts; Week17;n=1	1			

Hyaline casts; Week25;n=1	1			
Hyaline casts; disc/prog;n=1	1			
Glucose; Week5;n=5	2			
Glucose; Week9;n=5	1			
Glucose; Week17;n=2	1			
Ketones; Week9;n=5	1			
pH;Week5;n=5	4			
pH;Week9;n=5	3			
pH;Week17;n=2	2			
pH;Week25;n=1	1			
pH;disc/prog;n=4	3			
Protein; Week5; n=5	4			
Protein; Week9; n=5	4			
Protein; Week17; n=2	2			
Protein; Week25; n=1	1			
Erythrocytes; Week9; n=5	3			
Erythrocytes; Week17; n=2	1			
Erythrocytes; Week25; n=1	1			
Erythrocytes; disc/prog; n=1	1			
Specific gravity; Week5; n=5	2			
Specific gravity; Week9; n=5	2			
Specific gravity; Week17; n=2	1			
Specific gravity; Week25; n=1	1			
Specific gravity; disc/prog; n=4	1			
Leukocytes; Week5; n=4	4			
Leukocytes; Week9; n=5	5			
Leukocytes; Week17; n=2	1			
Leukocytes; Week25; n=1	1			
Leukocytes; disc/prog; n=1	1			

Notes:

[128] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with changes in pulse rate from Baseline-Part 1 QD

End point title	Number of participants with changes in pulse rate from Baseline-Part 1 QD[129][130]

End point description:

Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is <60 beats per minute and >100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level. Only those participants with data available at Baseline and the specified time point were analyzed.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

Notes:

[129] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[130] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[131]	8[132]	31[133]	9[134]
Units: Participants				
Pulse rate; decrease to <60	0	1	1	1
Pulse rate; Change to normal/no change	1	5	12	4
Pulse rate; increase to >100	3	2	18	5

Notes:

[131] - All Treated Population

[132] - All Treated Population

[133] - All Treated Population

[134] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[135]			
Units: Participants				
Pulse rate; decrease to <60	2			
Pulse rate; Change to normal/no change	4			
Pulse rate; increase to >100	5			

Notes:

[135] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with changes in pulse rate from Baseline-Part 1 BID

End point title	Number of participants with changes in pulse rate from Baseline-Part 1 BID[136][137]

End point description:

Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Notes:

[136] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[137] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[138]	10[139]	5[140]	
Units: Participants				
Pulse rate; decrease to <60	0	0	0	
Pulse rate; Change to normal/no change	3	4	2	
Pulse rate; increase to >100	1	6	3	

Notes:

[138] - All Treated Population

[139] - All Treated Population

[140] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with changes in pulse rate from Baseline-Part 2

End point title	Number of participants with changes in pulse rate from Baseline-Part 2[141]

End point description:

Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is <60 beats per minute and >100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Only those participants with data available at Baseline and the specified time point were analyzed.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Notes:

[141] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	Participants with SCLC	Participants with TNBC	Participants with NMC	Participants with CRPC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	14[142]	19[143]	11[144]	22[145]
Units: Participants				
Pulse rate; decrease to <60	1	0	0	0
Pulse rate; Change to normal/no change	10	11	7	13
Pulse rate; increase to >100	4	9	5	9

Notes:

[142] - All Treated Population

[143] - All Treated Population

[144] - All Treated Population

[145] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		

Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	20[146]	12[147]		
Units: Participants				
Pulse rate; decrease to <60	1	1		
Pulse rate; Change to normal/no change	9	8		
Pulse rate; increase to >100	10	3		

Notes:

[146] - All Treated Population

[147] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with changes in pulse rate from Baseline-Besylate sub-study

End point title	Number of participants with changes in pulse rate from Baseline-Besylate sub-study[148]

End point description:

Pulse rate was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for pulse rate is <60 beats per minute and >100 beats per minute. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

Notes:

[148] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[149]			
Units: Participants				
Pulse rate; decrease to <60	0			
Pulse rate; Change to normal/no change	4			
Pulse rate; increase to >100	6			

Notes:

[149] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with increase in blood pressure from Baseline-Part 1 QD

End point title	Number of participants with increase in blood pressure from Baseline-Part 1 QD[150][151]

End point description:

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in a supine or semi-

recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

Notes:

[150] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[151] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[152]	9[153]	32[154]	9[155]
Units: Participants				
DBP; Increase to Grade 1	0	3	9	0
DBP; Increase to Grade 2	1	0	10	1
DBP; Increase to Grade 3/4	0	1	2	2
SBP; Increase to Grade 1	1	2	11	1
SBP; Increase to Grade 2	3	1	9	3
SBP; Increase to Grade 3/4	0	2	5	2

Notes:

[152] - All Treated Population

[153] - All Treated Population

[154] - All Treated Population

[155] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[156]			
Units: Participants				
DBP; Increase to Grade 1	3			
DBP; Increase to Grade 2	2			
DBP; Increase to Grade 3/4	0			
SBP; Increase to Grade 1	4			
SBP; Increase to Grade 2	2			
SBP; Increase to Grade 3/4	1			

Notes:

[156] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with increase in blood pressure from Baseline-Part 1 BID

End point title	Number of participants with increase in blood pressure from Baseline-Part 1 BID[157][158]

End point description:

SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Only those participants with data available at Baseline and the specified time point were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Notes:

[157] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[158] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[159]	10[160]	5[161]	
Units: Participants				
DBP; Increase to Grade 1;n=4,10,4	2	4	1	
DBP; Increase to Grade 2;n=4,10,4	0	4	1	
DBP; Increase to Grade 3/4;n=4,10,4	0	0	1	
SBP; Increase to Grade 1;n=4,9,5	1	2	2	
SBP; Increase to Grade 2;n=4,9,5	1	6	1	
SBP; Increase to Grade 3/4;n=4,9,5	0	0	1	

Notes:

[159] - All Treated Population

[160] - All Treated Population

[161] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with changes in blood pressure from Baseline-Part 2

End point title	Number of participants with changes in blood pressure from Baseline-Part 2[162]

End point description:

SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase

in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Only those participants with data available at Baseline and the specified time point were analyzed (indicated by n=X in category titles).

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Notes:

[162] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	Participants with SCLC	Participants with TNBC	Participants with NMC	Participants with CRPC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	14[163]	19[164]	11[165]	22[166]
Units: Participants				
DBP; Increase to Grade 1;n=11,14,22,19,19,12	3	5	2	8
DBP; Increase to Grade 2;n=11,14,22,19,19,12	1	3	4	4
DBP; Increase to Grade 3/4;n=11,14,22,19,19,12	0	2	0	1
SBP; Increase to Grade 1;n=11,14,21,19,19,12	4	9	4	2
SBP; Increase to Grade 2;n=11,14,21,19,19,12	4	3	2	11
SBP; Increase to Grade 3/4;n=11,14,21,19,19,12	1	1	0	3

Notes:

[163] - All Treated Population

[164] - All Treated Population

[165] - All Treated Population

[166] - All Treated Population

End point values	Participants with GIST	Participants with ER+BC		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	12[167]	19[168]		
Units: Participants				
DBP; Increase to Grade 1;n=11,14,22,19,19,12	3	4		
DBP; Increase to Grade 2;n=11,14,22,19,19,12	1	6		
DBP; Increase to Grade 3/4;n=11,14,22,19,19,12	2	1		
SBP; Increase to Grade 1;n=11,14,21,19,19,12	1	7		
SBP; Increase to Grade 2;n=11,14,21,19,19,12	7	4		
SBP; Increase to Grade 3/4;n=11,14,21,19,19,12	0	1		

Notes:

[167] - All Treated Population

[168] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with increase in blood pressure from Baseline-Besylate sub-study

End point title	Number of participants with increase in blood pressure from Baseline-Besylate sub-study[169]

End point description:

SBP and DBP were measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. Grading of SBP and DBP were done using NCI-CTCAE version 4.0 where, SBP (millimeters of mercury): Grade 0 (<120), Grade 1 (120-139), Grade 2 (140-159), Grade 3/4 (>=160) and DBP: Grade 0 (<80), Grade 1 (80-89), Grade 2 (90-99), Grade 3/4 (>=100). An increase is defined as an increase in CTCAE grade relative to baseline grade. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

Notes:

[169] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[170]			
Units: Participants				
DBP; Increase to Grade 1	2			
DBP; Increase to Grade 2	3			
DBP; Increase to Grade 3/4	0			
SBP; Increase to Grade 1	2			
SBP; Increase to Grade 2	1			
SBP; Increase to Grade 3/4	0			

Notes:

[170] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with changes in temperature from Baseline-Part 1 QD

End point title	Number of participants with changes in temperature from Baseline-Part 1 QD[171][172]

End point description:

Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is <=35 degree Celsius and >=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.38 months of drug exposure

Notes:

[171] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[172] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[173]	9[174]	32[175]	9[176]
Units: Participants				
Decrease to <=35	0	0	2	1
Change to normal/No change	3	9	27	8
Increase to >=38	1	0	3	0

Notes:

[173] - All Treated Population

[174] - All Treated Population

[175] - All Treated Population

[176] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[177]			
Units: Participants				
Decrease to <=35	0			
Change to normal/No change	10			
Increase to >=38	1			

Notes:

[177] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with changes in temperature from Baseline-Part 1 BID

End point title	Number of participants with changes in temperature from Baseline-Part 1 BID[178][179]

End point description:

Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is <=35 degree Celsius and >=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Notes:

[178] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[179] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[180]	10[181]	5[182]	
Units: Participants				
Decrease to <=35	0	0	0	
Change to normal/No change	4	9	5	
Increase to >=38	0	1	0	

Notes:

[180] - All Treated Population

[181] - All Treated Population

[182] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with changes in temperature from Baseline-Part 2

End point title	Number of participants with changes in temperature from Baseline-Part 2[183]

End point description:

Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is <=35 degree Celsius and >=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Only those participants with data available at Baseline and the specified time points were analyzed.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.41 months of drug exposure

Notes:

[183] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	Participants with SCLC	Participants with TNBC	Participants with NMC	Participants with CRPC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	14[184]	19[185]	11[186]	22[187]
Units: Participants				
Decrease to <=35	0	0	1	0
Change to normal/No change	11	18	10	20
Increase to >=38	3	1	0	2

Notes:

[184] - All Treated Population

[185] - All Treated Population

[186] - All Treated Population

[187] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	20[188]	12[189]		
Units: Participants				
Decrease to <=35	1	0		
Change to normal/No change	18	12		
Increase to >=38	1	0		

Notes:

[188] - All Treated Population

[189] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with changes in temperature from Baseline-Besylate sub-study

End point title	Number of participants with changes in temperature from Baseline-Besylate sub-study[190]

End point description:

Temperature was measured in a supine or semi-recumbent position after at least 5 minutes rest for the participant. The clinical concern range for temperature is <=35 degree Celsius and >=38 degree Celsius. Baseline is the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Data for worst case post-Baseline is presented. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.

End point type	Primary

End point timeframe:

Baseline (pre-dose Week1 Day1) and median of 1.87 months of drug exposure

Notes:

[190] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[191]			
Units: Participants				
Decrease to <=35	0			
Change to normal/No change	9			
Increase to >=38	1			

Notes:

[191] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Overall response rate-Part 1 QD

End point title	Overall response rate-Part 1 QD[192][193]

End point description:

Overall response rate is defined as the percentage of participants who achieved a confirmed complete response (CR) or partial response (PR) from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST version (v) 1.1). CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 millimeters (mm) in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level.

End point type	Primary

End point timeframe:

Median of 1.38 months of drug exposure

Notes:

[192] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[193] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[194]	9[195]	32[196]	9[197]
Units: Percentage of participants				
number (confidence interval 95%)	0 (0.0 to 60.2)	0 (0.0 to 33.6)	3 (0.1 to 16.2)	11 (0.3 to 48.2)

Notes:

[194] - All Treated Population

[195] - All Treated Population

[196] - All Treated Population

[197] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[198]			
Units: Percentage of participants				
number (confidence interval 95%)	0 (0.0 to 28.5)			

Notes:

[198] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Overall response rate-Part 1 BID

End point title	Overall response rate-Part 1 BID[199][200]

End point description:

Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR

from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

End point type	Primary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[199] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[200] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[201]	10[202]	5[203]	
Units: Percentage of participants				
number (confidence interval 95%)	0 (0.0 to 60.2)	0 (0.0 to 30.8)	0 (0.0 to 52.2)	

Notes:

[201] - All Treated Population

[202] - All Treated Population

[203] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Overall response rate-Part 2

End point title	Overall response rate-Part 2[204]

End point description:

Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters.

End point type	Primary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[204] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	Participants with NMC	Participants with SCLC	Participants with CRPC	Participants with TNBC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	12[205]	14[206]	23[207]	19[208]
Units: Percentage of participants				
number (confidence interval 95%)	8 (0.2 to 38.5)	0 (0.0 to 23.2)	4 (0.1 to 21.9)	0 (0.0 to 17.6)

Notes:

[205] - All Treated Population

[206] - All Treated Population

[207] - All Treated Population

[208] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	21[209]	13[210]		
Units: Percentage of participants				
number (confidence interval 95%)	0 (0.0 to 16.1)	0 (0.0 to 24.7)		

Notes:

[209] - All Treated Population

[210] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Overall response rate-Besylate sub-study

End point title	Overall response rate-Besylate sub-study[211]

End point description:

Overall response rate is defined as the percentage of participants who achieved a confirmed CR or PR from the start of treatment until disease progression or the start of new anticancer therapy, among participants who received at least 1 dose of treatment. Overall response rate was determined by the investigator according to RECIST v 1.1. CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 mm in the short axis. PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.

End point type	Primary

End point timeframe:

Median of 1.87 months of drug exposure

Notes:

[211] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[212]			
Units: Percentage of participants				
number (confidence interval 95%)	0 (0.0 to 30.8)			

Notes:

[212] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with prostate specific antigen (PSA)50 response-Part 1 QD

End point title	Number of participants with prostate specific antigen (PSA)50 response-Part 1 QD[213][214]

End point description:

PSA 50 response rate is defined as the response rate that a PSA reduction from Baseline >=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA >=50% reduction is presented along with 95% confidence intervals. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level. 99999 indicates confidence interval could not be calculated as there were no responders.

End point type	Primary

End point timeframe:

Median of 1.38 months of drug exposure

Notes:

[213] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[214] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[215]	9[216]	32[217]	9[218]
Units: Participants				
number (confidence interval 95%)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)

Notes:

[215] - All Treated Population

[216] - All Treated Population

[217] - All Treated Population

[218] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[219]			
Units: Participants				
number (confidence interval 95%)	0 (0 to 0)			

Notes:

[219] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with PSA50 response rate-Part 1 BID

End point title	Number of participants with PSA50 response rate-Part 1

End point description:

PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline >=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA >=50% reduction is presented along with 95% confidence intervals. 99999 indicates confidence interval could not be calculated as there were no responders.

End point type	Primary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[220] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

[221] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[222]	10[223]	5[224]	
Units: Participants				
number (confidence interval 95%)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)	

Notes:

[222] - All Treated Population

[223] - All Treated Population

[224] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with PSA50 response-Part 2

End point title	Number of participants with PSA50 response-Part 2[225]

End point description:

PSA 50 response rate is defined as the response rate that a PSA reduction from Baseline >=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA >=50% reduction is presented along with 95% confidence intervals. 99999 indicates confidence interval could not be calculated as there were no responders.

End point type	Primary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[225] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	Participants with NMC	Participants with SCLC	Participants with CRPC	Participants with TNBC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	12[226]	14[227]	23[228]	19[229]
Units: Participants				
number (confidence interval 95%)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)

Notes:

[226] - All Treated Population

[227] - All Treated Population

[228] - All Treated Population

[229] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		

Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	21[230]	13[231]		
Units: Participants				
number (confidence interval 95%)	0 (0 to 0)	0 (0 to 0)		

Notes:

[230] - All Treated Population

[231] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with PSA50 response-Besylate sub-study

End point title	Number of participants with PSA50 response-Besylate sub-study[232]

End point description:

PSA 50 Response rate is defined as the response rate that a PSA reduction from Baseline >=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA >=50% reduction is presented along with 95% confidence intervals.

End point type	Primary

End point timeframe:

Median of 1.87 months of drug exposure

Notes:

[232] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[233]			
Units: Participants				
number (confidence interval 95%)	0 (0 to 0)			

Notes:

[233] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Primary: Area under the concentration-time curve (AUC) from time zero to 24 hours(AUC[0 to 24]); AUC from time 0 to last quantifiable concentration (AUC [0 to t]) and AUC extrapolated to infinity (AUC[0 to inf]) of GSK525762-Besylate sub-

End point title	Area under the concentration-time curve (AUC) from time zero to 24 hours(AUC[0 to 24]); AUC from time 0 to last quantifiable concentration (AUC [0 to t]) and AUC extrapolated to infinity (AUC[0 to inf]) of GSK525762-Besylate sub-study[234]

End point description:

Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. Besylate sub-study pharmacokinetic (PK) Parameter Population consisted of all participants in the PK Parameter Population who participated in the besylate substudy. Only those participants with data available at the specified time points were analyzed.

End point type	Primary

End point timeframe:

Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)

Notes:

[234] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	GSK525762 80 mg amorphous+6 mg stable isotope	GSK525762 80 mg besylate+6 mg stable isotope	GSK525762 30 mg besylate+6 mg stable isotope	GSK525762 80 mg besylate fed
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	9[235]	10[236]	10[237]	8[238]
Units: Hours*nanograms per milliliter				
geometric mean (geometric coefficient of variation)				
AUC(0 to 24)	6954.3 (± 59.1)	7377.9 (± 44.7)	2977.3 (± 42.8)	9123.8 (± 45.2)
AUC(0 to inf)	7292.0 (± 62.1)	7703.4 (± 49.9)	3096.9 (± 45.0)	9727.7 (± 48.5)
AUC(0 to t)	7227.1 (± 61.6)	7657.6 (± 49.9)	3053.9 (± 44.4)	9597.1 (± 48.9)

Notes:

[235] - Besylate Sub-Study PK Parameter Population

[236] - Besylate Sub-Study PK Parameter Population

[237] - Besylate Sub-Study PK Parameter Population

[238] - Besylate Sub-Study PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Primary: Maximum observed concentration (Cmax) of GSK525762-Besylate sub-study

End point title	Maximum observed concentration (Cmax) of GSK525762-Besylate sub-study[239]

End point description:

Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. Only those participants with data available at the specified time points were analyzed.

End point type	Primary

End point timeframe:

Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)

Notes:

[239] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	GSK525762 80 mg amorphous+6 mg stable isotope	GSK525762 80 mg besylate+6 mg stable isotope	GSK525762 30 mg besylate+6 mg stable isotope	GSK525762 80 mg besylate fed
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	9[240]	10[241]	10[242]	8[243]
Units: Nanograms per milliliter				
geometric mean (geometric coefficient	1431.41 (±	1483.21 (±	655.33 (±	1305.59 (±

of variation)	51.3)	49.8)	21.1)	46.6)

Notes:

[240] - Besylate Sub-Study PK Parameter Population

[241] - Besylate Sub-Study PK Parameter Population

[242] - Besylate Sub-Study PK Parameter Population

[243] - Besylate Sub-Study PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Primary: Apparent terminal phase elimination rate constant (lambda z) for GSK525762-Besylate sub-study

End point title	Apparent terminal phase elimination rate constant (lambda z) for GSK525762-Besylate sub-study[244]

End point description:

Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. Only those participants with data available at the specified time points were analyzed.

End point type	Primary

End point timeframe:

Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)

Notes:

[244] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	GSK525762 80 mg amorphous+6 mg stable isotope	GSK525762 80 mg besylate+6 mg stable isotope	GSK525762 30 mg besylate+6 mg stable isotope	GSK525762 80 mg besylate fed
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	9[245]	10[246]	10[247]	8[248]
Units: Per hour				
geometric mean (geometric coefficient of variation)	5.628 (± 25.9)	5.176 (± 20.6)	5.088 (± 23.8)	5.954 (± 20.2)

Notes:

[245] - Besylate Sub-Study PK Parameter Population

[246] - Besylate Sub-Study PK Parameter Population

[247] - Besylate Sub-Study PK Parameter Population

[248] - Besylate Sub-Study PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Primary: Time to reach Cmax (Tmax) for GSK525762-Besylate sub-study

End point title	Time to reach Cmax (Tmax) for GSK525762-Besylate sub-study[249]

End point description:

Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points. Only those participants with data available at the specified time points were analyzed.

End point type	Primary

End point timeframe:

Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)

Notes:

[249] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed.

End point values	GSK525762 80 mg amorphous+6 mg stable isotope	GSK525762 80 mg besylate+6 mg stable isotope	GSK525762 30 mg besylate+6 mg stable isotope	GSK525762 80 mg besylate fed
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	9[250]	10[251]	10[252]	8[253]
Units: Hours				
median (full range (min-max))	0.5833 (0.250 to 3.250)	0.8083 (0.500 to 3.000)	0.8333 (0.300 to 1.017)	2.0000 (0.500 to 6.050)

Notes:

[250] - Besylate Sub-Study PK Parameter Population

[251] - Besylate Sub-Study PK Parameter Population

[252] - Besylate Sub-Study PK Parameter Population

[253] - Besylate Sub-Study PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with increase in QT interval corrected for heart rate according to Fridericia's formula (QTcF)-Part 1 QD

End point title	Number of participants with increase in QT interval corrected for heart rate according to Fridericia's formula (QTcF)-Part 1 QD[254]

End point description:

Electrocardiogram (ECG) measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level.

End point type	Secondary

End point timeframe:

Median of 1.38 months of drug exposure

Notes:

[254] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	9	32	9
Units: Participants				
Any Grade increase	4	4	13	4
Increase to Grade 2	0	1	0	1
Increase to Grade 3	0	0	0	0

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11			
Units: Participants				
Any Grade increase	2			
Increase to Grade 2	0			
Increase to Grade 3	1			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with increase in QTcF-Part 1 BID

End point title	Number of participants with increase in QTcF-Part 1 BID[255]

End point description:

ECG measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported.

End point type	Secondary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[255] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	10	5	
Units: Participants				
Any Grade increase	3	4	2	
Increase to Grade 2	3	0	0	
Increase to Grade 3	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with increase in QTcF-Part 2

End point title	Number of participants with increase in QTcF-Part 2

End point description:

ECG measurements were done using an automated 12-lead ECG machine. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. Only those participants with data available at the specified time point were analyzed.

End point type	Secondary

End point timeframe:

Median of 1.41 months of drug exposure

End point values	Participants with SCLC	Participants with TNBC	Participants with NMC	Participants with CRPC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	14	19	11	22
Units: Participants				
Any Grade increase	2	1	1	6
Increase to Grade 2	0	0	0	0
Increase to Grade 3	0	0	1	0

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	20	12		
Units: Participants				
Any Grade increase	2	0		
Increase to Grade 2	2	0		
Increase to Grade 3	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with increase in QTcF-Besylate sub-study

End point title	Number of participants with increase in QTcF-Besylate sub-study

End point description:

ECG measurements were done using 12-lead ECG machine that automatically calculated the heart rate and measured PR, QRS, QT and QTcF intervals. QTc parameters were graded according to NCI-CTCAE version 4.0. Grade 0 (<450 milliseconds [msec]), Grade 1 (450-480 msec), Grade 2 (481-500 msec), Grade 3 (>=501 msec). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Number of participants with increase in QTcF at worst-case post Baseline is reported. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.

End point type	Secondary

End point timeframe:

Median of 1.87 months of drug exposure

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10			
Units: Participants				
Any Grade increase	5			
Increase to Grade 2	0			
Increase to Grade 3	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Progression free survival-Part 1 QD

End point title	Progression free survival-Part 1 QD[256]

End point description:

Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level.

End point type	Secondary

End point timeframe:

Median of 1.38 months of drug exposure

Notes:

[256] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[257]	9[258]	32[259]	9[260]
Units: Months				
median (confidence interval 95%)	3.8 (0.9 to 5.4)	3.6 (1.4 to 8.9)	6.5 (2.6 to 9.1)	7.5 (6.0 to 18.0)

Notes:

[257] - All Treated Population

[258] - All Treated Population

[259] - All Treated Population

[260] - All Treated Population

End point values	Part 1: GSK525762 2-			

	16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[261]			
Units: Months				
median (confidence interval 95%)	2.2 (0.9 to 9.1)			

Notes:

[261] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Progression free survival-Part 1 BID

End point title	Progression free survival-Part 1 BID[262]

End point description:

Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.

End point type	Secondary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[262] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[263]	10[264]	5[265]	
Units: Months				
median (confidence interval 95%)	7.7 (0.9 to 14.5)	5.6 (2.9 to 7.0)	8.0 (7.9 to 18.7)	

Notes:

[263] - All Treated Population

[264] - All Treated Population

[265] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Progression free survival-Part 2

End point title	Progression free survival-Part 2

End point description:

Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and the date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method.

End point type	Secondary

End point timeframe:

Median of 1.41 months of drug exposure

End point values	Participants with NMC	Participants with SCLC	Participants with CRPC	Participants with TNBC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	12[266]	14[267]	23[268]	19[269]
Units: Months				
median (confidence interval 95%)	4.8 (2.5 to 5.1)	2.2 (1.1 to 5.3)	8.0 (5.5 to 11.7)	2.4 (1.4 to 6.5)

Notes:

[266] - All Treated Population

[267] - All Treated Population

[268] - All Treated Population

[269] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	21[270]	13[271]		
Units: Months				
median (confidence interval 95%)	4.7 (3.3 to 9.2)	3.4 (1.9 to 7.3)		

Notes:

[270] - All Treated Population

[271] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Progression free survival-Besylate sub-study

End point title	Progression free survival-Besylate sub-study

End point description:

Progression free survival is defined as the interval of time (in months) between the date of first dose and the earlier of the date of disease progression and the date of death due to any cause. Confidence intervals were estimated using Brookmeyer Crowley method. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.

End point type	Secondary

End point timeframe:

Median of 1.87 months of drug exposure

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[272]			
Units: Months				
median (confidence interval 95%)	3.5 (1.0 to 10.9)			

Notes:
[272] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Time to response-Part 1 QD

End point title	Time to response-Part 1 QD[273]

End point description:

Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Confidence intervals were estimated using Brookmeyer Crowley method. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level. 99999 indicates confidence interval could not be calculated as only one participant was available at the specified time point. Only participants with confirmed PR or CR were analyzed.

End point type	Secondary

End point timeframe:

Median of 1.38 months of drug exposure

Notes:
[273] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[274]	0[275]	1[276]	0[277]
Units: Months				
median (confidence interval 95%)	(to)	(to)	1.0 (-99999 to 99999)	(to)

Notes:
[274] - All Treated Population
[275] - All Treated Population
[276] - All Treated Population
[277] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	1[278]			
Units: Months				
median (confidence interval 95%)	3.7 (-99999 to 99999)			

Notes:
[278] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Time to response-Part 1 BID

End point title	Time to response-Part 1 BID[279]

End point description:

Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Confidence intervals were estimated using Brookmeyer Crowley method. Only those participants with confirmed CR or PR were analyzed.

End point type	Secondary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[279] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0[280]	0[281]	0[282]	
Units: Months				
median (confidence interval 95%)	(to)	(to)	(to)	

Notes:

[280] - All Treated Population

[281] - All Treated Population

[282] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Time to response-Part 2

End point title	Time to response-Part 2

End point description:

Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Confidence intervals were estimated using Brookmeyer Crowley method. Only those participants with confirmed CR or PR were analyzed.

End point type	Secondary

End point timeframe:

Median of 1.41 months of drug exposure

End point values	Participants with NMC	Participants with SCLC	Participants with CRPC	Participants with TNBC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	2[283]	0[284]	0[285]	0[286]
Units: Months				
median (confidence interval 95%)	4.5 (2.8 to 6.2)	(to)	(to)	(to)

Notes:
[283] - All Treated Population
[284] - All Treated Population
[285] - All Treated Population
[286] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	0[287]	0[288]		
Units: Months				
median (confidence interval 95%)	(to)	(to)		

Notes:
[287] - All Treated Population
[288] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Time to response-Besylate sub-study

End point title	Time to response-Besylate sub-study

End point description:

Time to response is defined, for participants with a confirmed CR or PR, as the time from first dose to the first documented evidence of CR or PR. Confidence intervals were estimated using Brookmeyer Crowley method. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP. Only those participants with confirmed CR or PR were analyzed.

End point type	Secondary

End point timeframe:

Median of 1.87 months of drug exposure

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	0[289]			
Units: Months				
median (confidence interval 95%)	(to)			

Notes:
[289] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of response-Part 1 QD

End point title	Duration of response-Part 1 QD[290]

End point description:

Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a response (i.e. unconfirmed or

confirmed CR or PR). Confidence intervals were estimated using Brookmeyer Crowley method. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level. 99999 indicates data could not be estimated due to insufficient participants. Only participants who achieved a response were analyzed.

End point type	Secondary

End point timeframe:

Median of 1.38 months of drug exposure

Notes:

[290] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[291]	0[292]	1[293]	0[294]
Units: Months				
median (confidence interval 95%)	(to)	(to)	99999 (-99999 to 99999)	(to)

Notes:

[291] - All Treated Population

[292] - All Treated Population

[293] - All Treated Population

[294] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	1[295]			
Units: Months				
median (confidence interval 95%)	4.4 (-99999 to 99999)			

Notes:

[295] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of response-Part 1 BID

End point title	Duration of response-Part 1 BID[296]

End point description:

Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a response (i.e. unconfirmed or confirmed CR or PR). Confidence intervals were estimated using Brookmeyer Crowley method. Only those participants who achieved a response were analyzed.

End point type	Secondary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[296] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0[297]	0[298]	0[299]	
Units: Months				
median (confidence interval 95%)	(to)	(to)	(to)	

Notes:

[297] - All Treated Population

[298] - All Treated Population

[299] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of response-Part 2

End point title	Duration of response-Part 2

End point description:

Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a response (i.e. unconfirmed or confirmed CR or PR). Confidence intervals were estimated using Brookmeyer Crowley method. Only those participants who achieved a response were analyzed.

End point type	Secondary

End point timeframe:

Median of 1.41 months of drug exposure

End point values	Participants with NMC	Participants with SCLC	Participants with CRPC	Participants with TNBC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	2[300]	0[301]	0[302]	0[303]
Units: Months				
median (confidence interval 95%)	2.7 (2.3 to 3.1)	(to)	(to)	(to)

Notes:

[300] - All Treated Population

[301] - All Treated Population

[302] - All Treated Population

[303] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	0[304]	0[305]		
Units: Months				
median (confidence interval 95%)	(to)	(to)		

Notes:

[304] - All Treated Population

[305] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of response-Besylate sub-study

End point title	Duration of response-Besylate sub-study

End point description:

Duration of response is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause among participants who achieve a response (i.e. unconfirmed or confirmed CR or PR). Confidence intervals were estimated using Brookmeyer Crowley method. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP. Only those participants who achieved a response were analyzed.

End point type	Secondary

End point timeframe:

Median of 1.87 months of drug exposure

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	0[306]			
Units: Months				
median (confidence interval 95%)	(to)			

Notes:

[306] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival-Part 1 QD

End point title	Overall survival-Part 1 QD[307]

End point description:

Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. Low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose level.

End point type	Secondary

End point timeframe:

Median of 1.38 months of drug exposure

Notes:

[307] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[308]	9[309]	32[310]	9[311]
Units: Months				
median (confidence interval 95%)	3.8 (2.8 to 5.4)	8.9 (3.6 to 20.2)	7.1 (3.9 to 9.5)	9.8 (6.0 to 18.0)

Notes:

[308] - All Treated Population

[309] - All Treated Population

[310] - All Treated Population

[311] - All Treated Population

End point values	Part 1: GSK525762 2-16 mg QD			
Subject group type	Subject analysis set			
Number of subjects analysed	11[312]			
Units: Months				
median (confidence interval 95%)	5.6 (0.9 to 9.1)			

Notes:

[312] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival-Part 1 BID

End point title	Overall survival-Part 1 BID[313]

End point description:

Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. 99999 indicates values could not be estimated due to limited amount of observed follow-up time.

End point type	Secondary

End point timeframe:

Median of 1.41 months of drug exposure

Notes:

[313] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[314]	10[315]	5[316]	
Units: Months				
median (confidence interval 95%)	99999 (14.5 to	6.0 (2.9 to	13.3 (7.9 to	

	99999)	12.2)	18.7)

Notes:

[314] - All Treated Population

[315] - All Treated Population

[316] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival-Part 2

End point title	Overall survival-Part 2

End point description:

Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. 99999 indicates the upper limit of the 95% CI could not be estimated due to the low number of participants being analyzed.

End point type	Secondary

End point timeframe:

Median of 1.41 months of drug exposure

End point values	Participants with NMC	Participants with SCLC	Participants with CRPC	Participants with TNBC
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	12[317]	14[318]	23[319]	19[320]
Units: Months				
median (confidence interval 95%)	5.0 (4.3 to 99999)	2.6 (1.1 to 9.4)	9.1 (6.7 to 11.7)	5.0 (2.3 to 10.3)

Notes:

[317] - All Treated Population

[318] - All Treated Population

[319] - All Treated Population

[320] - All Treated Population

End point values	Participants with ER+BC	Participants with GIST		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	21[321]	13[322]		
Units: Months				
median (confidence interval 95%)	8.8 (3.6 to 13.1)	7.3 (3.4 to 99999)		

Notes:

[321] - All Treated Population

[322] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival-Besylate sub-study

End point title	Overall survival-Besylate sub-study

End point description:

Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method. Data for Besylate sub-study participants were combined for analysis to provide useful interpretation of study data as pre-specified in RAP.

End point type	Secondary

End point timeframe:

Median of 1.87 months of drug exposure

End point values	All participants in Besylate sub-study			
Subject group type	Subject analysis set			
Number of subjects analysed	10[323]			
Units: Months				
median (confidence interval 95%)	6.3 (3.6 to 10.9)			

Notes:

[323] - All Treated Population

Statistical analyses

No statistical analyses for this end point

Secondary: AUC (0 to t), AUC (0 to 24) and AUC (0 to inf) of GSK525762-Part 1 QD

End point title	AUC (0 to t), AUC (0 to 24) and AUC (0 to inf) of GSK525762-Part 1 QD[324]

End point description:

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. PK parameter population comprised of all participants in the PK Concentration Population (all participants in the All Treated Population for whom a blood sample for pharmacokinetics is obtained and analyzed) for whom a PK parameter has been obtained. Only those participants with data available at the specified time points were available (indicated by n=X in category titles). 99999 indicates geometric coefficient of variation could not be calculated as only one participant was analyzed at the specified time point.

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

Notes:

[324] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[325]	9[326]	32[327]	9[328]
Units: Hours*nanogram per milliliter				
geometric mean (geometric coefficient of variation)				

AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9	3943.2 (± 49.5)	4225.0 (± 39.2)	5692.4 (± 61.4)	6958.3 (± 43.5)
AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6	3146.2 (± 54.5)	2575.6 (± 47.3)	2959.8 (± 48.4)	3818.5 (± 35.8)
AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9	4464.5 (± 62.9)	4357.5 (± 42.1)	5887.2 (± 62.8)	7295.6 (± 45.2)
AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9	4147.8 (± 54.3)	4304.1 (± 40.7)	5667.3 (± 61.5)	7218.4 (± 45.1)
AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6	3164.3 (± 54.7)	2576.9 (± 47.3)	2953.8 (± 49.0)	3819.9 (± 35.9)

Notes:

[325] - PK Parameter Population

[326] - PK Parameter Population

[327] - PK Parameter Population

[328] - PK Parameter Population

End point values	Part 1: GSK525762 2 mg QD	Part 1: GSK525762 4 mg QD	Part 1: GSK525762 8 mg QD	Part 1: GSK525762 16 mg QD
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3[329]	4[330]	1[331]	3[332]
Units: Hours*nanogram per milliliter				
geometric mean (geometric coefficient of variation)				
AUC (0 to 24); Week1;n=3,4,1,3,4,9,32,9	169.2 (± 39.4)	354.3 (± 33.8)	431.5 (± 99999)	867.9 (± 39.5)
AUC (0 to 24); Week3;n=1,2,1,3,4,6,16,6	152.9 (± 99999)	334.6 (± 60.5)	329.5 (± 99999)	671.6 (± 21.4)
AUC (0 to inf); Week1;n=3,4,1,3,4,9,32,9	174.4 (± 44.3)	360.8 (± 35.1)	433.1 (± 99999)	887.1 (± 39.1)
AUC (0 to t); Week1;n=3,4,1,3,4,9,32,9	168.6 (± 44.5)	357.5 (± 34.8)	431.1 (± 99999)	877.7 (± 39.4)
AUC (0 to t); Week3;n=1,2,1,3,4,6,16,6	152.8 (± 99999)	334.3 (± 60.3)	330.6 (± 99999)	672.3 (± 21.5)

Notes:

[329] - PK Parameter Population

[330] - PK Parameter Population

[331] - PK Parameter Population

[332] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum observed concentration for GSK525762-Part 1 QD

End point title	Maximum observed concentration for GSK525762-Part 1

End point description:

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). 99999 indicates geometric coefficient of variation could not be calculated as only one participant was analyzed at the specified time point.

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

Notes:

[333] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[334]	9[335]	32[336]	9[337]
Units: Nanogram per milliliter				
geometric mean (geometric coefficient of variation)				
Week1;n=3,4,1,3,4,9,32,9	603.92 (± 30.3)	889.52 (± 24.5)	1099.81 (± 62.7)	1080.49 (± 38.8)
Week3;n=1,2,1,3,4,6,16,6	602.70 (± 17.2)	633.71 (± 52.6)	815.40 (± 41.1)	918.56 (± 41.4)

Notes:

[334] - PK Parameter Population

[335] - PK Parameter Population

[336] - PK Parameter Population

[337] - PK Parameter Population

End point values	Part 1: GSK525762 2 mg QD	Part 1: GSK525762 4 mg QD	Part 1: GSK525762 8 mg QD	Part 1: GSK525762 16 mg QD
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3[338]	4[339]	1[340]	3[341]
Units: Nanogram per milliliter				
geometric mean (geometric coefficient of variation)				
Week1;n=3,4,1,3,4,9,32,9	50.95 (± 41.5)	70.46 (± 29.2)	120.35 (± 99999)	179.45 (± 39.9)
Week3;n=1,2,1,3,4,6,16,6	52.04 (± 99999)	53.37 (± 16.3)	103.18 (± 99999)	137.57 (± 25.1)

Notes:

[338] - PK Parameter Population

[339] - PK Parameter Population

[340] - PK Parameter Population

[341] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Lambda z for GSK525762-Part 1 QD

End point title	Lambda z for GSK525762-Part 1 QD[342]

End point description:

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). 99999 indicates geometric coefficient of variation could not be calculated as only one participant was analyzed at the specified time point.

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

Notes:

[342] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[343]	9[344]	32[345]	9[346]
Units: Per hour				
geometric mean (geometric coefficient of variation)				
Week1;n=3,4,1,3,4,9,32,9	0.07863 (± 53.1)	0.12468 (± 28.2)	0.15613 (± 34.1)	0.10992 (± 16.0)
Week3;n=1,2,1,3,4,6,16,6	0.12513 (± 12.7)	0.17629 (± 26.3)	0.16667 (± 30.6)	0.17560 (± 21.1)

Notes:

[343] - PK Parameter Population

[344] - PK Parameter Population

[345] - PK Parameter Population

[346] - PK Parameter Population

End point values	Part 1: GSK525762 2 mg QD	Part 1: GSK525762 4 mg QD	Part 1: GSK525762 8 mg QD	Part 1: GSK525762 16 mg QD
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3[347]	4[348]	1[349]	3[350]
Units: Per hour				
geometric mean (geometric coefficient of variation)				
Week1;n=3,4,1,3,4,9,32,9	0.21411 (± 98.4)	0.13554 (± 37.4)	0.23126 (± 99999)	0.09903 (± 43.5)
Week3;n=1,2,1,3,4,6,16,6	0.15579 (± 99999)	0.15472 (± 11.2)	0.14087 (± 99999)	0.15599 (± 21.7)

Notes:

[347] - PK Parameter Population

[348] - PK Parameter Population

[349] - PK Parameter Population

[350] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Tmax for GSK525762-Part 1 QD

End point title	Tmax for GSK525762-Part 1 QD[351]

End point description:

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

Notes:

[351] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[352]	9[353]	32[354]	9[355]
Units: Hours				
median (full range (min-max))				
Week1;n=3,4,1,3,4,9,32,9	2.0083 (0.967 to 2.233)	1.0000 (0.517 to 4.000)	1.0000 (0.250 to 4.000)	1.0000 (0.667 to 3.950)
Week3;n=1,2,1,3,4,6,16,6	0.9000 (0.317 to 4.000)	1.0583 (0.500 to 2.033)	0.5667 (0.300 to 4.017)	1.5000 (0.500 to 2.000)

Notes:

[352] - PK Parameter Population

[353] - PK Parameter Population

[354] - PK Parameter Population

[355] - PK Parameter Population

End point values	Part 1: GSK525762 2 mg QD	Part 1: GSK525762 4 mg QD	Part 1: GSK525762 8 mg QD	Part 1: GSK525762 16 mg QD
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3[356]	4[357]	1[358]	3[359]
Units: Hours				
median (full range (min-max))				
Week1;n=3,4,1,3,4,9,32,9	0.5833 (0.500 to 0.633)	1.2250 (0.500 to 2.000)	1.1000 (1.100 to 1.100)	2.0167 (0.333 to 3.967)
Week3;n=1,2,1,3,4,6,16,6	1.0000 (1.000 to 1.000)	2.5083 (1.017 to 4.000)	0.5000 (0.500 to 0.500)	1.0500 (0.767 to 4.000)

Notes:

[356] - PK Parameter Population

[357] - PK Parameter Population

[358] - PK Parameter Population

[359] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Apparent clearance of GSK525762-Part 1 QD

End point title	Apparent clearance of GSK525762-Part 1 QD[360]

End point description:

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). 99999 indicates geometric coefficient of variation could not be calculated as only one participant was analyzed at the specified time point.

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

Notes:

[360] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[361]	9[362]	32[363]	9[364]
Units: Liter per hour				
geometric mean (geometric coefficient of variation)				
Week1;n=3,4,1,3,4,9,32,9	6.720 (± 62.9)	13.769 (± 42.1)	13.589 (± 62.8)	13.707 (± 45.2)
Week3;n=1,2,1,3,4,6,16,6	9.535 (± 54.5)	23.296 (± 47.3)	27.029 (± 48.4)	26.188 (± 35.8)

Notes:

[361] - PK Parameter Population

[362] - PK Parameter Population

[363] - PK Parameter Population

[364] - PK Parameter Population

End point values	Part 1: GSK525762 2 mg QD	Part 1: GSK525762 4 mg QD	Part 1: GSK525762 8 mg QD	Part 1: GSK525762 16 mg QD
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3[365]	4[366]	1[367]	3[368]
Units: Liter per hour				
geometric mean (geometric coefficient of variation)				
Week1;n=3,4,1,3,4,9,32,9	11.467 (± 44.3)	11.085 (± 35.1)	18.470 (± 99999)	18.036 (± 39.1)
Week3;n=1,2,1,3,4,6,16,6	13.082 (± 99999)	11.955 (± 60.5)	24.277 (± 99999)	23.823 (± 21.4)

Notes:

[365] - PK Parameter Population

[366] - PK Parameter Population

[367] - PK Parameter Population

[368] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Volume of distribution of GSK525762-Part 1 QD

End point title	Volume of distribution of GSK525762-Part 1 QD[369]

End point description:

Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles). 99999 indicates geometric coefficient of variation could not be calculated as only one participant was analyzed at the specified time point.

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4

Notes:

[369] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4[370]	9[371]	32[372]	9[373]
Units: Liters				
geometric mean (geometric coefficient of variation)				
Week1;n=3,4,1,3,4,9,32,9	85.46 (± 30.3)	110.44 (± 23.5)	87.03 (± 56.4)	124.70 (± 42.6)
Week3;n=1,2,1,3,4,6,16,6	76.20 (± 44.0)	132.14 (± 34.7)	162.17 (± 40.6)	149.14 (± 26.9)

Notes:

[370] - PK Parameter Population

[371] - PK Parameter Population

[372] - PK Parameter Population

[373] - PK Parameter Population

End point values	Part 1: GSK525762 2 mg QD	Part 1: GSK525762 4 mg QD	Part 1: GSK525762 8 mg QD	Part 1: GSK525762 16 mg QD
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3[374]	4[375]	1[376]	3[377]
Units: Liters				
geometric mean (geometric coefficient of variation)				
Week1;n=3,4,1,3,4,9,32,9	53.56 (± 65.9)	81.79 (± 34.7)	79.87 (± 99999)	182.13 (± 92.7)
Week3;n=1,2,1,3,4,6,16,6	83.97 (± 99999)	77.27 (± 47.0)	172.33 (± 99999)	152.72 (± 44.5)

Notes:

[374] - PK Parameter Population

[375] - PK Parameter Population

[376] - PK Parameter Population

[377] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: AUC (0 to inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID

End point title	AUC (0 to inf), AUC (0 to 24) and AUC (0 to t) of GSK525762-Part 1 BID[378]

End point description:

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3

Day4

Notes:

[378] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[379]	10[380]	5[381]	
Units: Hours*nanogram per milliter				
geometric mean (geometric coefficient of variation)				
AUC (0 to 24); Week1 AM dose;n=3,10,5	856.1 (± 123.7)	3067.0 (± 43.9)	2794.4 (± 31.8)	
AUC (0 to 24); Week1 PM dose;n=4,7,5	981.4 (± 84.8)	3261.1 (± 59.9)	2607.6 (± 36.2)	
AUC (0 to 24); Week3 AM dose;n=3,7,3	1279.0 (± 116.2)	2725.3 (± 92.4)	1184.6 (± 17.8)	
AUC (0 to 24); Week3 PM dose;n=3,5,3	1155.8 (± 102.4)	1662.1 (± 29.2)	1131.6 (± 28.5)	
AUC (0 to inf); Week1 AM dose;n=3,10,5	860.4 (± 124.4)	3118.3 (± 45.3)	2825.8 (± 32.8)	
AUC (0 to t); Week1 AM dose;n=4,10,5	932.2 (± 97.6)	2727.2 (± 40.8)	2579.0 (± 28.0)	
AUC (0 to t); Week1 PM dose;n=4,9,5	927.5 (± 82.5)	2840.4 (± 43.4)	2446.7 (± 34.2)	
AUC (0 to t); Week3 AM dose;n=3,7,3	1194.6 (± 110.1)	2472.4 (± 89.8)	1140.9 (± 16.9)	
AUC (0 to t); Week3 PM dose;n=3,6,3	1053.6 (± 96.6)	1490.8 (± 23.3)	1073.6 (± 29.2)	

Notes:

[379] - PK Parameter Population

[380] - PK Parameter Population

[381] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum observed concentration of GSK525762-Part 1 BID

End point title	Maximum observed concentration of GSK525762-Part 1 BID[382]

End point description:

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

Notes:

[382] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[383]	10[384]	5[385]	
Units: Nanogram per milliter				
geometric mean (geometric coefficient of variation)				
Week1 AM dose;n=4,10,5	231.68 (± 70.6)	628.01 (± 40.0)	703.31 (± 34.2)	
Week1 PM dose;n=4,9,5	166.62 (± 62.0)	445.17 (± 27.6)	425.76 (± 29.3)	
Week3 AM dose;n=3,7,3	284.71 (± 87.1)	604.38 (± 66.4)	419.15 (± 18.1)	
Week3 PM dose;n=3,6,3	256.08 (± 94.0)	263.72 (± 41.3)	229.91 (± 34.8)	

Notes:

[383] - PK Parameter Population

[384] - PK Parameter Population

[385] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Lambda z for GSK525762-Part 1 BID

End point title	Lambda z for GSK525762-Part 1 BID[386]

End point description:

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

Notes:

[386] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[387]	10[388]	5[389]	
Units: Per hour				
geometric mean (geometric coefficient of variation)				
Week1 AM dose;n=3,10,5	0.23463 (± 19.4)	0.19989 (± 29.6)	0.23721 (± 39.4)	
Week1 PM dose;n=3,7,3	0.21171 (± 23.1)	0.14307 (± 36.6)	0.18789 (± 25.2)	
Week3 AM dose;n=3,7,3	0.23565 (± 27.2)	0.21751 (± 27.7)	0.30868 (± 19.6)	
Week3 PM dose;n=3,5,3	0.20507 (± 21.5)	0.19263 (± 27.7)	0.29133 (± 15.8)	

Notes:

[387] - PK Parameter Population

[388] - PK Parameter Population

[389] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Tmax for GSK525762-Part 1 BID

End point title	Tmax for GSK525762-Part 1 BID[390]

End point description:

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

Notes:

[390] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[391]	10[392]	5[393]	
Units: Hour				
median (full range (min-max))				
Week1 AM dose;n=4,10,5	1.5500 (0.583 to 4.283)	0.9667 (0.550 to 2.100)	0.5500 (0.517 to 1.033)	
Week1 PM dose;n=4,9,5	1.9583 (1.917 to 4.000)	1.9667 (0.967 to 4.167)	1.9833 (1.017 to 7.733)	
Week3 AM dose;n=3,7,3	1.1833 (1.167 to 2.067)	1.0667 (0.250 to 2.017)	0.5833 (0.183 to 1.000)	
Week3 PM dose;n=3,6,3	1.0000 (0.500 to 2.083)	1.4500 (0.000 to 2.083)	2.0667 (1.900 to 2.067)	

Notes:

[391] - PK Parameter Population

[392] - PK Parameter Population

[393] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Apparent clearance of GSK525762-Part 1 BID

End point title	Apparent clearance of GSK525762-Part 1 BID[394]

End point description:

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM)

dose for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

Notes:

[394] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[395]	10[396]	5[397]	
Units: Liter per hour				
geometric mean (geometric coefficient of variation)				
Week1 AM dose;n=3,10,5	23.246 (± 124.4)	9.621 (± 45.3)	14.155 (± 32.8)	
Week1 PM dose;n=4,7,5	21.745 (± 82.7)	11.057 (± 48.1)	16.382 (± 34.6)	
Week3 AM dose;n=3,7,3	16.731 (± 110.1)	11.949 (± 86.1)	34.623 (± 18.7)	
Week3 PM dose;n=3,5,3	18.867 (± 96.0)	20.133 (± 26.2)	37.097 (± 29.4)	

Notes:

[395] - PK Parameter Population

[396] - PK Parameter Population

[397] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Secondary: Volume of distribution of GSK525762-Part 1 BID

End point title	Volume of distribution of GSK525762-Part 1 BID[398]

End point description:

Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).

End point type	Secondary

End point timeframe:

pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4

Notes:

[398] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The end point is reported only in arms with once daily dose.

End point values	Part 1: GSK525762 20 mg BID	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4[399]	10[400]	5[401]	
Units: Liters				
geometric mean (geometric coefficient of variation)				
Week1 AM dose;n=3,10,5	99.07 (± 91.0)	48.13 (± 40.8)	59.67 (± 35.0)	
Week1 PM dose;n=3,7,3	116.52 (± 66.0)	77.28 (± 16.6)	81.11 (± 52.6)	
Week3 AM dose;n=3,7,3	71.00 (± 72.8)	54.94 (± 61.4)	112.17 (± 37.6)	
Week3 PM dose;n=3,5,3	92.00 (± 65.3)	104.52 (± 29.5)	127.34 (± 41.7)	

Notes:

[399] - PK Parameter Population

[400] - PK Parameter Population

[401] - PK Parameter Population

Statistical analyses

No statistical analyses for this end point

Adverse events information

Timeframe for reporting adverse events:

Adverse events and serious adverse events were collected for a duration of Median of 1.38 months of drug exposure-Part 1 QD, Median of 1.41 months of drug exposure-Part 1 BID and Part 2 and Median of 1.87 months of drug exposure-Besylate sub-study.

Adverse event reporting additional description:

Adverse events were collected in the All Treated Population. Data for low doses (GSK525762 2-16 mg QD) were combined to better interpret study data as there were small numbers of participants within a single low dose. Data for besylate sub-study participants were combined for analysis to provide useful interpretation of study data.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	21.0

Reporting groups

Reporting group title	Part 1: GSK525762 2-16 mg QD

Reporting group description:

Participants were administered once daily (QD) oral dose of 2 to 16 milligrams (mg) GSK525762.

Reporting group title	Part 1: GSK525762 30 mg QD

Reporting group description:

Participants were administered once daily oral dose of 30 mg GSK525762.

Reporting group title	Part 1: GSK525762 60 mg QD

Reporting group description:

Participants were administered once daily oral dose of 60 mg GSK525762.

Reporting group title	Part 1: GSK525762 80 mg QD

Reporting group description:

Participants were administered once daily oral dose of 80 mg GSK525762.

Reporting group title	Part 1: GSK525762 100 mg QD

Reporting group description:

Participants were administered once daily oral dose of 100 mg GSK525762.

Reporting group title	Part 1: GSK525762 20 mg BID

Reporting group description:

Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.

Reporting group title	Part 1: GSK525762 30 mg BID

Reporting group description:

Participants were administered twice daily oral dose of 30 mg GSK525762.

Reporting group title	Part 1: GSK525762 40 mg BID

Reporting group description:

Participants were administered twice daily oral dose of 40 mg GSK525762.

Reporting group title	Part 2: Participants with NMC

Reporting group description:

Participants with NUT Midline Carcinoma (NMC) were administered continuous once daily oral dose of 75 mg GSK525762.

Reporting group title	Part 2: Participants with SCLC

Reporting group description:

Participants with small cell lung cancer(SCLC) were administered continuous once daily oral dose of 75 mg GSK525762

Reporting group title	Part 2: Participants with CRPC

Reporting group description:

Participants with Castrate-Resistant Prostate Cancer (CRPR) were administered continuous once daily

oral dose of 75 mg GSK525762

Reporting group title	Part 2: Participants with TNBC

Reporting group description:

Participants with Triple Negative Breast Cancer (TNBC) were administered continuous once daily oral dose of 75 mg GSK525762.

Reporting group title	Part 2: Participants with ER+BC

Reporting group description:

Participants with estrogen receptor positive breast cancer (ER+BC) were administered continuous once daily oral dose of 75 mg GSK525762

Reporting group title	Part 2: Participants with GIST

Reporting group description:

Participants with Gastrointestinal Stromal Tumor (GIST) were administered continuous once daily oral dose of 75 mg GSK525762.

Reporting group title	Besylate Substudy

Reporting group description:

All participants who entered besylate substudy and received 80 mg amor free-base tablet along with 6 mg stable iso in solution in fasted state; 80 mg bes tablet along with 6 mg stable iso in solution in fasted state, 30 mg bes tablet along with 6 mg stable iso in solution in fasted state and 80 mg bes tablet with FDA recommended high fat breakfast in one of the treatment periods were included

Serious adverse events	Part 1: GSK525762 2-16 mg QD	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 11 (18.18%)	1 / 4 (25.00%)	2 / 9 (22.22%)
number of deaths (all causes)	10	4	7
number of deaths resulting from adverse events			
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranasal sinus haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumothorax			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 11 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amylase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Blood creatinine increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulation factor VII level decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prothrombin time prolonged			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin I increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Post procedural haematoma			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiotoxicity			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyrotoxic cardiomyopathy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Haemorrhage intracranial			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Histiocytosis haematophagic			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal toxicity			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritoneal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varices oesophageal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cellulitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 11 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD	Part 1: GSK525762 20 mg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	21 / 32 (65.63%)	3 / 9 (33.33%)	0 / 4 (0.00%)
number of deaths (all causes)	30	7	1
number of deaths resulting from adverse events			
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pyrexia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranasal sinus haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amylase increased			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulation factor VII level decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prothrombin time prolonged			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin I increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Post procedural haematoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Atrial fibrillation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiotoxicity			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyrotoxic cardiomyopathy			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Haemorrhage intracranial			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Histiocytosis haematophagic			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	8 / 32 (25.00%)	2 / 9 (22.22%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	9 / 10	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal toxicity			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	4 / 32 (12.50%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	4 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritoneal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varices oesophageal			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	3 / 32 (9.38%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cellulitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			

subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	Part 2: Participants with NMC
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 10 (40.00%)	2 / 5 (40.00%)	6 / 12 (50.00%)
number of deaths (all causes)	9	3	8
number of deaths resulting from adverse events			
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pyrexia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranasal sinus haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amylase increased			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulation factor VII level decreased			
subjects affected / exposed	1 / 10 (10.00%)	2 / 5 (40.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	1 / 1	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prothrombin time prolonged			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin I increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Post procedural haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Atrial fibrillation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiotoxicity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyrotoxic cardiomyopathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Haemorrhage intracranial			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	2 / 12 (16.67%)
occurrences causally related to treatment / all	1 / 1	1 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Histiocytosis haematophagic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	3 / 12 (25.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	5 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal toxicity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritoneal haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varices oesophageal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cellulitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 2: Participants with SCLC	Part 2: Participants with CRPC	Part 2: Participants with TNBC
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 14 (64.29%)	16 / 23 (69.57%)	11 / 19 (57.89%)
number of deaths (all causes)	12	21	16
number of deaths resulting from adverse events			
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	1 / 14 (7.14%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pyrexia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranasal sinus haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Respiratory failure			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amylase increased			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulation factor VII level decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prothrombin time prolonged			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin I increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Post procedural haematoma			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Atrial fibrillation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiotoxicity			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyrotoxic cardiomyopathy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Haemorrhage intracranial			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 14 (0.00%)	3 / 23 (13.04%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Histiocytosis haematophagic			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	4 / 14 (28.57%)	9 / 23 (39.13%)	4 / 19 (21.05%)
occurrences causally related to treatment / all	5 / 5	10 / 10	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			

subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal toxicity			
subjects affected / exposed	1 / 14 (7.14%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 14 (0.00%)	3 / 23 (13.04%)	2 / 19 (10.53%)
occurrences causally related to treatment / all	0 / 0	2 / 3	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritoneal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			

subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varices oesophageal			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 14 (7.14%)	4 / 23 (17.39%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	1 / 1	3 / 4	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 14 (0.00%)	3 / 23 (13.04%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cellulitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Respiratory tract infection			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 14 (0.00%)	2 / 23 (8.70%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 14 (7.14%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 2: Participants with ER+BC	Part 2: Participants with GIST	Besylate Substudy
Total subjects affected by serious adverse events			
subjects affected / exposed	15 / 21 (71.43%)	8 / 13 (61.54%)	6 / 10 (60.00%)
number of deaths (all causes)	17	5	9
number of deaths resulting from adverse events			
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pyrexia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Vaginal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemothorax			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranasal sinus haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amylase increased			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulation factor VII level decreased			
subjects affected / exposed	2 / 21 (9.52%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	2 / 2	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ejection fraction decreased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prothrombin time prolonged			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin I increased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Post procedural haematoma			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Atrial fibrillation			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiotoxicity			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyrotoxic cardiomyopathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Haemorrhage intracranial			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Loss of consciousness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Histiocytosis haematophagic			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	4 / 10 (40.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal toxicity			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Large intestinal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritoneal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varices oesophageal			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic haemorrhage			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cellulitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			

subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Part 1: GSK525762 2-16 mg QD	Part 1: GSK525762 30 mg QD	Part 1: GSK525762 60 mg QD
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 11 (100.00%)	3 / 4 (75.00%)	9 / 9 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Infected neoplasm			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haematoma			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hypotension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Axillary pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Catheter site inflammation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Face oedema			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	2 / 11 (18.18%)	1 / 4 (25.00%)	3 / 9 (33.33%)
occurrences (all)	2	1	3
Gait disturbance			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Non-cardiac chest pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Oedema peripheral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Xerosis			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Breast pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Metrorrhagia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pelvic haematoma			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Perineal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vaginal discharge			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vaginal odour			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			

Acute respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	3 / 9 (33.33%)
occurrences (all)	1	0	3
Dysphonia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Haemoptysis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Laryngeal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nocturnal dyspnoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0

Orthopnoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pharyngeal oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Pleural effusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pneumonia aspiration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pulmonary alveolar haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Respiratory symptom			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sputum discoloured			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Throat clearing			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Upper-airway cough syndrome			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Wheezing			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Anhedonia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	2 / 11 (18.18%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	2	1	0
Confusional state			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Depression			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Disorientation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hallucination			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hallucination, visual			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Mental status changes			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Mood altered			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Alanine aminotransferase increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Amylase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 11 (9.09%)	1 / 4 (25.00%)	1 / 9 (11.11%)
occurrences (all)	1	1	1
Bacterial test positive			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bilirubin conjugated increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood albumin increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			

subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Blood bilirubin unconjugated increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood chloride decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase MB increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Blood creatinine increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood fibrinogen decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood fibrinogen increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood insulin increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Blood triglycerides increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Blood uric acid increased			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Brain natriuretic peptide increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Coagulation factor VII level decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QRS complex prolonged			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Lipase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
N-terminal prohormone brain natriuretic peptide increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Occult blood positive			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Oxygen saturation decreased			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Protein urine present			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Prothrombin time ratio decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Thyroxine free decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Thyroxine free increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Transaminases increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tri-iodothyronine free decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Troponin T increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
White blood cells urine positive			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Allergic transfusion reaction			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Animal bite			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cystitis radiation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Fall			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Genital contusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Postoperative wound complication			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Radiation oesophagitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Transfusion reaction			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic			

disorders			
Factor V deficiency			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nodal rhythm			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pericardial effusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Supraventricular tachycardia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cervical radiculopathy			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 11 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Drug withdrawal headache			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysaesthesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 4 (25.00%)	3 / 9 (33.33%)
occurrences (all)	0	1	5
Headache			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Intercostal neuralgia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Loss of consciousness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Post herpetic neuralgia			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Syncope			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tension headache			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Ischaemic stroke			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haemorrhage intracranial			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 4 (25.00%)	1 / 9 (11.11%)
occurrences (all)	0	2	1
Haemorrhagic diathesis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Increased tendency to bruise			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Leukocytosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Leukopenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 4 (25.00%)	2 / 9 (22.22%)
occurrences (all)	1	1	2
Ear and labyrinth disorders			
Ear haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Vertigo			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Optic neuropathy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Orbital oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Xerophthalmia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Abdominal hernia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0

Abdominal pain lower			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Abdominal tenderness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Anal fissure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Anal inflammation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Chapped lips			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cheilitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	4 / 11 (36.36%)	1 / 4 (25.00%)	2 / 9 (22.22%)
occurrences (all)	4	1	2
Diarrhoea			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	2

Dry mouth			
subjects affected / exposed	3 / 11 (27.27%)	2 / 4 (50.00%)	0 / 9 (0.00%)
occurrences (all)	3	2	0
Dyspepsia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Dysphagia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Faeces discoloured			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Faeces soft			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	2 / 11 (18.18%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastric haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal fistula			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gingival pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Glossitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haematemesis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Impaired gastric emptying			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Lip dry			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	3 / 11 (27.27%)	3 / 4 (75.00%)	2 / 9 (22.22%)
occurrences (all)	4	3	2
Odynophagia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Oesophagitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Perianal erythema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	3 / 11 (27.27%)	1 / 4 (25.00%)	2 / 9 (22.22%)
occurrences (all)	3	1	2
Varices oesophageal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hepatic pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Liver disorder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Portal vein thrombosis			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Dermatitis bullous			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Dermatitis contact			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Ecchymosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Guttate psoriasis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hair colour changes			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hidradenitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Hyperhidrosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Ingrowing nail			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Leukoplakia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Madarosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Night sweats			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Onycholysis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pigmentation disorder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Purpura			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rash			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Rash erythematous			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin burning sensation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Skin lesion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			

subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Urticaria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Anuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Chromaturia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Haematuria			
subjects affected / exposed	0 / 11 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Hydronephrosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypertonic bladder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Neurogenic bladder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Urinary hesitation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Urinary retention			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Urinary tract disorder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Urine odour abnormal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Arthritis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Bone pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Connective tissue disorder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Joint swelling			

subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal disorder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Angular cheilitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Catheter site infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Cellulitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Endometritis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Genital herpes simplex			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Herpes dermatitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Herpes virus infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Herpes zoster			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Infected cyst			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Infected skin ulcer			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lip infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lung infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nail infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Pharyngitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rhinovirus infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin candida			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Subcutaneous abscess			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vaginal infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Clostridium difficile colitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 11 (18.18%)	1 / 4 (25.00%)	2 / 9 (22.22%)
occurrences (all)	2	1	2
Dehydration			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypermagnesaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hypoalbuminaemia			
subjects affected / exposed	4 / 11 (36.36%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	4	0	0
Hypocalcaemia			

subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Hypocholesterolaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Hypomagnesaemia			
subjects affected / exposed	3 / 11 (27.27%)	1 / 4 (25.00%)	0 / 9 (0.00%)
occurrences (all)	3	1	0
Hyponatraemia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Iron deficiency			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Metabolic acidosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 4 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Part 1: GSK525762 80 mg QD	Part 1: GSK525762 100 mg QD	Part 1: GSK525762 20 mg BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	31 / 32 (96.88%)	9 / 9 (100.00%)	4 / 4 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Infected neoplasm			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			

Flushing			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hypertension			
subjects affected / exposed	2 / 32 (6.25%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Hypotension			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Lymphoedema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	10 / 32 (31.25%)	0 / 9 (0.00%)	1 / 4 (25.00%)
occurrences (all)	13	0	1
Axillary pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Catheter site inflammation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	1 / 32 (3.13%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Chills			

subjects affected / exposed	1 / 32 (3.13%)	1 / 9 (11.11%)	1 / 4 (25.00%)
occurrences (all)	1	1	1
Face oedema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	11 / 32 (34.38%)	5 / 9 (55.56%)	1 / 4 (25.00%)
occurrences (all)	12	6	1
Gait disturbance			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Mucosal inflammation			
subjects affected / exposed	3 / 32 (9.38%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
Non-cardiac chest pain			
subjects affected / exposed	3 / 32 (9.38%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
Oedema peripheral			
subjects affected / exposed	2 / 32 (6.25%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Pain			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Pyrexia			

subjects affected / exposed	6 / 32 (18.75%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	8	0	0
Xerosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Breast pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Metrorrhagia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pelvic haematoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Perineal pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vaginal discharge			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vaginal odour			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pain			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	4 / 32 (12.50%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	4	2	0
Dysphonia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Dyspnoea			
subjects affected / exposed	5 / 32 (15.63%)	5 / 9 (55.56%)	0 / 4 (0.00%)
occurrences (all)	7	6	0
Dyspnoea exertional			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	5 / 32 (15.63%)	2 / 9 (22.22%)	0 / 4 (0.00%)
occurrences (all)	5	2	0
Haemoptysis			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
Laryngeal pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nocturnal dyspnoea			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Orthopnoea			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Pharyngeal oedema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Pneumonia aspiration			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Pulmonary alveolar haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Respiratory symptom			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Rhinorrhoea			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Sputum discoloured			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Throat clearing			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Anhedonia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	2 / 32 (6.25%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	2	2	0
Confusional state			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 32 (0.00%)	2 / 9 (22.22%)	0 / 4 (0.00%)
occurrences (all)	0	2	0
Disorientation			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0

Hallucination			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Hallucination, visual			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Mental status changes			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Mood altered			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	2 / 32 (6.25%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	3	1	0
Alanine aminotransferase increased			
subjects affected / exposed	4 / 32 (12.50%)	2 / 9 (22.22%)	0 / 4 (0.00%)
occurrences (all)	5	2	0
Amylase increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	5 / 32 (15.63%)	2 / 9 (22.22%)	0 / 4 (0.00%)
occurrences (all)	6	2	0
Bacterial test positive			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Bilirubin conjugated increased			
subjects affected / exposed	1 / 32 (3.13%)	2 / 9 (22.22%)	0 / 4 (0.00%)
occurrences (all)	1	2	0
Blood albumin increased			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Blood bilirubin unconjugated increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood chloride decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase MB increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 32 (3.13%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	1	2	0
Blood creatinine increased			
subjects affected / exposed	3 / 32 (9.38%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
Blood fibrinogen decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood fibrinogen increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood insulin increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Blood triglycerides increased			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Brain natriuretic peptide increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Coagulation factor VII level decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QRS complex prolonged			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
International normalised ratio increased			
subjects affected / exposed	7 / 32 (21.88%)	2 / 9 (22.22%)	1 / 4 (25.00%)
occurrences (all)	7	2	1
Lipase increased			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
N-terminal prohormone brain natriuretic peptide increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Occult blood positive			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Oxygen saturation decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Protein urine present			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	4 / 32 (12.50%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	5	0	0
Prothrombin time ratio decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Thyroxine free decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Thyroxine free increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Tri-iodothyronine free decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Troponin T increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Weight decreased			
subjects affected / exposed	3 / 32 (9.38%)	4 / 9 (44.44%)	0 / 4 (0.00%)
occurrences (all)	3	5	0
White blood cells urine positive			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural			

complications			
Allergic transfusion reaction			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Animal bite			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	2 / 32 (6.25%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Cystitis radiation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	1 / 32 (3.13%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Genital contusion			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Postoperative wound complication			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Procedural pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Radiation oesophagitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Transfusion reaction			

subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Congenital, familial and genetic disorders			
Factor V deficiency			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Nodal rhythm			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Palpitations			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Pericardial effusion			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Sinus tachycardia			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Balance disorder			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cervical radiculopathy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	3 / 32 (9.38%)	2 / 9 (22.22%)	0 / 4 (0.00%)
occurrences (all)	3	3	0
Drug withdrawal headache			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dysaesthesia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	8 / 32 (25.00%)	5 / 9 (55.56%)	1 / 4 (25.00%)
occurrences (all)	9	6	1
Headache			
subjects affected / exposed	3 / 32 (9.38%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	5	1	0
Intercostal neuralgia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Loss of consciousness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Somnolence			
subjects affected / exposed	3 / 32 (9.38%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
Syncope			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tension headache			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Tremor			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Ischaemic stroke			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Haemorrhage intracranial			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	11 / 32 (34.38%)	5 / 9 (55.56%)	2 / 4 (50.00%)
occurrences (all)	14	5	2
Haemorrhagic diathesis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Increased tendency to bruise			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Leukopenia			
subjects affected / exposed	2 / 32 (6.25%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Lymphopenia			
subjects affected / exposed	4 / 32 (12.50%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	7	0	0
Neutropenia			
subjects affected / exposed	2 / 32 (6.25%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	3	1	0
Thrombocytopenia			
subjects affected / exposed	18 / 32 (56.25%)	5 / 9 (55.56%)	1 / 4 (25.00%)
occurrences (all)	39	8	1
Ear and labyrinth disorders			
Ear haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dry eye			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Optic neuropathy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Orbital oedema			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Vision blurred			
subjects affected / exposed	3 / 32 (9.38%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Xerophthalmia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Abdominal hernia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Abdominal pain			
subjects affected / exposed	4 / 32 (12.50%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Abdominal tenderness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Anal fissure			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Anal inflammation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Chapped lips			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Cheilitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	1 / 32 (3.13%)	3 / 9 (33.33%)	1 / 4 (25.00%)
occurrences (all)	1	3	1

Diarrhoea			
subjects affected / exposed	11 / 32 (34.38%)	4 / 9 (44.44%)	0 / 4 (0.00%)
occurrences (all)	16	5	0
Dry mouth			
subjects affected / exposed	3 / 32 (9.38%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0
Dyspepsia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Dysphagia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Eructation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Faeces discoloured			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Faeces soft			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Flatulence			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Gastric haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Gastrointestinal fistula			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 32 (3.13%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Gingival bleeding			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	6	0	0
Gingival pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Glossitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Haematemesis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Haemorrhoids			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia oral			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Impaired gastric emptying			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	15 / 32 (46.88%)	7 / 9 (77.78%)	2 / 4 (50.00%)
occurrences (all)	19	10	2

Odynophagia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Perianal erythema			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Toothache			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	11 / 32 (34.38%)	4 / 9 (44.44%)	3 / 4 (75.00%)
occurrences (all)	20	5	3
Varices oesophageal			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hepatic pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	9 / 32 (28.13%)	5 / 9 (55.56%)	1 / 4 (25.00%)
occurrences (all)	11	6	1
Liver disorder			

subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Portal vein thrombosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Blister			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Dermatitis acneiform			
subjects affected / exposed	3 / 32 (9.38%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	3	1	0
Dermatitis bullous			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	2 / 32 (6.25%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Ecchymosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Guttate psoriasis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hair colour changes			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0

Hidradenitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ingrowing nail			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Leukoplakia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Madarosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Onycholysis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pigmentation disorder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	2 / 32 (6.25%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Purpura			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	5 / 32 (15.63%)	2 / 9 (22.22%)	0 / 4 (0.00%)
occurrences (all)	5	2	0
Rash erythematous			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Rash macular			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Rash papular			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Rash pruritic			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Skin burning sensation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin lesion			

subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	3 / 32 (9.38%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	3	1	0
Anuria			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Chromaturia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	3 / 32 (9.38%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
Haematuria			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hydronephrosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypertonic bladder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Neurogenic bladder			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Nocturia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Proteinuria			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Urinary hesitation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Urinary tract disorder			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Urine odour abnormal			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 32 (9.38%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
Arthritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	4 / 32 (12.50%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	6	1	0
Bone pain			
subjects affected / exposed	1 / 32 (3.13%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Connective tissue disorder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Groin pain			

subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Joint swelling			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	3 / 32 (9.38%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	4	1	0
Musculoskeletal disorder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	1 / 32 (3.13%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	1	1	0
Myalgia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	2 / 32 (6.25%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	2	1	0
Pain in jaw			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Angular cheilitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Catheter site infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Cystitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Endometritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Fungal skin infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Genital herpes simplex			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Herpes dermatitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Herpes virus infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Infected cyst			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Infected skin ulcer			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Lip infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Lung infection			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Nail infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Oral herpes			
subjects affected / exposed	3 / 32 (9.38%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0

Otitis media			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Rhinitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rhinovirus infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin candida			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Subcutaneous abscess			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	3 / 32 (9.38%)	1 / 9 (11.11%)	1 / 4 (25.00%)
occurrences (all)	3	1	1

Vaginal infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Clostridium difficile colitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	15 / 32 (46.88%)	6 / 9 (66.67%)	1 / 4 (25.00%)
occurrences (all)	19	8	1
Dehydration			
subjects affected / exposed	2 / 32 (6.25%)	2 / 9 (22.22%)	0 / 4 (0.00%)
occurrences (all)	2	2	0
Hypercalcaemia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Hypercholesterolaemia			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Hyperglycaemia			
subjects affected / exposed	6 / 32 (18.75%)	1 / 9 (11.11%)	1 / 4 (25.00%)
occurrences (all)	6	1	1
Hyperkalaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypermagnesaemia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 9 (11.11%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Hyperphosphataemia			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Hypertriglyceridaemia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hypoalbuminaemia			

subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	3	0	0
Hypocalcaemia			
subjects affected / exposed	2 / 32 (6.25%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Hypocholesterolaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	5 / 32 (15.63%)	1 / 9 (11.11%)	1 / 4 (25.00%)
occurrences (all)	6	1	1
Hypomagnesaemia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Hyponatraemia			
subjects affected / exposed	4 / 32 (12.50%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Iron deficiency			
subjects affected / exposed	1 / 32 (3.13%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Metabolic acidosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 9 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Part 1: GSK525762 30 mg BID	Part 1: GSK525762 40 mg BID	Part 2: Participants with NMC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)	5 / 5 (100.00%)	11 / 12 (91.67%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Infected neoplasm			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Tumour pain			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Hypertension			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Hypotension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	7 / 10 (70.00%)	3 / 5 (60.00%)	5 / 12 (41.67%)
occurrences (all)	8	4	6
Axillary pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Catheter site inflammation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Catheter site pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Chest discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Chest pain			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	0	2
Chills			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Facial pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	4 / 12 (33.33%)
occurrences (all)	1	1	4
Gait disturbance			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Localised oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Non-cardiac chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	1	1	1
Pain			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	3	0	0
Xerosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Breast pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Metrorrhagia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pelvic haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Perineal pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vaginal discharge			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Vaginal odour			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Vulvovaginal pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	3 / 10 (30.00%)	1 / 5 (20.00%)	3 / 12 (25.00%)
occurrences (all)	3	1	3
Dysphonia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Dyspnoea			
subjects affected / exposed	3 / 10 (30.00%)	1 / 5 (20.00%)	2 / 12 (16.67%)
occurrences (all)	4	1	2
Dyspnoea exertional			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	5 / 12 (41.67%)
occurrences (all)	0	0	6
Haemoptysis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Laryngeal pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Nasal dryness			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Nocturnal dyspnoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Orthopnoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pharyngeal oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pneumonia aspiration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pulmonary alveolar haemorrhage			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Respiratory symptom			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Sputum discoloured			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Throat clearing			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Anhedonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Anxiety			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Confusional state			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1

Disorientation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hallucination			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hallucination, visual			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Mental status changes			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Mood altered			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Amylase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	0	3
Bacterial test positive			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Bilirubin conjugated increased			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Blood albumin increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Blood bilirubin unconjugated increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood chloride decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase MB increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Blood creatinine increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	1	0	2
Blood fibrinogen decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Blood fibrinogen increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Blood insulin increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone decreased			

subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	1	0
Blood triglycerides increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	2 / 12 (16.67%)
occurrences (all)	0	1	2
Blood uric acid increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Brain natriuretic peptide increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Coagulation factor VII level decreased			
subjects affected / exposed	3 / 10 (30.00%)	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	3	1	1
Ejection fraction decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QRS complex prolonged			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	3 / 12 (25.00%)
occurrences (all)	0	0	3
Lipase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
N-terminal prohormone brain natriuretic peptide increased			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Occult blood positive			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Oxygen saturation decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Protein urine present			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	3 / 10 (30.00%)	2 / 5 (40.00%)	3 / 12 (25.00%)
occurrences (all)	4	2	3
Prothrombin time ratio decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Thyroxine free decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Thyroxine free increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Tri-iodothyronine free decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Troponin T increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Weight decreased			
subjects affected / exposed	3 / 10 (30.00%)	1 / 5 (20.00%)	3 / 12 (25.00%)
occurrences (all)	4	2	4
White blood cells urine positive			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Allergic transfusion reaction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Animal bite			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	3 / 12 (25.00%)
occurrences (all)	0	0	5
Cystitis radiation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Genital contusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Limb injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Postoperative wound complication			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Radiation oesophagitis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Transfusion reaction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Factor V deficiency			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Nodal rhythm			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pericardial effusion			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Sinus tachycardia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	2 / 10 (20.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	3	1	0
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Aphasia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Cervical radiculopathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Drug withdrawal headache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dysaesthesia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Dysgeusia			
subjects affected / exposed	4 / 10 (40.00%)	2 / 5 (40.00%)	4 / 12 (33.33%)
occurrences (all)	4	2	4
Headache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	3 / 12 (25.00%)
occurrences (all)	0	0	4
Intercostal neuralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Loss of consciousness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Neuralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Neuropathy peripheral			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	1	0
Syncope			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Tension headache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Ischaemic stroke			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Haemorrhage intracranial			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	4 / 10 (40.00%)	1 / 5 (20.00%)	3 / 12 (25.00%)
occurrences (all)	4	2	3

Haemorrhagic diathesis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Increased tendency to bruise			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Lymphopenia			
subjects affected / exposed	2 / 10 (20.00%)	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	4	1	1
Neutropenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	0	2
Thrombocytopenia			
subjects affected / exposed	7 / 10 (70.00%)	5 / 5 (100.00%)	3 / 12 (25.00%)
occurrences (all)	8	5	5
Ear and labyrinth disorders			
Ear haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Eye disorders			
Cataract			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Diplopia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Keratitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Optic neuropathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Orbital oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Visual acuity reduced			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Xerophthalmia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Abdominal hernia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	2 / 10 (20.00%)	2 / 5 (40.00%)	0 / 12 (0.00%)
occurrences (all)	2	2	0
Abdominal pain lower			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Abdominal pain upper			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	1	0	2
Abdominal tenderness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Anal fissure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Anal inflammation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Ascites			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Chapped lips			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Cheilitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Constipation			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	3 / 12 (25.00%)
occurrences (all)	3	0	3
Diarrhoea			
subjects affected / exposed	6 / 10 (60.00%)	5 / 5 (100.00%)	5 / 12 (41.67%)
occurrences (all)	10	8	6
Dry mouth			
subjects affected / exposed	3 / 10 (30.00%)	1 / 5 (20.00%)	2 / 12 (16.67%)
occurrences (all)	3	1	2
Dyspepsia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Eructation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Faeces discoloured			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Faeces soft			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Frequent bowel movements			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gastric haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Gastrointestinal fistula			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Gingival pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Glossitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Haematemesis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Impaired gastric emptying			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1

Nausea			
subjects affected / exposed	6 / 10 (60.00%)	1 / 5 (20.00%)	5 / 12 (41.67%)
occurrences (all)	9	2	6
Odynophagia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Oesophagitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Perianal erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Stomatitis			
subjects affected / exposed	3 / 10 (30.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	3	0	1
Toothache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	3 / 10 (30.00%)	1 / 5 (20.00%)	4 / 12 (33.33%)
occurrences (all)	6	1	5
Varices oesophageal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hepatic pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			

subjects affected / exposed	4 / 10 (40.00%)	2 / 5 (40.00%)	5 / 12 (41.67%)
occurrences (all)	4	3	6
Liver disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Portal vein thrombosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Dermatitis bullous			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Dry skin			
subjects affected / exposed	2 / 10 (20.00%)	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	2	1	1
Ecchymosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Guttate psoriasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Hair colour changes			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hidradenitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Ingrowing nail			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Leukoplakia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Madarosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Onycholysis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Pigmentation disorder			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Pruritus			

subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Purpura			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	5 / 12 (41.67%)
occurrences (all)	3	0	5
Rash erythematous			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	0	1	1
Scab			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin burning sensation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			

subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Skin lesion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Anuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Chromaturia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Haematuria			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Hydronephrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypertonic bladder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Neurogenic bladder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Nocturia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Urinary hesitation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Urinary tract disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Urine odour abnormal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	0	2
Arthritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Bone pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	2 / 12 (16.67%)
occurrences (all)	0	0	2
Connective tissue disorder			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	1	1	2
Musculoskeletal chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Musculoskeletal disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	1 / 12 (8.33%)
occurrences (all)	0	1	1
Myalgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Angular cheilitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0

Bronchitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Catheter site infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Cellulitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Conjunctivitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Cystitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	2	0	0
Ear infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Endometritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Folliculitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Genital herpes simplex			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Gingivitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Herpes dermatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Herpes virus infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	1	0	0
Infected cyst			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Infected skin ulcer			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lip infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Lung infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Nail infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Oral herpes			
subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	1	1	0
Otitis media			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Rhinovirus infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin candida			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Subcutaneous abscess			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1

Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Vaginal infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Clostridium difficile colitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	7 / 10 (70.00%)	4 / 5 (80.00%)	4 / 12 (33.33%)
occurrences (all)	10	5	4
Dehydration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	4 / 10 (40.00%)	1 / 5 (20.00%)	2 / 12 (16.67%)
occurrences (all)	7	1	2
Hyperkalaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hypermagnesaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Hypertriglyceridaemia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	0	0	1
Hypoalbuminaemia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	2	0	1
Hypocalcaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Hypocholesterolaemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 12 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	4 / 10 (40.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	4	0	0
Hypomagnesaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Hyponatraemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	1 / 12 (8.33%)
occurrences (all)	1	0	1
Hypophosphataemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Iron deficiency			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
Metabolic acidosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Part 2: Participants with SCLC	Part 2: Participants with CRPC	Part 2: Participants with TNBC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	14 / 14 (100.00%)	23 / 23 (100.00%)	19 / 19 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Infected neoplasm			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Tumour pain			
subjects affected / exposed	0 / 14 (0.00%)	2 / 23 (8.70%)	2 / 19 (10.53%)
occurrences (all)	0	2	2
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Hypertension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	4 / 14 (28.57%)	6 / 23 (26.09%)	7 / 19 (36.84%)
occurrences (all)	5	6	9
Axillary pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Catheter site inflammation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Chills			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	3 / 19 (15.79%)
occurrences (all)	0	0	3
Facial pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	5 / 14 (35.71%)	12 / 23 (52.17%)	7 / 19 (36.84%)
occurrences (all)	5	15	7
Gait disturbance			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	2 / 19 (10.53%)
occurrences (all)	0	0	2
Localised oedema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Mucosal inflammation			
subjects affected / exposed	1 / 14 (7.14%)	2 / 23 (8.70%)	1 / 19 (5.26%)
occurrences (all)	1	2	1
Non-cardiac chest pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			

subjects affected / exposed	1 / 14 (7.14%)	3 / 23 (13.04%)	3 / 19 (15.79%)
occurrences (all)	1	3	3
Pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	4 / 14 (28.57%)	1 / 23 (4.35%)	4 / 19 (21.05%)
occurrences (all)	6	1	4
Xerosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Breast pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Metrorrhagia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Pelvic haematoma			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Perineal pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Vaginal discharge			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Vaginal odour			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	1 / 14 (7.14%)	2 / 23 (8.70%)	1 / 19 (5.26%)
occurrences (all)	1	2	1
Dysphonia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Dyspnoea			
subjects affected / exposed	4 / 14 (28.57%)	5 / 23 (21.74%)	4 / 19 (21.05%)
occurrences (all)	4	5	4
Dyspnoea exertional			
subjects affected / exposed	1 / 14 (7.14%)	2 / 23 (8.70%)	0 / 19 (0.00%)
occurrences (all)	1	2	0
Epistaxis			
subjects affected / exposed	0 / 14 (0.00%)	6 / 23 (26.09%)	1 / 19 (5.26%)
occurrences (all)	0	6	1
Haemoptysis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Laryngeal pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Nocturnal dyspnoea			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 14 (7.14%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Orthopnoea			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Pharyngeal oedema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Pneumonia aspiration			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Pulmonary alveolar haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Pulmonary haemorrhage			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Respiratory symptom			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Sputum discoloured			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Throat clearing			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Anhedonia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Depression			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Disorientation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hallucination			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hallucination, visual			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Insomnia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Mental status changes			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Mood altered			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	2 / 14 (14.29%)	3 / 23 (13.04%)	4 / 19 (21.05%)
occurrences (all)	2	3	5
Amylase increased			
subjects affected / exposed	1 / 14 (7.14%)	2 / 23 (8.70%)	1 / 19 (5.26%)
occurrences (all)	2	2	1
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 14 (14.29%)	6 / 23 (26.09%)	4 / 19 (21.05%)
occurrences (all)	2	8	4
Bacterial test positive			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Bilirubin conjugated increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Blood albumin increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Blood bilirubin unconjugated increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Blood chloride decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Blood creatine phosphokinase MB increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Blood creatinine increased			
subjects affected / exposed	3 / 14 (21.43%)	3 / 23 (13.04%)	0 / 19 (0.00%)
occurrences (all)	3	3	0
Blood fibrinogen decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Blood fibrinogen increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Blood insulin increased			

subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Blood triglycerides increased			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	2 / 19 (10.53%)
occurrences (all)	0	1	2
Blood uric acid increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Brain natriuretic peptide increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Coagulation factor VII level decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	3 / 19 (15.79%)
occurrences (all)	0	0	3
Ejection fraction decreased			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Electrocardiogram QRS complex prolonged			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
International normalised ratio increased			
subjects affected / exposed	0 / 14 (0.00%)	5 / 23 (21.74%)	3 / 19 (15.79%)
occurrences (all)	0	5	3
Lipase increased			

subjects affected / exposed	2 / 14 (14.29%)	2 / 23 (8.70%)	1 / 19 (5.26%)
occurrences (all)	2	3	1
N-terminal prohormone brain natriuretic peptide increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Occult blood positive			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Oxygen saturation decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Protein urine present			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Prothrombin time prolonged			
subjects affected / exposed	0 / 14 (0.00%)	4 / 23 (17.39%)	2 / 19 (10.53%)
occurrences (all)	0	4	3
Prothrombin time ratio decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Thyroxine free decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Thyroxine free increased			
subjects affected / exposed	0 / 14 (0.00%)	2 / 23 (8.70%)	1 / 19 (5.26%)
occurrences (all)	0	2	1
Transaminases increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Tri-iodothyronine free decreased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Troponin T increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Weight decreased			
subjects affected / exposed	0 / 14 (0.00%)	2 / 23 (8.70%)	2 / 19 (10.53%)
occurrences (all)	0	2	3
White blood cells urine positive			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Allergic transfusion reaction			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Animal bite			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 14 (0.00%)	5 / 23 (21.74%)	0 / 19 (0.00%)
occurrences (all)	0	5	0
Cystitis radiation			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Eye contusion			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Genital contusion			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Postoperative wound complication			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Procedural pain			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Radiation oesophagitis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Transfusion reaction			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Factor V deficiency			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Nodal rhythm			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Pericardial effusion			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	2	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Nervous system disorders			

Ageusia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Aphasia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Balance disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Cervical radiculopathy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Drug withdrawal headache			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Dysaesthesia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	2 / 14 (14.29%)	10 / 23 (43.48%)	5 / 19 (26.32%)
occurrences (all)	2	12	6
Headache			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	4 / 19 (21.05%)
occurrences (all)	0	1	4
Intercostal neuralgia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Lethargy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Loss of consciousness			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Neuralgia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Post herpetic neuralgia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Syncope			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Tension headache			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Ischaemic stroke			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Haemorrhage intracranial			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	6 / 14 (42.86%)	13 / 23 (56.52%)	7 / 19 (36.84%)
occurrences (all)	6	14	7
Haemorrhagic diathesis			
subjects affected / exposed	0 / 14 (0.00%)	2 / 23 (8.70%)	0 / 19 (0.00%)
occurrences (all)	0	2	0
Increased tendency to bruise			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Leukocytosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 14 (0.00%)	3 / 23 (13.04%)	2 / 19 (10.53%)
occurrences (all)	0	3	2
Neutropenia			
subjects affected / exposed	3 / 14 (21.43%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences (all)	3	2	1
Thrombocytopenia			
subjects affected / exposed	7 / 14 (50.00%)	12 / 23 (52.17%)	13 / 19 (68.42%)
occurrences (all)	12	23	15
Ear and labyrinth disorders			
Ear haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Eye disorders			

Cataract			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Optic neuropathy			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Orbital oedema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Xerophthalmia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			

subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Abdominal distension			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Abdominal hernia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Abdominal pain lower			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	2	0
Abdominal tenderness			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Anal fissure			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Anal inflammation			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Chapped lips			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Cheilitis			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	2
Colitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 14 (7.14%)	5 / 23 (21.74%)	5 / 19 (26.32%)
occurrences (all)	1	5	6
Diarrhoea			
subjects affected / exposed	4 / 14 (28.57%)	12 / 23 (52.17%)	7 / 19 (36.84%)
occurrences (all)	6	24	7
Dry mouth			
subjects affected / exposed	0 / 14 (0.00%)	3 / 23 (13.04%)	1 / 19 (5.26%)
occurrences (all)	0	3	1
Dyspepsia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Dysphagia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Eructation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Faeces discoloured			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Faeces soft			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Frequent bowel movements			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Gastric haemorrhage			

subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Gastric ulcer			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal fistula			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Gingival bleeding			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Gingival pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Glossitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Haematemesis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Impaired gastric emptying			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Lip dry			

subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Mouth ulceration			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	8 / 14 (57.14%)	11 / 23 (47.83%)	8 / 19 (42.11%)
occurrences (all)	8	16	12
Odynophagia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Perianal erythema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	2 / 14 (14.29%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences (all)	3	1	1
Toothache			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	4 / 14 (28.57%)	9 / 23 (39.13%)	8 / 19 (42.11%)
occurrences (all)	4	18	11
Varices oesophageal			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Hepatic pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Hyperbilirubinaemia			
subjects affected / exposed	4 / 14 (28.57%)	7 / 23 (30.43%)	2 / 19 (10.53%)
occurrences (all)	5	9	3
Liver disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Portal vein thrombosis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Blister			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Dermatitis acneiform			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Dermatitis bullous			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	3 / 19 (15.79%)
occurrences (all)	0	0	3
Ecchymosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Erythema			

subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Guttate psoriasis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hair colour changes			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hidradenitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Ingrowing nail			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Leukoplakia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Madarosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Onycholysis			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Petechiae			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0

Pigmentation disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	3 / 14 (21.43%)	0 / 23 (0.00%)	4 / 19 (21.05%)
occurrences (all)	4	0	5
Purpura			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	4 / 14 (28.57%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences (all)	5	1	1
Rash erythematous			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Rash maculo-papular			
subjects affected / exposed	2 / 14 (14.29%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	2	1	0
Rash papular			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Skin burning sensation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Skin fissures			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Skin ulcer			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Anuria			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Chromaturia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	1 / 14 (7.14%)	2 / 23 (8.70%)	0 / 19 (0.00%)
occurrences (all)	1	2	0
Haematuria			
subjects affected / exposed	0 / 14 (0.00%)	7 / 23 (30.43%)	0 / 19 (0.00%)
occurrences (all)	0	10	0
Hydronephrosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hypertonic bladder			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Neurogenic bladder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Proteinuria			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Urinary hesitation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Urinary tract disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Urine odour abnormal			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Arthritis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Back pain			

subjects affected / exposed	0 / 14 (0.00%)	4 / 23 (17.39%)	0 / 19 (0.00%)
occurrences (all)	0	4	0
Bone pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Connective tissue disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Groin pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Muscle spasms			
subjects affected / exposed	0 / 14 (0.00%)	3 / 23 (13.04%)	1 / 19 (5.26%)
occurrences (all)	0	3	1
Musculoskeletal chest pain			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 14 (0.00%)	4 / 23 (17.39%)	3 / 19 (15.79%)
occurrences (all)	0	4	3
Pain in extremity			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Pain in jaw			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			

Anal abscess			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Angular cheilitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Catheter site infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Device related infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Endometritis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Genital herpes simplex			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Herpes dermatitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Herpes virus infection			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Herpes zoster			
subjects affected / exposed	1 / 14 (7.14%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Infected cyst			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Infected skin ulcer			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Lip infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Lung infection			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	1	0	1
Nail infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Nasopharyngitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Otitis media			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Pneumonia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Rhinovirus infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Skin candida			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Skin infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1

Subcutaneous abscess			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	1 / 14 (7.14%)	4 / 23 (17.39%)	3 / 19 (15.79%)
occurrences (all)	1	7	3
Vaginal infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Clostridium difficile colitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	5 / 14 (35.71%)	15 / 23 (65.22%)	8 / 19 (42.11%)
occurrences (all)	5	16	8
Dehydration			
subjects affected / exposed	3 / 14 (21.43%)	2 / 23 (8.70%)	0 / 19 (0.00%)
occurrences (all)	3	2	0
Hypercalcaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	1 / 14 (7.14%)	2 / 23 (8.70%)	3 / 19 (15.79%)
occurrences (all)	1	2	4
Hyperkalaemia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Hypermagnesaemia			

subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	1 / 14 (7.14%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	1	1	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
Hypoalbuminaemia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	3 / 19 (15.79%)
occurrences (all)	0	1	3
Hypocalcaemia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 23 (4.35%)	0 / 19 (0.00%)
occurrences (all)	0	1	0
Hypocholesterolaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	2 / 14 (14.29%)	3 / 23 (13.04%)	1 / 19 (5.26%)
occurrences (all)	2	4	1
Hypomagnesaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Hyponatraemia			
subjects affected / exposed	1 / 14 (7.14%)	1 / 23 (4.35%)	2 / 19 (10.53%)
occurrences (all)	1	1	2
Hypophosphataemia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	1	0	0
Iron deficiency			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Metabolic acidosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 23 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Part 2: Participants with ER+BC	Part 2: Participants with GIST	Besylate Substudy
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 21 (100.00%)	12 / 13 (92.31%)	10 / 10 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Infected neoplasm			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Haematoma			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Hypertension			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Hypotension			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	2 / 10 (20.00%)
occurrences (all)	0	1	2
Lymphoedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	11 / 21 (52.38%)	3 / 13 (23.08%)	0 / 10 (0.00%)
occurrences (all)	12	3	0
Axillary pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Catheter site inflammation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Catheter site pain			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Chest discomfort			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Chills			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	2	0	1
Face oedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	4 / 21 (19.05%)	3 / 13 (23.08%)	6 / 10 (60.00%)
occurrences (all)	4	3	6
Gait disturbance			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Localised oedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	0	1	1

Non-cardiac chest pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	4	0	1
Pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	2	0	1
Xerosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Breast pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Metrorrhagia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pelvic haematoma			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Pelvic pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Perineal pain			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vaginal discharge			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vaginal odour			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Cough			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	2	0	1
Dysphonia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	2	0	1
Dyspnoea			
subjects affected / exposed	8 / 21 (38.10%)	4 / 13 (30.77%)	3 / 10 (30.00%)
occurrences (all)	8	4	3
Dyspnoea exertional			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Haemoptysis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Laryngeal pain			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Nocturnal dyspnoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Orthopnoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pharyngeal oedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pneumonia aspiration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Productive cough			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Pulmonary alveolar haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pulmonary haemorrhage			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Respiratory symptom			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Sputum discoloured			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Throat clearing			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Wheezing			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Anhedonia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	2 / 10 (20.00%)
occurrences (all)	1	0	2
Confusional state			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0

Delirium			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Disorientation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hallucination			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hallucination, visual			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	4 / 21 (19.05%)	1 / 13 (7.69%)	3 / 10 (30.00%)
occurrences (all)	4	1	3
Mental status changes			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Mood altered			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	3 / 21 (14.29%)	0 / 13 (0.00%)	5 / 10 (50.00%)
occurrences (all)	3	0	5
Alanine aminotransferase increased			
subjects affected / exposed	4 / 21 (19.05%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	4	1	0
Amylase increased			
subjects affected / exposed	1 / 21 (4.76%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Aspartate aminotransferase increased			

subjects affected / exposed	6 / 21 (28.57%)	2 / 13 (15.38%)	2 / 10 (20.00%)
occurrences (all)	7	2	6
Bacterial test positive			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Bilirubin conjugated increased			
subjects affected / exposed	3 / 21 (14.29%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	3	0	1
Blood albumin increased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 21 (4.76%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Blood bilirubin unconjugated increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Blood chloride decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase MB increased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 21 (14.29%)	5 / 13 (38.46%)	1 / 10 (10.00%)
occurrences (all)	3	6	1
Blood creatinine increased			
subjects affected / exposed	4 / 21 (19.05%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	5	0	1
Blood fibrinogen decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood fibrinogen increased			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood insulin increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	2 / 21 (9.52%)	1 / 13 (7.69%)	2 / 10 (20.00%)
occurrences (all)	2	1	2
Blood uric acid increased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Brain natriuretic peptide increased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Coagulation factor VII level decreased			
subjects affected / exposed	4 / 21 (19.05%)	3 / 13 (23.08%)	0 / 10 (0.00%)
occurrences (all)	6	3	0
Ejection fraction decreased			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Electrocardiogram QRS complex prolonged			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			

subjects affected / exposed	4 / 21 (19.05%)	4 / 13 (30.77%)	5 / 10 (50.00%)
occurrences (all)	4	4	5
Lipase increased			
subjects affected / exposed	0 / 21 (0.00%)	2 / 13 (15.38%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
N-terminal prohormone brain natriuretic peptide increased			
subjects affected / exposed	1 / 21 (4.76%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Occult blood positive			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Oxygen saturation decreased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Protein urine present			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	4 / 21 (19.05%)	4 / 13 (30.77%)	3 / 10 (30.00%)
occurrences (all)	7	4	3
Prothrombin time ratio decreased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Thyroxine free decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Thyroxine free increased			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Transaminases increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tri-iodothyronine free decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Troponin T increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	5 / 21 (23.81%)	2 / 13 (15.38%)	1 / 10 (10.00%)
occurrences (all)	5	2	1
White blood cells urine positive			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Allergic transfusion reaction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Animal bite			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
Cystitis radiation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Genital contusion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Postoperative wound complication			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Radiation oesophagitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Transfusion reaction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Factor V deficiency			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nodal rhythm			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Pericardial effusion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tachycardia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Balance disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Cervical radiculopathy			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Dizziness			
subjects affected / exposed	4 / 21 (19.05%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	4	0	0
Drug withdrawal headache			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Dysaesthesia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	7 / 21 (33.33%)	5 / 13 (38.46%)	5 / 10 (50.00%)
occurrences (all)	8	5	5
Headache			
subjects affected / exposed	2 / 21 (9.52%)	3 / 13 (23.08%)	1 / 10 (10.00%)
occurrences (all)	2	3	1
Intercostal neuralgia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Loss of consciousness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Paraesthesia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Post herpetic neuralgia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Presyncope			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Sciatica			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Syncope			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Tension headache			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Ischaemic stroke			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1

Haemorrhage intracranial			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	9 / 21 (42.86%)	2 / 13 (15.38%)	7 / 10 (70.00%)
occurrences (all)	11	2	7
Haemorrhagic diathesis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Increased tendency to bruise			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	4 / 10 (40.00%)
occurrences (all)	1	0	4
Lymphopenia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Neutropenia			
subjects affected / exposed	4 / 21 (19.05%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	4	1	1
Thrombocytopenia			
subjects affected / exposed	13 / 21 (61.90%)	3 / 13 (23.08%)	9 / 10 (90.00%)
occurrences (all)	18	3	11
Ear and labyrinth disorders			
Ear haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Hypoacusis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vertigo			

subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Eye disorders			
Cataract			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Diplopia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Dry eye			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Eye pruritus			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Optic neuropathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Orbital oedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Visual acuity reduced			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Vitreous floaters			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Xerophthalmia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0

Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	1 / 21 (4.76%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Abdominal hernia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	1 / 21 (4.76%)	2 / 13 (15.38%)	2 / 10 (20.00%)
occurrences (all)	1	3	3
Abdominal pain lower			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	5 / 21 (23.81%)	0 / 13 (0.00%)	2 / 10 (20.00%)
occurrences (all)	6	0	2
Abdominal tenderness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Anal fissure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Anal inflammation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Chapped lips			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Cheilitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Colitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 21 (4.76%)	2 / 13 (15.38%)	4 / 10 (40.00%)
occurrences (all)	2	2	4
Diarrhoea			
subjects affected / exposed	8 / 21 (38.10%)	4 / 13 (30.77%)	4 / 10 (40.00%)
occurrences (all)	11	5	6
Dry mouth			
subjects affected / exposed	3 / 21 (14.29%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	4	1	1
Dyspepsia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Dysphagia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Eructation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Faeces discoloured			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Faeces soft			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Frequent bowel movements			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastric haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal fistula			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gingival pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Glossitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Haematemesis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Impaired gastric emptying			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	9 / 21 (42.86%)	5 / 13 (38.46%)	5 / 10 (50.00%)
occurrences (all)	12	5	6
Odynophagia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Oesophagitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Perianal erythema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Stomatitis			
subjects affected / exposed	3 / 21 (14.29%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	3	1	1
Toothache			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	6 / 21 (28.57%)	2 / 13 (15.38%)	5 / 10 (50.00%)
occurrences (all)	8	2	5
Varices oesophageal			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Hepatobiliary disorders			

Cholangitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hepatic pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	9 / 21 (42.86%)	2 / 13 (15.38%)	4 / 10 (40.00%)
occurrences (all)	12	2	4
Liver disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Portal vein thrombosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Blister			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	2	0	0
Dermatitis bullous			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Ecchymosis			

subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Erythema			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Guttate psoriasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Hair colour changes			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hidradenitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Ingrowing nail			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Leukoplakia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Madarosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Onycholysis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Petechiae			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pigmentation disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Purpura			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	3 / 21 (14.29%)	0 / 13 (0.00%)	2 / 10 (20.00%)
occurrences (all)	4	0	2
Rash erythematous			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Scab			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Skin burning sensation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Skin fissures			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Anuria			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Chromaturia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
Dysuria			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Haematuria			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hydronephrosis			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Hypertonic bladder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Neurogenic bladder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Urinary hesitation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Urinary tract disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Urine odour abnormal			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Arthritis			

subjects affected / exposed	1 / 21 (4.76%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Back pain			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	2	0	1
Bone pain			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Connective tissue disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	3 / 21 (14.29%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	3	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	2 / 10 (20.00%)
occurrences (all)	2	0	2
Myalgia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
Pain in extremity			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Pain in jaw			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Angular cheilitis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Bronchitis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Catheter site infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Device related infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Endometritis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Fungal skin infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Genital herpes simplex			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Herpes dermatitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Herpes virus infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	2 / 21 (9.52%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	2	1	1
Infected cyst			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Infected skin ulcer			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Infection			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Lip infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Lung infection			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0

Nail infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Oral candidiasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	1 / 21 (4.76%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
Otitis media			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rhinovirus infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Sepsis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Skin candida			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Skin infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Subcutaneous abscess			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Vaginal infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Clostridium difficile colitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	10 / 21 (47.62%)	6 / 13 (46.15%)	4 / 10 (40.00%)
occurrences (all)	11	6	4
Dehydration			
subjects affected / exposed	2 / 21 (9.52%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	2	1	1
Hypercalcaemia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Hypercholesterolaemia			
subjects affected / exposed	2 / 21 (9.52%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	2	1	1
Hyperglycaemia			
subjects affected / exposed	6 / 21 (28.57%)	5 / 13 (38.46%)	3 / 10 (30.00%)
occurrences (all)	7	5	3
Hyperkalaemia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Hypermagnesaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	1	1	1
Hypertriglyceridaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 13 (0.00%)	2 / 10 (20.00%)
occurrences (all)	3	0	2
Hypocalcaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Hypocholesterolaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	1 / 21 (4.76%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	1	1	1
Hypomagnesaemia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 13 (0.00%)	2 / 10 (20.00%)
occurrences (all)	1	0	2
Hyponatraemia			
subjects affected / exposed	2 / 21 (9.52%)	1 / 13 (7.69%)	1 / 10 (10.00%)
occurrences (all)	2	1	1
Hypophosphataemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Iron deficiency			
subjects affected / exposed	0 / 21 (0.00%)	0 / 13 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Metabolic acidosis			

subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 13 (0.00%) 0	1 / 10 (10.00%) 1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
09 January 2012	Amendment 1: Modifications include updated medical monitoring information due to a personnel change on the GSK team. In addition, following review of the protocol by the FDA, the following changes are made: For Part 1, the starting dose of GSK525762 is reduced from 5 mg/day to 2 mg/day. Cardiac troponin T level assessments are required as a part of the inclusion criteria and thereafter. An observation of CTCAE Grade 2 drug related toxicity, including grade 2 troponin T elevation, in one participant will end accelerated dose titration in Part 1. Participants with a history of gastrointestinal bleeding or active bleeding (positive guaiac fecal occult blood monitoring) will be excluded. In addition, wording for dose escalation decisions has been modified to state that no more than a 2-fold increase in dose will occur between successive cohorts. A staggered dosing approach will be implemented in the 3+3 dosing design to minimize potential for toxicity in multiple participants. Alternative dosing regimens will not be implemented without consultation with FDA and a protocol amendment. For Part 2 of the trial, stopping rules based on lack of efficacy and the futility rule have been modified. Additionally the disease assessment scans may be reviewed retrospectively by an independent radiologist. Finally, multiple Time and Event Tables have been revised for consistency across Part 1 and Part 2 of the protocol.
29 August 2012	Changes via Amendment 2 include the addition of participants with tumor types other than NMC [including multiple myeloma (MM), small cell lung cancer (SCLC), colorectal cancer (CRC), neuroblastoma (NB), and any solid tumor that demonstrates N-Myc amplification or over expression (such as NSCLC with N-myc amplification)] and associated changes in the study design and inclusion criteria; definition of adult participants as those 16 and older; addition of pediatric participants 12 to ≤15 years old; modification of the initial staggered dosing schedule to shorten the dose escalation period from 6 weeks to 4 weeks; allowance for treatment beyond tumor progression (decision made in consultation with GSK Medical Monitor); minor clarifications to the Risk Assessment section; updates to Exploratory Objectives/Endpoints to ensure adequate assessment of the effect of drug on tumor biology; and addition of drug preparation guidelines for GSK525762 administered via an enteral feeding tube.
04 February 2014	Amendment 3 applies to all study sites and includes the addition of the NMC Pharmacodynamic (PD) Expansion Cohort to evaluate the pharmacodynamic effects of GSK525762 across the predicted efficacious dose range at doses that have been previously cleared during 3+3 dose escalation. The collection of ECGs, PK samples and liver chemistry were clarified or corrected. The inclusion of a pediatric cohort in Part1B, implemented in protocol amendment 2, was clarified and emphasis was added regarding the preservation of reproductive capacity.
06 October 2014	Amendment 4 applies to all study sites and includes the addition of participants with the following solid tumor types: castration-resistant prostate cancer (CRPC), triple negative breast cancer (TNBC), estrogen receptor positive breast cancer (ER positive), and non-small cell lung cancer (NSCLC). Multiple myeloma (MM), a hematological malignancy previously included in the trial, is now removed from this trial as it is included in a separate trial open for hematologic malignancies with dose escalation to better define the benefit/risk balance. Additional details of twice daily (BID) dosing during dose escalation have been included. A Besylate Sub-Study has been added to determine the relative bioavailability (BA), food effect, and dose proportionality of the besylate formulation of GSK525762 at or near the maximum tolerated dose (MTD). An update to inclusion criteria has been made to allow participants with evaluable disease to be enrolled in the NMC PD cohort. An updated imaging schedule for NMC participants has been included.

24 March 2015	Amendment 5 applies to all study sites and includes the following additional expansion cohorts for Part 2 of the trial: castration-resistant prostate cancer (CRPC), triple negative breast cancer (TNBC), estrogen receptor positive breast cancer (ER positive) and small cell lung cancer (SCLC). An update was included regarding the Besylate Sub-Study to clarify that this sub-study would only be conducted at centers in the United States. The pediatric cohort in Part 1B was removed for further evaluation in a separate study. An update to the QTc management guidelines has been included.
19 June 2015	Amendment 6 applies to all study sites and includes updated guidance on contraception use based on emerging data from preclinical studies. Clarified how the Holter monitoring data will be reviewed and analyzed. Additionally, updates were made throughout to correct minor inconsistencies and provide further clarification, specifically with the Time and Events Tables. Furthermore, the dosing schedule was updated from a staggered (1,3,5,7) dosing schedule in the first two weeks to a continuous daily dosing schedule. Finally, after an internal QTc analysis and evaluation of cardiac safety data collected from all participants up to the 100 mg QD cohort available by 15-May-2015, the 48-hour telemetry requirement has been removed for all parts of the study and the frequency of Holter monitoring has been decreased in Part 1.
10 March 2016	Amendment 7 updates were made, to include the final dose and regimen for Part 2, which was determined to be 75 mg once daily based on emerging data from Part 1 and Besylate Sub-Study; to clarify that the besylate salt tablets will be the formulation used for participants enrolled in Part 2 (and potentially for ongoing or newly enrolled participants in Part 1); to update required number of participants to be enrolled in the Part 1; to update the subject and study completion details; to update the Visit window for Discontinuation and End of Treatment; to update diagnosis criteria of NMC for Part 1 and 2 for NMC subjects; to update dosing, handling and storage instruction for GSK525762 Besylate tablet; to modify the meals and dietary restrictions based on the results of the besylate sub-study, the fasting requirement is being lifted , except on Serial PK sampling days in Part 2 (Week 1 and Week 4); to include the details about interim and final analysis. Additionally, following updates were in the time and event table, 12-lead ECGs monitoring for prolonged QTcF for Part 1 and 2 was updated, tumor sampling time point was updated for Part 1 and 2; optional Sweat PK sampling for Part1 was removed; optional saliva sampling for time points for part 1 was updated; pain assessments was included for Part 2; Week1 Day1, echocardiogram (ECHO) was made optional for Part 2; and computed tomography (CT) scan, magnetic resonance imaging (MRI) and positron emission tomography (PET) scan detail were updated for Part 2.
02 December 2016	Amendment 8 includes changes as the result of the Dear Investigator Letter, dated 16 November 2016 which outlines the updated thrombocytopenia management guidelines, as outlined in the Dear Investigator Letter, dated 16 November 2016. This amendment also includes increased coagulation monitoring for Part 2 (added at Week2 Day1, Week3 Day1 and changed from once every 8 weeks [q8W] to once every 4 weeks [q4W] after Week 13), addition of Factor VII monitoring in Part 2 (at Screening, Week3 Day1 and reflex testing if PT or INR are ≥1.5 times ULN) and addition of laboratory values required prior to performing the post-dose biopsy.

24 February 2017	Amendment 9: The following changes have been made: addition of exclusion criteria for exclusionary medications; updated exclusion of bleeding to include all history of bleeding and added known bleeding disorders; addition of laboratory monitoring required prior to surgeries; addition of guidance for dose reduction levels; updated dose adjustment/stopping safety criteria; updated prohibited medications. In addition, other changes include: addition of a GIST cohort in Part 2, including background information, updated endpoints, overall Part 2 sample size, futility information, eligibility criteria and, Data Analysis and Statistical Considerations; updated Risk Assessment to include current available data; removal of cytokines throughout protocol; updated sample size for MTD dose level in Part 1; update to contraception use in Inclusion and clarifications in Lifestyle Requirements; removal of Holter monitoring; changes to Part 1 Time and Events Tables which includes removal of certain ECG time points, change from required to optional for urine PK samples and certain PK/ECG/biomarker tests, addition of Factor VII assay testing, additional lab samples at Week 7 and Week 11, change in timing of on-treatment biopsy; changes to Part 2 Time and Events Tables which includes additional lab samples at Week 7 and 11 and increase in Factor VII testing, addition of pregnancy/testosterone test at W1D1; change in timing of on-treatment biopsy and removal of an ECHO time point; change to the pregnancy reporting guidelines to 24 hours; addition of wording that subjects are to abstain from consuming certain fruits; updates to Concomitant Medications and Non-Drug Therapies to reorganize and update the prohibited, cautionary medication tables and drug interaction information; removal of fever and diarrhea information. Additionally, Appendix was updated with the current GSK Liver Event and follow-up information, but the liver event criteria did not change.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported